INDEX TO VOLUME XL

Page numbers preceded by "(P)" refer to the summaries of symposia and papers at the meetings of the British Thoracic Society. "(E)" refers to editorials.

A

Abdominal wall compliance, measurement of (P), 701
Abscess, pulmonary, and empyema (P), 691
  pulmonary, and lobar pneumonia, indium 111 autologous leucocyte scanning in, 925
N-Acetylcysteine, oral, effect on exacerbation rates in chronic bronchitis complicated by severe airways obstruction, multicentre study (P), 227; 832
Achalasia, squamous carcinoma *in situ* of oesophagus in patient with, 795
  swallowing difficulties in first degree relatives of patients with, 391
Acid test for gastro-oesophageal reflux in childhood asthma, 592
Actinomycosis, thoracic, presenting as brachial plexus syndrome, case of, 74
ADAMS J, TREASURE T: Variable anatomy of the right coronary artery supply to the left ventricle, 618
ADAMS PC. *See* VEALE D, GILMARTIN JJ, *et al*
ADDIS B. *See* HAY JG, DEWAR A, *et al*
——. *See* MOSS FM, BOBROW LG, *et al*
ADELROTH E. *See* O'BYRNE PM, ADELROTH E, *et al*
Adenocarcinoma in cystic fibrosis, case of, 199
  pulmonary, and malignant mesothelioma, comparison of tumour markers in, 91
Adenosine monophosphate, cyclic, metabolism of, effect of plasma theophylline (P), 211
Adrenaline, changes in plasma K^+ induced by, as index of $beta_2$ receptor responsiveness in normal and asthmatic subjects (P), 706
  circulating, protective role against exercise induced bronchoconstriction? (P), 715
Adrenergic response, peripheral, hydrocortisone enhancement of (P), 212
Adrenoceptor responsiveness of airways in asthma (P), 715
Aerosols, nebulised, for bronchodilation, droplet size matters? (P), 222
Aged. *See* Elderly
AGIUS RM, GODFREY RC, HOLGATE ST: Mast cell and histamine content of human bronchoalveolar lavage fluid, 760
——, JONES D, HOLGATE ST: Staining characteristics of human pulmonary mast cells (P), 214
——, KNIGHT RK, COLE PJ: The persistence of alveolar macrophages with smokers' inclusions after stopping cigarette smoking (P), 725
——, PETRICEVIC I, KNIGHT RK, COLE PJ: Is cell density a determinant of bronchoalveolar clearance? (P), 239
——, ROBINSON C, HOLGATE ST: Release of histamine and newly generated mediators from human bronchoalveolar lavage cells (P), 220
——. *See also* BRITTON JR, AGIUS RM, *et al*
AGNEW JE. *See* GEORGE RJD, JOHNSON MA, *et al*
——. *See* MILLAR AB, AGNEW JE, *et al*
——. *See* PAVIA D, BATEMAN JRM, *et al*
——. *See* TAYLOR RG, PAVIA D, *et al*
AHMAD F. *See* GOULD GA, RHIND GB, *et al*
——. *See* MCLEOD DT, AHMAD F, *et al*
AHMEDZAI S, CARTER R, MILLS RJ, MORAN F: Do cannabinoids depress respiration? (P), 723
AIDS and persistent generalised lymphadenopathy, value of TLCO estimation in (P), 223
  lung disease in, management of (P), 703
  pneumonia in (P), 227
  pneumonia in Britain associated with, bronchoalveolar lavage and transbronchial biopsy in diagnosis of, early experience and difficulties, 166
  pulmonary complications of, diagnosis of, 571
Air, inspired, warm, humid, exercise in asthma with, absence of refractoriness after, 418
Airflow limitation, chronic, stable, comparison of domiciliary salbutamol nebuliser and metered dose inhaler in (P), 232
  obstruction, asthma, and skin atopy in adult coeliac disease (P), 224
  obstruction, chronic, acute effects of corticosteroids in (P), 232
  obstruction, chronic, nebuliser therapy and cardiac dysrhythmias in (P), 704
  obstruction, chronic, relationship between saliva and free and total plasma theophylline concentrations in, 526
  obstruction, chronic, respiratory resistance in, effects of correcting arterial hypoxaemia (P), 709
  obstruction, chronic, transtracheal oxygen via micro-catheter in (P), 709
  obstruction in adults with cystic fibrosis, prednisolone in treatment of (P), 211
  obstruction, irreversible, and asthma (*Letters*), 80
  obstruction, lung volume measurement in, rapid gas dilution method for (P), 226
  obstruction, normocapnic, chronic aminophylline therapy in (P), 720
  obstruction, persistent, beta stimulant in, can effects be enhanced? (P), 212
  obstruction, reversible, case of non-Hodgkin's lymphoma of bronchial mucosa presenting with, 954
  obstruction, reversible, in sarcoidosis (P), 722
  obstruction, severe, chronic bronchitis complicated by, effect of oral *N*-acetylcysteine on exacerbation rates in, multicentre study (P), 227; 832
Airway adrenoceptor responsiveness in asthma (P), 715
  calibre and lung volumes and compliance, measurements of, preferential sites of action of bronchoconstrictor agents differentiated by? (P), 718
  calibre, baseline, response to inhaled histamine in asthmatics affected by? (P), 216
  central, malignant narrowing of, functional effects of laser therapy in (P), 723
  disease, obstructive. *See* Airflow obstruction
  function, effect of inhaled and intravenous substance P (P), 714
  human, intraepithelial nerves in, ultrastructural organisation of, 488
  nasal, response to topical histamine, assessment of, comparison of 3 methods (P), 216
  obstruction. *See* Airflow obstruction
  pressure, positive, continuous, nasal, long term, in treatment of severe obstructive sleep apnoea, 45
  reactivity, cold air inhalation in simplified standard test for (P), 216
  reactivity, temporal relationship to late asthmatic reactions induced by occupational agents (P), 703
  receptors, role in breathing pattern in chronic obstructive lung disease, 268; (*Letters*), 879, 880
  responsiveness and clinical state in asthmatics, effect of intramuscular killed influenza virus (P), 217
  responsiveness to histamine *in vivo* and *in vitro*, and effect of atropine, 261
  responsiveness to methacholine during natural menstrual cycle and

effect of oral contraceptives (P), 718
smooth muscle, ^{45}Ca efflux from, effects of leucotriene D_4 and other agonists (P), 713
smooth muscle, calcitonin gene related peptide as potent constrictor of (P), 713
smooth muscle, isolated, electrophysiological and mechanical behaviour of (P), 712
smooth muscle, muscarinic receptors and phosphatidylinositol turnover in (P), 713
Airways, small, disease, alternative name for *(Letters)*, 479
small, obstruction in sarcoidosis (P), 722
Albendazole treatment of pulmonary hydatid cysts in naturally infected sheep and implications for man, 453
AL-HILLAWI AH, CRAMER D, DENISON DM: Some observations on TLCO during exercise in normal subjects and patients with fibrosing alveolitis (P), 236
ALI NJ, HARRISON BDW, JENKINS PF: Fibreoptic bronchoscopy in the investigation of community acquired pneumonia (P), 210
ALLAWAY A. *See* CORRIN B, DANEL C, *et al*
ALLEN SL, FOSTER RW, MORGAN GP, SMALL RC: Studies of the electrophysiological and mechanical behaviour of isolated airways smooth muscle (P), 712
Allergen and exercise, asthma induced by, nedocromil inhibition of (P), 219
late phase asthmatic reactions induced by, eosinophils and eosinophil major basic protein in (P), 218
Allergic alveolitis, extrinsic, due to antigen from humidifier at 15°C (P), 229
reactions, type I, in man, mast cell involvement in, direct evidence for (P), 218
rhinitis, allergen induced release of high molecular weight neutrophil chemotactic activity in nasal secretions in (P), 719
Allergy, smoking, and differential white blood cell count, 17; *Erratum*, 208
to isphaghula in workers manufacturing bulk laxative (P), 702
Alpha$_1$-proteinase. *See* α_1-Proteinase
AL-SUHALI AR. *See* ORPHANIDOU D, AL-SUHALI AR, *et al*
ALTON EW, HAY JG, MUNRO C, GEDDES DM: Nasal electrical potential recordings—a new diagnostic test for cystic fibrosis? (P), 704
ALTOSE MD. *See* REDLINE S, TOMASHEFSKI JF, jun, *et al*
Aluminium smelters, lung function in *(Letters)*, 319
Alveolar macrophages, function and role in lung disorders (E), 321
macrophages, human, expression of α_1 proteinase inhibitor gene by (P), 219
macrophages, human, mediators released by IgE/anti-IgE complexes from (P), 716
macrophages, human, neutrophil activating factor derived from, identification and partial characterisation of (P), 221
macrophages, phagocytosis in sarcoidosis (P), 220
macrophages, release of reactive oxygen species by, modification by serum factors and proteinase inhibitors (P), 219
macrophages with inclusions in cigarette smokers, persistence after stopping smoking (P), 725
microlithiasis, observation of case over 22 years and recovery of material by lavage, 952
soft part sarcoma presenting as asymptomatic pulmonary nodules, case with ultrastructural diagnosis, 203
walls, cell number and proliferation in, effect of cigarette smoking (P), 214
Alveolar-capillary barrier. *See* Capillary-alveolar barrier
Alveolitis, allergic, extrinsic, due to antigen from humidifier at 15°C (P), 229
fibrosing, cryptogenic, lung tissue from patients with, immunohistological analysis suggesting local immune response (P), 221; 405
fibrosing, TLCO during exercise in (P), 236
in sarcoidosis, intensity of, reflected by serum angiotensin converting enzyme? 497
Aminophylline, effect on human diaphragm, 288
effect on minute ventilation and ventilatory response to carbon dioxide, comparison with salbutamol (P), 234
effect on respiratory and quadriceps muscles (P), 720
effect on sternomastoid muscle fatigue (P), 720
therapy, chronic, in normocapnic obstructive airways disease (P), 720
Amoxycillin, treatment response of bronchiectatic secretions with 3 regimes of (P), 238
Ampicillin or trimethoprim and increasing incidence of *Branhamella catarrhalis* bronchopulmonary infection (P), 691
Amyloidosis of respiratory tract treated by laser therapy, case of, 544
tracheobronchial, treatment of 2 cases by carbon dioxide laser photoresection, 870
Amyotrophy, neuralgic, with bilateral diaphragmatic palsy, case of, 635
Anaerobic threshold, estimation of, observer error in (P), 236
ANDERSON D. *See* MILROY R, SMITH L, *et al*
ANDERSON G, PEEL ET: Advanced squamous carcinoma of the lung: trials of etoposide *v* no treatment and etoposide *v* etoposide + cyclophosphamide (P), 703
ANDERSON HR. *See* JOHNSTON I, ANDERSON HR, *et al*
——. *See* JOHNSTON I, PATEL S, *et al*
ANDERSON J. *See* CHAN TB, ANDERSON J, *et al*
ANDERSON K, MCSHARRY CP, BOYD G: Immunoglobulin measurements in humidifier fever (P), 703
——, ——, ——: Radiographic changes in humidifier fever, 312
ANDERSON LE. *See* FERGUSSON RJ, CARMICHAEL J, *et al*
ANDERSON M. *See* FRANCE AJ, CAPEWELL SJ, *et al*
ANDERSON SD. *See* BLACK JL, SCHOEFFEL RE, *et al*
ANDRIANOPOULOS E. *See* JEYASINGHAM K, ANDRIANOPOULOS E, *et al*
Aneurysms, aortic and pulmonary artery, simultaneous, due to giant cell arteritis, case of, 156
ANGEBAULT M. *See* HOMASSON JP, BONNIOT JP, *et al*
ANGELETTI CA. *See* MUSSI A, JANNI A, *et al*
Angiofollicular lymphoid hyperplasia in pulmonary fissure, case of, 686
Angiography, digital subtraction, intravenous, in suspected pulmonary embolism, comparison with radionuclide ventilation-perfusion lung scanning, 576
Angiotensin converting enzyme activity in lung in chronically hypoxic rats, 587
converting enzyme activity in serum, reflects intensity of alveolitis in sarcoidosis?, 497
converting enzyme and *E coli* endotoxin induced lung damage in mouse, 774
converting enzyme and septic acute respiratory distress syndrome in mouse (P), 239
converting enzyme in serum in diagnosis and evaluation of pulmonary sarcoidosis (P), 228
II, transpulmonary formation in chronic stable cor pulmonale (P), 225
Antibiotics, nebulised, in treatment of purulent bronchiectasis (P), 704
Antibodies, monoclonal. *See* Monoclonal antibodies
to enteric Gram negative bacilli, increase after open heart surgery, postoperative pyrexia due to?, 538
Anticancer drugs, assessment of, heterotransplantation of human bronchial tumours to immunosuppressed mice as model for (P), 698
Anticholinergic agents. *See* Oxitropium bromide
Anticoagulation, 3-week versus 6-week regime in treatment of deep vein thrombosis and pulmonary embolus (P), 707
Antiendotoxin, *E coli*, in prevention of fever and Gram negative infection after open heart surgery, 846
Antithrombin III deficiency, inherited, effect of danazol on biochemical abnormality of, 646
Anti-tuberculosis drugs, combined and single, comparison of effects on *in vitro* sensitivity patterns of *M malmoense* and *M xenopi* (P), 697
Aortic and pulmonary artery aneurysms, simultaneous, due to giant cell arteritis, case of, 156

stenosis associated with aberrant origin of left coronary artery, case of, 152
Aortocoronary bypass grafting, state of vein grafts, native coronary arteries, and myocardium and principal cause of death in patients dying after, 940
Apnoea during sleep and hypoventilation in obesity (P), 235
during sleep, obstructive, severe, treated with long term nasal continuous positive airway pressure, 45
APPERLEY J. *See* KENNEDY HG, WYATT SE, *et al*
APPS MCP, KOPELMAN PG, WALLIS PJW, COPE T, EMPEY DW: Sleep apnoea and hypoventilation in obesity (P), 235
——, WALLIS PJW, INGRAM DA, DOPE T, EMPEY DW: Respiration during sleep in normal men and women (P), 235
——. *See also* WALLIS PJW, APPS MCP, *et al*
ARMIGER LC, THOMSON RW, STRICKETT MG, BARRATT-BOYES BG: Morphology of heart valves preserved by liquid nitrogen freezing, 778
ARNOLD AG. *See* SIMPSON FG, ARNOLD AG, *et al*
AROUN G. *See* CADRANEL J, MILLERON B, *et al*
Arterial hypoxaemia, correction of, effects on respiratory resistance in chronic airflow obstruction (P), 709
oxygenation, evaluation of Biox IIA ear oximeter for measurement of (P), 708; 825
Arteritis, giant cell, simultaneous aortic and pulmonary artery aneurysms due to, case of, 156
Asbestos and other exogenous particles in lymph nodes in shrinking pleuritis with atelectasis, 948
workers without evidence of asbestosis, bronchoalveolar lavage and clearance of ^{99m}Tc labelled DTPA in (P), 221
Asbestosis assessment by bronchoalveolar lavage and measurement of pulmonary epithelial permeability, 508
pulmonary epithelial permeability in, regional distribution of, 734
ASHCROFT T. *See* GILMARTIN JJ, MOHAMEDANI AA, *et al*
——. *See* VEALE D, MARSH C, *et al*
ASHFORD N, CRACKNELL N, MCCARTY J, DOYLE P, HIGENBOTTAM TW: Complement activation and the change in lung function with intravenous radiological contrast material (P), 240
ASHOUR M: Chest injury complicated by shock induced necrosis of the colon, 556
——, CAMPBELL IA, UMACHANDRAN V, BUTCHART EG: Late complication of plombage thoracoplasty, 394
Asians resident in UK, thoracic lymphadenopathy in, role of mediastinoscopy in initial diagnosis, 121
Aspergillosis, pulmonary, non-invasive, trial of ketoconazole in (P), 231
Aspergillus fumigatus spores, ingested by phagocytic cells? (P), 237
Aspiration, needle, transbronchial, in clinical practice, 756
place in treatment of spontaneous pneumothorax, 66
Aspirin, bronchial hyperreactivity to histamine in asthmatics sensitive to, relationship to aspirin threshold and effect of aspirin desensitisation, 598
ASQUITH P. *See* WILLIAMS AJ, ASQUITH P, *et al*
ASSOUFI BK, DALLY MB, NEWMAN-TAYLOR AJ, DENISON DM: Cold air test: a simplified standard method for airway reactivity (P), 216
Astemizole and terfenadine as non-sedative H_1 antihistamines for hay fever, comparative trial of *(Letters)*, 399, 799
Asthma, acute, admissions for, in Asian immigrant population (P), 229
acute, severe, nebulised salbutamol without oxygen in, trial of efficacy and safety, 180
adult, house dust allergen avoidance in, trial of (P), 224
airway adrenoceptor responsiveness in (P), 715
airway responsiveness and clinical state in, effect of intramuscular killed influenza virus (P), 217
airways obstruction, and skin atopy in adult coeliac disease (P), 224
and acute bronchitis, diagnosis in general practice (P), 689
and chronic bronchitis, hyperventilation and methacholine in, differences in responsiveness to, 422
and indoor mould exposure (P), 688
and irreversible airflow obstruction *(Letters)*, 80
and rhinitis after glutaraldehyde exposure (P), 224
assessment and management in accident and emergency department, 897
autumnal, winter acute bronchitis, respiratory syncytial virus and parainfluenza viruses 1 and 2 in general practice in UK (1976–84) (P), 690
beta$_2$ receptor responsiveness in, adrenaline induced changes in plasma K^+ as index of (P), 706
bronchial hyperreactivity to histamine in aspirin sensitive patients, relationship to aspirin threshold and effect of aspirin desensitisation, 598
bronchial, nedocromil sodium for management of, trial of *(Letters)*, 400
bronchial, neutrophil function in, effect of corticosteroids (P), 211
bronchoalveolar lavage in (P), 717
bronchoalveolar lavage mast cells in (P), 717
bronchoconstriction induced by leucotriene D_4 in, effect of verapamil (P), 714
childhood, gastro-oesophageal reflux in, acid test for, 592
chronic, severe, comparison of oral prednisolone and intramuscular depot triamcinolone *(Letters)*, 207
cough response to inhaled citric acid in, effect of bronchodilators, 662
diagnosis and treatment, expert system for improvement of (P), 689
due to contaminated humidifiers *(Letter)*, 560
exacerbations of, oral corticosteroids in treatment of, dose-response characteristics of (P), 228
glucocorticoid hypersensitivity in patient with, presentation and treatment, 477
histamine and epithelial permeability in (P), 217
histamine provoked bronchospasm in, refractory period following (P), 216
hyperresponsiveness to inhaled (but not intravenous) atropine in (P), 217
in Avon schoolchildren (P), 694
induced by allergen and exercise, nedocromil inhibition of (P), 219
induced by exercise, heterogeneity of mechanisms in (E), 481
induced by exercise, neutrophil and monocyte cytotoxicity enhanced after (P), 218
induced by exercise, plasma sodium cromoglycate levels with nebuliser and metered dose aerosol in (P), 212
induced by exercise, sodium cromoglycate aerosol in, dose-duration effect of (P), 706
induced by exercise, sodium cromoglycate pressurised aerosol in, dose-response effect of, 41
induced by gluten in adult coeliac disease (P), 229
late summer, *Didymella exitialis* as cause of (P), 223
lung permeability in, effect of histamine, 603
management, differences between British and European chest specialists (P), 689
management in schools (P), 688
methacholine and histamine in, increased responsiveness to, after challenge with ultrasonically nebulised water, 427
nocturnal, sodium cromoglycate effective in?, 793
nocturnal, treatment with inhaled anticholinergic drug (oxitropium bromide) (P), 705
occupational, due to formaldehyde, 255
occupational, due to heated freon *(Letters)*, 320
occupational, due to methyl methacrylate and cyanoacrylates, 836
occupational, epidemiology of, computerised interactive questionnaire in (P), 702
occupational, in factory with contaminated humidifiers, 248
occupational, prognosis in (E), 241
overnight bronchoconstriction in, reduction by sleep depriyation (P), 225
paradoxical vocal cord motion in (P), 689
preschool, slow release theophylline in (P), 230
pseudo-occupational (P), 229
pulmonary platelet kinetics in, 412
refractoriness in, absence after exercise with warm, humid inspi-

rate, 418
relative potency of inhaled leucotrienes C_4 and D_4 compared with methacholine in patients and non-asthmatics (P), 717
relevance of IgG mediated release of leucotriene C_4 from human eosinophils to (P), 716
respiratory symptoms and bronchial reactivity (P), 695
response to inhaled histamine in, affected by baseline airway calibre? (P), 216
salbutamol measurement in urine for monitoring of patients' compliance in (P), 705
severe, chronic, intramuscular triamcinolone in (P), 228
severe, chronic, monthly intramuscular triamcinolone acetonide compared with daily oral prednisolone in, 840
symptoms, patients' experience and assessment of (P), 688
therapeutic bronchial lavage in (P), 707
tracheobronchial mucociliary clearance in, impairment during remission, 171
treatment, use by patients in general practice (P), 230
unstable, local fat necrosis secondary to continuous subcutaneous terbutaline infusion in (P), 705
xanthine derivatives administered by inhalation in, bronchodilator actions of, 176
xanthines and other remedies for, medical history and contribution of HH Salter, 881
Asthmatic reactions induced by occupational exposure, neutrophil chemotactic activity in (P), 218
reactions, late, induced by allergen, eosinophils and eosinophil major basic protein in (P), 218
reactions, late, induced by occupational agents, temporal relationship to airway reactivity (P), 703
response, late, induced by exercise, factors predisposing to (P), 219
Atelectasis, shrinking pleuritis with, asbestos and other exogenous particles in lymph nodes in, 948
shrinking pleuritis with, long term results of operation for, 448
ATHERTON ST. *See* GORDON IJ, COAKLEY J, *et al*
ATKINSON M. *See* MAYBERRY JF, ATKINSON M
Atopy in byssinosis, prevalence and effects (P), 224
respiratory symptoms and bronchial reactivity in young population sample (P), 695
Atropine, effect on comparison of airway responsiveness to histamine *in vivo* and *in vitro*, 261
inhaled (but not intravenous), asthmatic subjects hyperresponsive to (P), 217
ATTFIELD MD: Longitudinal decline in FEV_1 in United States coalminers, 132
AUSTWICK P. *See* BURGE PS, FINNEGAN M, *et al*
Axonemal structure and function, normal, in case of Kartagener's syndrome, 956
AYRES JG: Acute asthma admissions in an Asian immigrant population (P), 229
——, NOAH ND: Respiratory syncytial virus, parainfluenza viruses 1 and 2, winter acute bronchitis and autumnal asthma in general practice in the United Kingdom 1976–1984 (P), 690
——, POPE FM, REIDY JF, CLARK TJH: Abnormalities of the lungs and thoracic cage in the Ehlers-Danlos syndrome, 300
——. *See also* RUFFLES SP, AYRES JG

B

Bacterial infections, secondary, in children with proved *Mycoplasma pneumoniae*, 5 cases of, 546
products, effect on human ciliary function *in vitro*, 125
BAILEY A. *See* LEWIS RA, ELLIS CJ, *et al*
BAILEY JS. *See* FARROW PR, JONES DA, *et al*
BAILEY C. *See* CORDIER JF, BAILLY C, *et al*
BAIN WH. *See* KHALIL Y, SETHIA B, *et al*
BAKER SB DE C. *See* PARKES SA, BAKER SB DE C, *et al*
BALACHANDRAN W. *See* LEWIS RA, ELLIS CJ, *et al*
BALDWIN DL. *See* CORRADO OJ, GOMEZ E, *et al*
BALL SG. *See* BERKIN KE, INGLIS CC, *et al*
Balloon pumping, intra-aortic, 7 years' experience, 858
BANHAM S. *See* MILROY R, SMITH L, *et al*
BANHAM SW. *See* NEILLY JB, CARTER R, *et al*
BANKS J, BEVAN C, FENNERTY AG, EBDEN P, WALTERS EH, SMITH AP: Effect of intramuscular killed influenza virus on airway responsiveness and clinical state in patients with asthma (P), 217
——, JENKINS PA: The effect of combined versus single antituberculosis drugs on *in vitro* sensitivity patterns of *M malmoense* and *M xenopi* (P), 697
——. *See also* FENNERTY AG, BANKS J, *et al*
——. *See also* WALTERS EH, EBDEN P, *et al*
BANKS RA. *See* SWINBURN CR, POZNIAK AL, *et al*
BANNER NR, GOVAN JR: Transtracheal oxygen via a micro-catheter in chronic obstructive airways disease (P), 709
BARBER R. *See* JONES DK, HIGENBOTTAM TW, *et al*
BARBOSA I. *See* GANT A, BARBOSA I, *et al*
BARKER J. *See* CHIODINI PL, WILLIAMS AJ, *et al*
BARKER V. *See* PHILLIPS MS, BARKER V
——. *See* ROBINSON AA, FLOWER CDR, *et al*
BARLOW Y, LAMB D: The effect of cigarette smoking on cell number and cell proliferation in the alveolar walls of man (P), 214
BARNES PJ. *See* COE CI, BARNES PJ
——. *See* CUSS FMC, PALMER JBD, *et al*
——. *See* FULLER RW, DIXON CMS, *et al*
——. *See* GRANDORDY B, CUSS FMC, *et al*
——. *See* GREENBERG B, RHODEN K, *et al*
——. *See* IND PW, BARNES PJ, *et al*
——. *See* PALMER JBD, CUSS FMC, *et al*
BARRATT-BOYES BG. *See* ARMIGER LC, THOMSON RW, *et al*
BARTER CE. *See* CAMPBELL AH, BARTER CE, *et al*
BARTON JR. *See* PEARCE SJ, POSNER V, *et al*
BARZILAY J. *See* RAHIMA MM, BARZILAY J
BATEMAN ED. *See* WILLCOX PA, BENATAR SR, *et al*
BATEMAN JRM. *See* PAVIA D, BATEMAN JRM, *et al*
BATEMAN NT. *See* GANT A, BARBOSA I, *et al*
——. *See* TREACHER DF, COWELL TK, *et al*
BATTEN JC. *See* HODSON ME, WISE AE, *et al*
——. *See* STEAD RJ, HODSON ME, *et al*
——. *See* STEAD RJ, KENNEDY HG, *et al*
——. *See* STEAD RJ, PANTIN CFA, *et al*
BAUER FE. *See* CHEUNG A, POLAK JM, *et al*
BAYLISS J. *See* JONES DK, HIGENBOTTAM TW, *et al*
BCG vaccination, efficacy in England and Wales in 1983 (P), 693
vaccination, still necessary in Edinburgh? (P), 222
BEAUMONT A, COCKCROFT A, GUZ A: A self paced treadmill walking test for breathless patients, 459
Behçet's syndrome, lung disease in (P), 231
BÉLANGER J. *See* CORMIER Y, BÉLANGER J, *et al*
BELCHER NG, REES PJ: Changes in pulmonary epithelial permeability in haemodialysis (P), 723
——. *See also* CHAIEB J, BELCHER NG, *et al*
——. *See also* REES PJ, BELCHER NG
BENATAR SR. *See* WILLCOX PA, BENATAR SR, *et al*
BENNETT J, TOOLEY M, D'SOUZA MF, DAVIES RJ: A general practice survey of bronchial reactivity (P), 695
BENNETT MK. *See* MOHAMEDANI AA, BENNETT MK
BEREND N. *See* BLACK JL, SCHOEFFEL RE, *et al*
BERENDSEN HH, HOFSTEE N, KAPSENBERG PD, SIEWERTSZ VAN REESEMA DR: Bronchocentric granulomatosis associated with seropositive polyarthritis, 396
BERGH J. *See* ESSCHER T, STEINHOLTZ L, *et al*
BERKIN KE, INGLIS CC, BALL SG, THOMSON NC: Adrenaline induced changes in plasma K^+ as an index of $beta_2$ receptor responsiveness in normal and asthmatic subjects (P), 706
Beta stimulant in persistant airflow obstruction, can effects be enhanced? (P), 212

Beta$_1$ receptor blockade, effect on pulmonary capillary blood volume and transit time (P), 712

Beta$_2$ adrenoceptor agonist, oral, long term therapy with, pulmonary haemodynamics in hypoxic chronic bronchitis improved by? (P), 707

adrenoceptor agonist, systemic administration during chronic hypoxia, polycythaemia and right ventricular hypertrophy enhanced by (P), 707

receptor responsiveness in normal and asthmatic subjects, adrenaline induced changes in plasma K^+ as index of (P), 706

Betamethasone alone and with neomycin nasal drops, effects on human nasal mucociliary clearance and ciliary beat frequency, 607

BETHUNE DW. *See* HAKIM M, WHEELDON D, *et al*

BEVAN C. *See* BANKS J, BEVAN C, *et al*

——. *See* FENNERTY AG, BANKS J, *et al*

——. *See* WALTERS EH, EBDEN P, *et al*

BEVERLEY PCL. *See* MOSS FM, BOBROW LG, *et al*

BIGNON JD. *See* CHAILLEUX E, BIGNON JD, *et al*

BIHARI D. *See* POZNIAK AL, BIHARI D, *et al*

Biopsy, bronchial, fluorescence as guide to, 38

lung, transbronchial, and bronchial lavage in diagnosis of legionnaires' disease, 3 cases of, 154

transbronchial, and bronchoalveolar lavage in diagnosis of AIDS associated pneumonia in Britain, early experience and difficulties, 166

BIRCH MJ. *See* POUNSFORD JC, BIRCH MJ, *et al*

BIRD R. *See* STUDDY PR, BIRD R, *et al*

Björk-Shiley mitral valve prosthesis, disc and strut embolisation after minor strut fracture in, case of, 158

BLACK JL, SCHOEFFEL RE, SUNDRUM R, BEREND N, ANDERSON SD: Increased responsiveness to methacholine and histamine after challenge with ultrasonically nebulised water in asthmatic subjects, 427

BLAINEY AD, OLLIER S, DAVIES RJ: A computerised interactive questionnaire in the epidemiology of occupational asthma (P), 702

BLAKE PR, CATTERALL M, EMERSON PA: Pleural mesothelioma treated by fast neutron therapy, 72

BLAND JM. *See* JOHNSTON I, ANDERSON HR, *et al*

BLEEHEN NM, FAYERS PM, GIRLING DJ, STEPHENS RJ (for MRC Lung Cancer Working Party): Adverse reactions and quality of life during combination chemotherapy compared with selective palliative treatment for small cell lung cancer (P), 699

——, ——, ——, —— (for MRC Lung Cancer Working Party): Controlled trial of maintenance *v* no maintenance chemotherapy in the treatment of small cell lung cancer (P), 699

Bleomycin and other drugs, pulmonary veno-occlusive disease after chemotherapy with, case of, 874

and tetracycline, intrapleural, comparison in treatment of malignant pleural effusion (P), 210

cisplatin, and vinblastine in inoperable non-small cell lung cancer, 346

intravenous, acute lung injury after, role of oxygen in induction of (P), 727

lung injury induced by, importance of iron in (P), 727

pulmonary fibrosis in rabbits induced by, progress of (P), 222

pulmonary fibrosis in rabbits induced by, secretion of fibroblast growth promoting activity by lavage inflammatory cells in (P), 222

Blood flow, bronchial, in sheep, measurement by video dilution technique, 143

flow in calf in secondary polycythaemia and cor pulmonale, effects of packed cell volume reduction (P), 237

flow, pulmonary capillary, and oxygen delivery to tissues, correlation in ventilated patients (P), 711

flow, pulmonary capillary, T_{LCO}, and lung tissue volume, simultaneous measurement of (P), 226

flow, systemic, coughs as cause of *(Letters)*, 160

peripheral, lymphocytes, phytohaemagglutinin responsiveness of, in sarcoidosis, 768

volume and transit time, pulmonary capillary, effect of β_1 receptor blockade (P), 712

BLOOM SR. *See* CHEUNG A, POLAK JM, *et al*

——. *See* PALMER JBD, CUSS FMC, *et al*

BOBROW LG. *See* MOSS FM, BOBROW LG, *et al*

BOERTH LW. *See* LEE TH, PENNINGTON JE, *et al*

BOLDY DAR. *See* LOZEWICZ S, DAVISON AG, *et al*

Bone marrow transplantation, lung function in, prospective study of (P), 233

tuberculosis in Brent (P), 697

tuberculosis in Leicestershire (1978–83) (P), 696

BONNIOT JP. *See* HOMASSON JP, BONNIOT JP, *et al*

Book notices, 77, 159, 186, 277, 393, 437, 447, 452, 543, 800, 878, 909

BOOKER HA, PANTIN CFA, DHILLON DP, DIMOND AH, COLLINS JV: Maximum activity questionnaire for evaluation of respiratory disability (P), 232

BORLAND C, HIGENBOTTAM TW: Are there enough oxygen centred free radicals in cigarette smoke to produce emphysema in smokers? (P), 220

BORZONE G, DIAZ M, MENDOZA J, FABA J, GRAY B: Bronchoalveolar lavage in silicosis (P), 726

BOTTONE EJ. *See* ROSEN MJ, TOW TWY, *et al*

BOTTRILL I, HARDY C, STERLING GM, HOLGATE ST: Do measurements of airway calibre, lung volumes and compliance differentiate preferential sites of action of bronchoconstrictor agents? (P), 718

BOURDILLON RE. *See* PARKES SA, BAKER SB DE C, *et al*

BOYD G, WALKER A: Long term protection in pigeon breeder's disease using face masks (P), 228

——. *See also* ANDERSON K, MCSHARRY CP, *et al*

BOYD PA, HASTIE ND, WOOD NE, GREENING AP: Human alveolar macrophages express the α_1 proteinase inhibitor gene (P), 219

Brachial plexus syndrome, case of thoracic actinomycosis presenting as, 74

BRADLEY RD. *See* TREACHER DF, COWELL TK, *et al*

Brain metastasis, solitary, and primary lung cancer, combined surgical treatment of, 191

BRANFOOT AC. *See* WALLIS PJW, BRANFOOT AC, *et al*

Branhamella catarrhalis bronchopulmonary infection, increasing incidence due to ampicillin or trimethoprim? (P), 691

BRANTHWAITE MA. *See* SAWICKA EH, LOH L, *et al*

——. *See* SAWICKA EH, PARKER RA, *et al*

——. *See* SIMONDS AK, BRANTHWAITE MA

——. *See* SIMONDS AK, PARKER RA, *et al*

Breath tests with single breath technique during bronchoscopy in prediction of functional results of lobectomy (P), 236

Breathing in tetraplegia, contribution of rib cage to, 613

pattern, effect of intermittent positive pressure breathing and jet nebuliser (P), 233

pattern in chronic obstructive lung diseae, role of airway receptors in, 268; *(Letters)*, 879, 880

pattern of resting normal subjects, vagal influence on (P), 234

patterns during weaning from mechanical ventilation after thoracic surgery (P), 213

Breathlessness caused by hypoxia not due only to stimulation of ventilation (P), 234

relationship to ventilation in cystic fibrosis, influence of regular exercise (P), 721

relief of, and improvement of exercise tolerance, portable oral high frequency oscillator for (P), 710

self paced treadmill walking test for, 459

BRENNAN N. *See* NOLAN MT, GIBNEY N, *et al*

BREUER R, SIMPSON GT, RUBINOW A, SKINNER M, COHEN AS: Tracheobronchial amyloidosis: treatment by carbon dioxide laser photoresection, 870

BREWIN M. *See* CARSWELL F, BREWIN M, *et al*

BRIDGES CE. *See* HETZEL MR, NIXON C, *et al*

British Lung Foundation and funding for respiratory research (E), 81

British Paediatric Association cystic fibrosis study (P), 693

British Throracic Society: Summer Meeting, 688

Thoracic Society: Winter Meeting, 209

Thoracic Society pneumonia study—design and outcome (P),

693—microbiological results (P), 693—mortality (P), 694—clinical features and *x* ray and laboratory data affecting prognosis (P), 694
BRITISH THORACIC SOCIETY RESEARCH COMMITTEE: Ceftazidime compared with gentamicin and carbenicillin in patients with cystic fibrosis, pulmonary pseudomonas infection, and an exacerbation of respiratory symptoms, 358; *Errata*, 728
—— —— —— —— ——: Lymph node tuberculosis: a controlled trial of nine versus 18 months' chemotherapy (P), 223
—— —— —— —— ——: Multicentre study of the effects of oral *N*-acetylcysteine in patients with chronic bronchitis and severe airways obstruction (P), 227
—— —— —— —— ——: Oral *N*-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction, 832
BRITTON JR, AGIUS RM, TATTERSFIELD AE: Airway adrenoceptor responsiveness in asthma (P), 715
——, BURNEY PGJ, CHINN S, PAPACOSTA AO, PEARSON D, TATTERSFIELD AE: The change in non-specific reactivity during the pollen season in a rural population sample (P), 694
——. *See also* HILL RA, BRITTON JR, *et al*
Bronchi, main, and trachea, inoperable malignant tumours of, treatment with iridium 192 and Neodym-YAG laser (P), 700
Bronchial asthma, nedocromil sodium for management of, trial of *(Letters)*, 400
asthma, neutrophil function in, effect of corticosteroids (P), 211
biopsy, fluorescence as guide to, 38
blood flow in sheep, measurement by video dilution technique, 143
carcinoma, acute respiratory failure after surgery for, mechanical ventilation for, 387
carcinoma, exercise performance and carbon monoxide transfer factor before and after lobectomy in (P), 723
carcinoma, extrathoracic lymph node aspiration in, 398
carcinoma, intraoperative assessment of nodal staging in (P), 700
carcinoma, non-small cell, chemotherapy in (E), 641
carcinoma, squamous, arising in case of multiple juvenile papillomatosis, 797
carcinomas, immunostaining with panel of monoclonal antibodies (P), 698
closure, automatic staplers in, clinical and laboratory evaluation of 2 types (P), 215
histamine reactivity in diabetics with and without autonomic neuropathy (P), 217
hyperreactivity to histamine in aspirin sensitive asthmatics, relationship to aspirin threshold and effect of aspirin desensitisation, 598
lavage and transbronchial lung biopsy in diagnosis of legionnaires' disease, 3 cases of, 154
lavage, therapeutic, in asthma (P), 707
mucosa, non-Hodgkin's lymphoma of, case presenting with reversible airflow obstruction, 954
reactivity, general practice survey of (P), 695
reactivity in patients with recent pulmonary sarcoidosis, 51
reactivity, non-specific, change during pollen season in rural population sample (P), 694
reactivity, respiratory symptoms and asthma (P), 695
reactivity, respiratory symptoms and atopy in young population sample (P), 695
reactivity, respiratory symptoms and lung function after pertussis in infancy (P), 690
reactivity to histamine and blood eosinophil and total white cell counts in smokers and ex-smokers (P), 718
reactivity to inhaled histamine and annual rate of decline in FEV_1 in male smokers and ex-smokers, 9; *Erratum*, 208
tumours, human, heterotransplantation to immunosuppressed mice as model for assessment of anticancer drugs (P), 698
Bronchiectasis and oligospermia in 2 families, 376
assessment by computed tomography, 920
diagnosis by computed tomography, assessment of accuracy and sensitivity (P), 692
progressive, due to 'vicious circle' host mediated damage, importance of 'colonising microbial load' in pathogenesis and treatment (P), 227
pulmonary epithelial permeability in (P), 238
purulent, treatment with nebulised antibiotics (P), 704
secretions in, treatment response with 3 amoxycillin regimes (P), 238
Bronchiolitis, obliterative, adult, lung permeability in (P), 722
Bronchioloalveolar carcinoma arising in longstanding lung cysts *(Letters)*, 960
Bronchitis, acute, and asthma, diagnosis in general practice (P), 689
acute, winter, autumnal asthma, respiratory syncytial virus and parainfluenza viruses 1 and 2 in general practice in UK (1976–84) (P), 690
chronic, acute exacerbations of, genesis of sputum histamine and role of bacteria in (P), 238
chronic, and asthma, hyperventilation and methacholine in, differences in responsiveness to, 422
chronic, and cancer, electron microscopic study of mast cells for associations with (P), 214
chronic, and emphysema, 'invalidity' due to, authenticity of, 828
chronic, and emphysema, oxygen conserving devices in, clinical assessment of 3 types, 820
chronic, and emphysema, right ventricular size at necropsy in, comparison with interstitial pulmonary fibrosis (P), 712
chronic, and emphysema, significance of single measurement of right ventricular ejection fraction in (P), 225
chronic, complicated by severe airways obstruction, effect of oral *N*-acetylcysteine on exacerbation rates in, multicentre study (P), 227; 832
chronic, decline of ventilatory function in, factors affecting, 741
chronic, hypoxic, pulmonary haemodynamics in, improved by long term therapy with oral $beta_2$ agonist? (P), 707
chronic, or α_1-proteinase inhibitor deficiency, lung lavage fluid cell profiles and neutrophil chemotactic factor in (P), 724
Bronchoalveolar cells, human, IgE dependent leucotriene C_4 and prostaglandin D_2 release from (P), 716
clearance, cell density as determinant of (P), 239
lavage and clearance of ^{99m}Tc labelled DTPA in asbestos workers without evidence of asbestosis (P), 221
lavage and measurement of pulmonary epithelial permeability in assessment of asbestosis, 508
lavage and transbronchial biopsy in diagnosis of AIDS associated pneumonia in Britain, early experience and difficulties, 166
lavage cells, human, newly generated mediators from, and histamine release (P), 220
lavage, diagnostic value in case of primary immunocytoma of lung, 542
lavage fluid cell profiles and neutrophil chemotactic factor in chronic bronchitis or α_1-proteinase inhibitor deficiency (P), 724
lavage fluid, human, mast cell and histamine content, 760
lavage fluid immunocompetent cells as reflection of cell populations in transbronchial biopsies in pulmonary sarcoidosis (P), 726
lavage fluid, lymphocyte fluctuation in normal volunteers, 651
lavage in asthma (P), 717
lavage in interstitial lung disease, macrophage like cells in, expression of abnormal phenotype by (P), 727
lavage in recovery of material from case of alveolar microlithiasis, 952
lavage in silicosis (P), 276
lavage inflammatory cells, secretion of fibroblast growth promoting activity by, in bleomycin induced pulmonary fibrosis in rabbit (P), 222
lavage mast cells in asthma and other respiratory diseases (P), 717
lavage, role in immunological monitoring after lung transplantation (P), 726
lavage samples from patients with chronic widespread pulmonary shadows, relevance of lipoprotein aggregates in (P), 221
lymphocytes and T cell subsets, changes in pulmonary sarcoidosis,

278
mast cells, hyperosmolar release of histamine from, and inhibition by sodium cromoglycate (P), 717
mast cells, hyperresponsiveness in sarcoidosis (P), 220
Bronchocentric granulomatosis associated with seropositive polyarthritis, case of, 396
Bronchoconstriction induced by exercise, protective role for circulating adrenaline against? (P), 715
induced by leucotriene D_4 in asthmatics, effect of verapamil (P), 714
induced by leukotriene D_4 in normal subjects, verapamil inhibition of (P), 217
induced by propranolol, plasma histamine concentration during, 903
overnight, in asthma, reduction by sleep deprivation (P), 225
Bronchoconstrictor agents, preferential sites of action differentiated by measurements of airway calibre and lung volumes and compliance? (P), 718
Bronchodilator actions of xanthine derivatives administered by inhalation in asthma, 176
effect of salbutamol, enhancement by nifedipine *(Letters)*, 399
Bronchodilators, effect on cough response to inhaled citric acid in normal and asthmatic subjects, 662
Bronchographic abnormalities in patients chronically producing purulent sputum, reporting and interpretation of (P), 692
Bronchography in assessment of patients with haemoptysis, reevaluation of, with analysis of 96 cases (1975–83), 668
Bronchopleural fistula, aetiology of, role of automatic staplers in, 27; *(Letters)*, 879
Bronchopulmonary endocrine cells immunoreactive for calcitonin in lungs of fetal and neonatal rats, 862
endocrine cells immunoreactive for calcitonin in normal adult human lung, quantitative study, 866
endocrine cells immunoreactive for calcitonin, widespread distribution in lung of normal adult rat, 194
infection with *Branhamella catarrhalis*, increasing incidence due to ampicillin or trimethoprim? (P), 691
Bronchoscope, rigid, new, for bronchoscopic laser therapy (P), 700
Bronchoscopic single breath tests in prediction of functional results of lobectomy (P), 236
Bronchoscopies, medical, UK postal survey of, drugs and safety precautions in (P), 210
Bronchoscopy, fibreoptic, flexible, in rapid diagnosis of sputum negative miliary tuberculosis (P), 696
fibreoptic, in investigation of community acquired pneumonia (P), 210
Bronchospasm provoked by histamine in asthmatics, refractory period following (P), 216
Bronchus, squamous papilloma of, solitary, 68
BROOKS JR. *See* HOLGATE ST, BROOKS JR, *et al*
BROPHY CJ, MIER AK, LANIGAN C, MOXHAM J, GREEN M: Aminophylline and skeletal muscle (P), 720
——. *See also* MIER AK, MILLER J, *et al*
——. *See also* SPITERI MA, MIER AK, *et al*
BROSTOFF J. *See* FLINT KC, HUDSPITH BN, *et al*
——. *See* FLINT KC, POZNIAK AL, *et al*
BROUGHTON DL, GIBSON CJ, CRAKE T, PEARCE SJ, LEONARD RCF: Gallium scanning by conventional imaging and emission computed tomography in the pretreatment evaluation of lung cancer, 96
BROWN K. *See* VENABLES K, DAVISON A, *et al*
BROWN MJ. *See* IND PW, BARNES PJ, *et al*
BROWN PJ: Asthma and irreversible airflow obstruction *(Letter)*, 80
BROWN RC. *See* DAVIES PDO, BROWN RC, *et al*
BROWNING MCK. *See* CLEE MD, FERGUSON J, *et al*
BRUNE J. *See* CORDIER JF, BAILLY C, *et al*
——. *See* CORDIER JF, CELLIER CC, *et al*
——. *See* WEYNANTS P, CORDIER JF, *et al*
BRYSON SE, RAEBURN D, RODGER IW: Effects of leucotriene D_4 and other agonists on ^{45}Ca efflux from airway smooth muscle (P), 713
BUIST TAS. *See* MACNEE W, BUIST TAS, *et al*
BULL TB. *See* MCCARTNEY A, BULL TB, *et al*
Bullous lung disease, assesment of (P), 214
lung disease, structure and function in (P), 710
BUNTING PS. *See* COHEN RD, BUNTING PS, *et al*
BUONAGUIDI R. *See* MUSSI A, JANNI A, *et al*
BURGE PS, FINNEGAN M, HORSFIELD N, EMERY D, AUSTWICK P, DAVIES PS, PICKERING CAC: Occupational asthma in a factory with a contaminated humidifier, 248
——, HARRIES MG, LAM WK, O'BRIEN IM, PATCHETT PA: Occupational asthma due to formaldehyde, 255
——. *See also* DURHAM SR, LEE TH, *et al*
——. *See also* GOVE RI, BURGE PS
——. *See also* LOZEWICZ S, DAVISON AG, *et al*
——. *See also* ROBERTSON AS, BURGE PS, *et al*
BURNETT D. *See* STOCKLEY RA, HILL SL, *et al*
——. *See* STOCKLEY RA, MORRISON HM, *et al*
BURNEY PGJ. *See* BRITTON JR, BURNEY PGJ, *et al*
BURR M. *See* CARSWELL F, BREWIN M, *et al*
BURR ML, MULLINS J, MERRET TG, STOTT NCH: Asthma and indoor mould exposure (P), 688
——, PHILLIPS KM, HURST DN: Lung function in the elderly, 54
BURTON GH, SEED WA, VERNON P: Computer analysis of ventilation-perfusion scans for detection and assessment of lung disease, 519
BURTON GR. *See* HAHN AG, NOGRADY SG, *et al*
BUSH A, BUSST CM, SHINEBOURNE EA, DENISON DM: Comparison of the effects of oxygen and prostacyclin as pulmonary vasodilators (P), 716
BUSS D. *See* EBDEN P, LEOPOLD D, *et al*
BUSST CM. *See* BUSH A, BUSST CM, *et al*
——. *See* MORGAN MDL, BUSST CM, *et al*
BUTCHART EG. *See* ASHOUR M, CAMPBELL IA, *et al*
BUTLAND RJA, COULSON IH: Pulmonary eosinophilia associated with cutaneous larva migrans, 76
——, JOSEPH AEA, SAUNDERS KB, WILSON AG: Cavitation in aseptic pulmonary infarction (P), 209
BUTLER J. *See* CARY JM, BUTLER J
BYFIELD SP. *See* DARBYSHIRE JH, BYFIELD SP, *et al*
——. *See* NUNN AJ, BYFIELD SP, *et al*
Byssinosis, atopy in, prevalence and effects (P), 224

C

CADIEUX A. *See* CHEUNG A, POLAK JM, *et al*
CADRANEL J, MILLERON B, GARABEDIAN M, AROUN G: Serum concentrations of vitamin D metabolites in untreated tuberculosis *(Letter)*, 639
Calcitonin, bronchopulmonary endocrine cells immunoreactive for, in lungs of fetal and neonatal rats, 862
bronchopulmonary endocrine cells immunoreactive for, in normal adult human lung, quantitative study, 866
bronchopulmonary endocrine cells immunoreactive for, widespread distribution in lung of normal adult rat, 194
gene related peptide as potent constrictor of airway smooth muscle (P), 713
Calcium, ^{45}Ca efflux from airway smooth muscle, effect of leucotriene D_4 and other agonists (P), 713
CALDER MA. *See* GOULD GA, RHIND GB, *et al*
——. *See* MCLEOD DT, AHMAD F, *et al*
CALVERLEY PMA, FLENLEY DC: Long term oxygen for hypoxic cor pulmonale—eight year follow up and prognostic factors (P), 711
——. *See also* MCLEOD DT, CALVERLEY PMA, *et al*
CAMERON IR. *See* COOPER CB, DAVIDSON AC, *et al*
CAMPBELL AH, BARTER CE, O'CONNELL JM, HUGGINS R: Factors affecting the decline of ventilatory function in chronic bronchitis, 741

CAMPBELL DA, DU BOIS RM, JANOSSY G, POULTER LW: Macrophage like cells in BAL fluid from patients with interstitial lung disease express abnormal phenotype (P), 727
——, POULTER LW, JANOSSY G, DU BOIS RM: Immunocompetent cells in BAL fluids reflect the cell populations in transbronchial biopsies in pulmonary sarcoidosis (P), 726
——, ——, ——, ——: Immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis suggesting local expression of immune hypersensitivity, 405
——, ——, ——, ——: Immunohistological analysis of lung tissue in cryptogenic fibrosing alveolitis (P), 221
CAMPBELL IA. *See* ASHOUR M, CAMPBELL IA, *et al*
——. *See* EBEJER MJ, SINGH H, *et al*
——. *See* FENNERTY AG, DOLBEN J, *et al*
——. *See* SINGH H, EBEJER MJ, *et al*
Cannabinoids. *See* Nabilone
CANT BR. *See* FRITH RW, CANT BR
CAPEWELL SJ (for Edinburgh Lung Cancer Group): Lung cancer in south east Scotland 1981–1984: the Edinburgh lung cancer group (P), 209
——, FRANCE AJ, UZEL N, LEITCH AG: Is BCG vaccination still necessary in Edinburgh? (P), 222
——. *See also* FRANCE AJ, CAPEWELL SJ, *et al*
——. *See also* MCLEOD DT, AHMAD F, *et al*
——. *See also* MCLEOD DT, CAPEWELL SJ, *et al*
Capillary plexus in gas exchange zone of human neonatal lung, ultrastructural study, 787
Capillary-alveolar barrier in adult respiratory distress syndrome, preservation of selective permeability at (P), 239
Carbenicillin and gentamicin in cystic fibrosis with pulmonary pseudomonas infection and exacerbation of respiratory symptoms, comparison with ceftazidime, 358; *Errata*, 728
Carbon dioxide laser photoresection in treatment of 2 cases of tracheobronchial amyloidosis, 870
dioxide, ventilatory response to, and minute ventilation, comparison of effects of aminophylline and salbutamol (P), 234
monoxide transfer factor and exercise performance in bronchial carcinoma before and after lobectomy (P), 723
monoxide transfer factor during exercise in normal subjects and in fibrosing alveolitis (P), 236
monoxide transfer factor, effect of ethanol (P), 233
monoxide transfer factor estimation, value in AIDS and persistent generalised lymphadenopathy (P), 223
monoxide transfer factor, pulmonary capillary blood flow, and lung tissue volume, simultaneous measurement of (P), 226
Carcinoid tumours, atypical, of lung, histological features and prognosis after surgery (P), 215
Carcinoma and chronic bronchitis, electron microscopic study of mast cells for associations with (P), 214
bronchial, acute respiratory failure after surgery for, mechanical ventilation for, 387
bronchial, exercise performance and carbon monoxide transfer factor before and after lobectomy in (P), 723
bronchial, extrathoracic lymph node aspiration in, 398
bronchial, intraoperative assessment of nodal staging in (P), 700
bronchial, non-small cell, chemotherapy in (E), 641
bronchial, squamous, arising in case of multiple juvenile papillomatosis, 797
bronchioloalveolar, arising in longstanding lung cysts *(Letter)*, 960
of lung, gallium scanning by conventional imaging and emission computed tomography in pretreatment evaluation of, 96
of lung in south east Scotland, 1981–84, Edinburgh Lung Cancer Group survey (P), 209
of lung, mediastinal imaging in (P), 209
of lung, non-small cell, inoperable, cisplatin, vinblastine, and bleomycin in, 346
of lung, oat cell, 5 year survival after surgery for, influence of tumour size and positive lymph nodal invasion (P), 701
of lung, primary, and solitary brain metastasis, combined surgical treatment of, 191
of lung, small-cell, combination chemotherapy or selective palliative treatment for, adverse reactions and quality of life during (P), 699
of lung, small cell, maintenance *v* no maintenance chemotherapy for, trial of (P), 699
of lung, small cell, neurone specific enolase as diagnostic serum marker for, 85
of lung, small cell, treatment policy of surgery in, analysis of 874 consecutive patients (1973–81), 272
of lung, squamous cell, advanced, trials of etoposide *v* no treatment and etoposide *v* etoposide + cyclophosphamide (P), 703
of oesophagus, squamous, *in situ*, in patient with achalasia, 795
renal, regression of pulmonary metastases with long term remission in patient with, 201
squamous cell, and granular cell myoblastoma, contiguous, in oesophagus, case of, 551
Carcinomas, bronchial, immunostaining with panel of monoclonal antibodies (P), 698
Cardiac and metabolic effects of nebulised salbutamol in normal volunteers (P), 706
dysrhythmias and nebuliser therapy in COAD (P), 704
tamponade due to Lancefield group A β haemolytic streptococcal pericarditis, case of, 549
See also Heart
Cardiopulmonary bypass, haemodialysis and haemofiltration during, 101
bypass, oxidative injury associated with, and neutrophil kinetics (P), 240
bypass, raised hemidiaphragm after, incidence and aetiology, 444
Cardiorespiratory consequences of idiopathic scoliosis (P), 701
CARMICHAEL J. *See* FERGUSSON RJ, CARMICHAEL J, *et al*
CARNOT F. *See* HOMASSON JP, BONNIOT JP, *et al*
CARR D. *See* OPENSHAW PJM, HUGHES JMB, *et al*
CARROLL M. *See* MOQBEL R, DURHAM SR, *et al*
CARSWELL AM. *See* CARSWELL F, BREWIN M, *et al*
CARSWELL F, BREWIN M, HUGHES AO, BURR M, CARSWELL AM: Asthma in Avon schoolchildren (P), 694
CARTER R. *See* AHMEDZAI S, CARTER R, *et al*
——. *See* NEILLY JB, CARTER R, *et al*
CARY JM, BUTLER J: Coughs cause systemic blood flow *(Letter)*, 160
Catalase and methionine sulfoxide-peptide reductase, effects *in vitro* and *in vivo* on oxidation of α_1-proteinase inhibitor (P), 724
CATTERALL JC. *See* RHIND GB, CATTERALL, JC, *et al*
CATTERALL M. *See* BLAKE PR, CATTERALL M, *et al*
CAVANAGH P. *See* JONES DK, CAVANAGH P, *et al*
CAYTON RM. *See* PACKE GE, CAYTON RM, *et al*
——. *See* PACKE GE, EDWARDS CW, *et al*
Ceftazidime in cystic fibrosis with pulmonary pseudomonas infection and exacerbation of respiratory symptoms, comparison with gentamicin and carbenicillin, 358; *Errata*, 728
nebulised, in adults with cystic fibrosis infected with *Ps aeruginosa*, comparison with gentamicin and carbenicillin (P), 704
CELESTINO D. *See* WARDLAW AJ, CROMWELL O, *et al*
CELLIER CC. *See* CORDIER JF, CELLIER CC, *et al*
——. *See* WEYNANTS P, CORDIER JF, *et al*
Cells, number and proliferation in alveolar walls, effect of cigarette smoking (P), 214
CHADWICK GA, GLAZEBROOK K, STRADLING JR, LANE DJ: Effect of intermittent positive pressure breathing and jet nebuliser on the breathing pattern (P), 233
——, STRADLING JR, FREW AJ: Changes in ventilation and its components in normal subjects during sleep (P), 235
——. *See also* STRADLING JR, CHADWICK GA, *et al*
CHAIEB J, BELCHER NG, REES PJ, CLARK TJH: Can you better a beta stimulant? (P), 212
CHAILLEUX E, BIGNON JD, PEYRAT MA, GODARD A, SOULILLOU JP: Lymphocyte subsets, phytohaemagglutinin responsiveness of blood lymphocytes, and interleukin 2 production in sarcoidosis, 768
CHAMBERLAIN DW. *See* COHEN RD, BUNTING PS, *et al*

CHAN TB, ANDERSON J, EISER NM, REES PJ: Pulmonary epithelial permeability in bronchiectasis (P), 238
——, SHELTON DM, REES PJ, EISER NM: Histamine induced changes in pulmonary epithelial permeability via H_1-receptors (P), 720
——. *See also* REES PJ, SHELTON DM, *et al*
——. *See also* SHELTON DM, REES PJ, *et al*
——. *See also* SHELTON DM, YOULTEN LJF, *et al*
CHAPEL H. *See* SHAW DJ, CHAPEL H, *et al*
CHARETTE L. *See* WILSON N, CHARETTE L, *et al*
CHEIX F. *See* CORDIER JF, BAILLY C, *et al*
Chest disease, monoclonal gammopathies in, 629
injury complicated by shock induced necrosis of colon, case of, 556
radiograph, plain, estimation of tumour volume from, accuracy of (P), 699
wall and neuromuscular disease, cuirass assisted ventilation in (P), 701
wall disease, restrictive, nocturnal hypoventilation in, protriptyline for (P), 702
CHETTY MN. *See* KELLY CA, CHETTY MN
CHEUNG A, POLAK JM, BAUER FE, CADIEUX A, CHRISTOFIDES ND, SPRINGALL DR, BLOOM SR: Distribution of galanin immunoreactivity in the respiratory tract of pig, guinea pig, rat, and dog, 889
CHINN DJ, NARUSE Y, COTES JE: External quality assessment of lung function laboratories (P), 710
——. *See also* EL-GAMAL FM, CHINN DJ, *et al*
CHINN S. *See* BRITTON JR, BURNEY PGJ, *et al*
CHINNERY JB. *See* MORRIS DL, CLARKSON MJ, *et al*
CHIODINI PL, WILLIAMS AJ, BARKER J, INNES JA: Bronchial lavage and transbronchial lung biopsy in the diagnosis of legionnaires' disease, 154
Cholinergic blockade, effect of intravenous VIP after (P), 714
CHOWIENCZYK P, LAWSON C, PARRY D, REES PJ, COCHRANE GM: A computerised low cost respiratory testing machine (P), 710
CHRISTOFIDES ND. *See* CHEUNG A, POLAK JM, *et al*
CHRYSTYN H. *See* PEAKE MD, CHRYSTYN H, *et al*
CHUANG MT. *See* ROSEN MJ, TOW TWY, *et al*
CHURG A. *See* SINCLAIR W, WRIGHT JL, *et al*
Chylothorax after surgery for patent ductus arteriosus *(Letter)*, 960
Cilia from sites of purulent infection, beat frequency reduced *in vitro* (P), 691
Ciliary beat frequency and mucociliary clearance, nasal, human, effects of betamethasone alone and with neomycin nasal drops, 607
function, human, *in vitro*, effect of bacterial products, 125
Ciliioinhibitory factor produced by *Pseudomonas aeruginosa*, characterisation of (P), 238
Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer, 346
Citric acid, cough response to, in normal humans, effect of inhaled codeine (P), 708
acid, inhaled, cough response to, diurnal variation and adaptation in normal subjects, 657
acid, inhaled, cough response to, effect of bronchodilators in normal and asthmatic subjects, 662
CITRON KM. *See* DARBYSHIRE JH, BYFIELD SP, *et al*
——. *See* NUNN AJ, BYFIELD SP, *et al*
CLARK CJ. *See* NEILLY JB, CLARK CJ, *et al*
CLARK RA. *See* CLEE MD, FERGUSON J, *et al*
CLARK TJH. *See* AYRES JG, POPE FM, *et al*
——. *See* CHAIEB J, BELCHER N, *et al*
——. *See* REES PJ, SHELTON DM, *et al*
——. *See* SHELTON DM, REES PJ, *et al*
——. *See* VERMEIRE P, JANSSENS E, *et al*
CLARKE JH. *See* HETZEL MR, CLARKE JH, *et al*
CLARKE SW. *See* CLAY MM, PAVIA D, *et al*
——. *See* GEORGE RJD, JOHNSON MA, *et al*
——. *See* MILLAR AB, AGNEW JE, *et al*
——. *See* MILLAR AB, O'REILLY AP, *et al*
——. *See* NEWMAN SP, PELLOW PGD, *et al*
——. *See* PAVIA D, BATEMAN JRM, *et al*
——. *See* TAYLOR RG, PAVIA D, *et al*
——. *See* TAYLOR RG, WOODMAN F, *et al*
CLARKSON MJ. *See* MORRIS DL, CLARKSON MJ, *et al*
CLAY MM, PAVIA D, CLARKE SW: Does nebulised bronchodilator aerosol droplet size matter? (P), 222
——. *See also* NEWMAN SP, PELLOW PGD, *et al*
CLEE MD, FERGUSON J, BROWNING MCK, JUNG RT, CLARK RA: Glucocorticoid hypersensitivity in an asthmatic patient: presentation and treatment, 477
CLITSAKIS D. *See* RUSSO PA, WRIGHT JEC, *et al*
COADY T. *See* REEVE P, LAPP NL, *et al*
COAKLEY J. *See* GORDON IJ, COAKLEY J, *et al*
Coalminers in US, longitudinal decline in FEV_1 in, 132
COATES AS. *See* STUART-HARRIS R, FOX RM, *et al*
COCHRANE GM. *See* CHOWIENCZYK P, LAWSON C, *et al*
——. *See* HORN CR, COCHRANE GM
——. *See* HORN CR, ESSEX E, *et al*
——. *See* LEWIS LD, O'DRISCOLL R, *et al*
COCKCROFT A. *See* BEAUMONT A, COCKCROFT A, *et al*
COCKRILL BL. *See* ROBERTSON AS, BURGE PS, *et al*
Codeine, inhaled, effect on cough response to citric acid in normal humans (P), 708
COE CI, BARNES PJ: Treatment of nocturnal asthma with an inhaled anticholinergic (P), 705
——, PRIDE NB: Effects of correcting arterial hypoxaemia on respiratory resistance in patients with chronic airflow obstruction (P), 709
Coeliac disease, adult, airways obstruction, asthma, and skin atopy in (P), 224
disease, adult, gluten induced asthma in (P), 229
COFFEY M, MCNICHOLAS WT, FITZGERALD MX: ventilation and gas exchange during sleep in patients with pulmonary fibrosis (P), 236
COHEN AS. *See* BREUER R, SIMPSON GT, *et al*
COHEN RD, BUNTING PS, MEINDOK HO, CHAMBERLAIN DW, REBUCK AS: Does serum angiotensin converting enzyme reflect intensity of alveolitis in sarcoidosis?, 497
Cold air inhalation in simplified in simplified standard test for airway reactivity (P), 216
COLE PJ, ROBERTS D, HIGGS E, PRIOR C: 'Colonising microbial load': a cardinal concept in the pathogenesis and treatment of progressive bronchiectasis due to 'vicious circle' host mediated damage (P), 227
——. *See also* AGIUS RM, KNIGHT RK, *et al*
——. *See also* AGIUS RM, PETRICEVIE I, *et al*
——. *See also* COOKE J, CURRIE DC, *et al*
——. *See also* CURRIE DC, COLE PJ
——. *See also* GREENSTONE MA, RUTMAN A, *et al*
——. *See also* GREENSTONE MA, STANLEY PJ, *et al*
——. *See also* MORRISON HM, SYKES D, *et al*
——. *See also* MUNRO CS, MITCHELL DN, *et al*
——. *See also* OLIVER MH, COLE PJ, *et al*
——. *See also* ROBERTS D, HIGGS E, *et al*
——. *See also* STANLEY PJ, GRIFFIN WM, *et al*
——. *See also* SYKES D, WILSON R, *et al*
——. *See also* WILSON R, COLE PJ
——. *See also* WILSON R, PITT T, *et al*
——. *See also* WILSON R, ROBERTS D, *et al*
Colitis, ulcerative, and pyoderma gangrenosum, severe steroid responsive pneumonitis associated with, case of, 314
COLLINS G. *See* MCCONNOCHIE K, EDWARDS J, *et al*
COLLINS JV. *See* BOOKER HA, PANTIN CFA, *et al*
——. *See* WARDLAW AJ, CROMWELL O, *et al*
Colon, necrosis of, induced by shock, chest injury complicated by, case of, 556
Complement activation and change in lung function with intravenous radiological contrast material (P), 240
Computed tomography in assessment of bronchiectasis, 920
tomography in diagnosis of bronchiectasis, assessment of accuracy and sensitivity (P), 692

Computer analysis of ventilation-perfusion scans for detection and assessment of lung disease, 519
system for prescibing of theophylline (and other drugs) (P), 230
Computerised low cost respiratory testing machine (P), 710
CONNOLLY MJ, HENDRICK DJ: Refractory period following histamine provoked bronchospasm in asthmatic subjects (P), 216
Contraceptives, oral, effect on airway responsiveness to methacholine, and changes during natural menstrual cycle (P), 718
COOKE J, CURRIE DC, MORGAN A, KERR I, DELANY D, STRICKLAND B, COLE PJ: Assessment of the accuracy and sensitivity of computerised tomography in the diagnosis of bronchiectasis (P), 692
——, ——, ——, ——, ——, ——, ——: What is the meaning of bronchographic abnormalities seen in patients chronically producing purulent sputum? (P), 692
COOKE NJ. *See* SIMPSON FG, ARNOLD AG, *et al*
COOKSON JB. *See* FARROW PR, JONES DA, *et al*
——. *See* FARROW PR, PILLAI DK, *et al*
COOKSON WOCM, JOHN S, MCCARTHY G, MCCARTHY S, LANE DJ: Nebuliser therapy and cardiac dysrhthmias in patients with COAD (P), 704
——, MUSK AW, RYAN G: Respiratory symptoms, atopy and bronchial reactivity: a random young population sample (P), 695
——, WISEMAN MS, SHALE DJ: Angiotensin converting enzyme and endotoxin induced lung damage in the mouse, 774
——, ——, ——: Angiotensin converting enzyme and septic acute respiratory distress syndrome in the mouse (P), 239
COOPER BG. *See* GILMARTIN JJ, VEALE D, *et al*
COOPER CB, DAVIDSON AC, CAMERON IR: Chronic aminophylline therapy in normocapnic obstructive airways disease (P), 720
——, TREND P ST J, WILES CM: Severe diaphragm weakness in multiple sclerosis, 633
COPE T. *See* APPS MCP, KOPELMAN PG, *et al*
——. *See* APPS MCP, WALLIS PJW, *et al*
Cor pulmonale, acute and chronic, right ventricular function in, acute effects of oxygen (P), 711
pulmonale and secondary polycythaemia, calf blood flow in, effects of packed cell volume reduction (P), 237
pulmonale, chronic, acute haemodynamic effects of nifedipine at rest and during maximal exercise in, 910
pulmonale, chronic, hormones and haemodynamics at rest and on exercise before and after nifedipine in (P), 225
pulmonale, hypoxic, long term oxygen for, 8-year follow up and prognostic factors (P), 711
pulmonale, hypoxic, renin-angiotensin system in, effects of reversal of polycythaemia (P), 226
pulmonale, stable, chronic, transpulmonary formation of angiotensin II in (P), 225
CORBISHLEY C. *See* HURLEY P, CORBISHLEY C, *et al*
CORDIER JF, BAILLY C, TABONE E, CHEIX F, BRUNE J, TOURAINE R: Alveolar soft part sarcoma presenting as asymptomatic pulmonary nodules: report of a case with ultrastructural diagnosis, 203
——, CELLIER CC, VINCENT M, LOIRE R, CREYSSEL R, BRUNE J: Monoclonal gammopathies in chest disease, 629
——. *See also* WEYNANTS P, CORDIER JF, *et al*
CORMIER Y, BÉLANGER J, DURAND P: Factors influencing the development of serum precipitins to farmer's lung antigen in Quebec dairy farmers, 138
Coronary artery bypass grafting, phrenic nerve and diaphragm function after, 293
artery bypass. *See also* Aortocoronary bypass
artery, left, aberrant origin of, with associated aortic stenosis, case of, 152
artery, right, supply to left ventricle, variable anatomy of, 618
CORRADO OJ, GOMEZ E, BALDWIN DL, SWANSTON AR, DAVIES RJ: Direct evidence for mast cell involvement in type I allergic reactions in man (P), 218
——. *See also* OSMAN J, CORRADO OJ, *et al*
Corrections, 80, 208, 400, 728
CORRIN B, DANEL C, ALLAWAY A, WARNER JO, LENNEY W: Intralobar pulmonary sequestration of ectopic pancreatic tissue with gastropancreatic duplication, 637
——. *See also* HYDERMAN E, LARKIN S, *et al*
CORRIS PA, GIBSON GJ: Nifedipine enhances the bronchodilator effect of salbutamol *(Letter)*, 399
——, KENDRICK AH, GIBSON GJ: Exercise performance and carbon monoxide transfer factor in patients with carcinoma of the bronchus before and after lobectomy (P), 723
——, ——, ——: Use of bronchoscopic single breath tests to predict functional results of lobectomy (P), 236
Corticosteroids, acute effects in chronic airflow obstruction (P), 232
effect on neutrophil function in bronchial asthma (P), 211
oral, in treatment of exacerbations of asthma, dose-response characteristics of (P), 228
Corynebacterium parvum pleurodesis in malignant pleural effusion, survival after, comparison with mustine pleurodesis, 515
CORY-PEARCE R. *See* LARGE SR, HEYWOOD LJ, *et al*
COSTELLO JF. *See* HEATON RE, GUY RJC, *et al*
COTES JE. *See* CHINN DJ, NARUSE Y, *et al*
——. *See* EL-GAMAL FM, CHINN DJ, *et al*
——. *See* PEARCE SJ, POSNER V, *et al*
Cough induced by ultrasonically nebulised water related to aerosol particle charge (P), 718
oral salbutamol and pholcodine for (P), 210
response to citric acid in normal humans, effect of inhaled codeine (P), 708
response to inhaled citric acid, diurnal variation and adaptation in normal subjects, 657
response to inhaled citric acid, effect of bronchodilators in normal and asthmatic subjects, 662
Coughs as cause of systemic blood flow *(Letters)*, 160
COULSON IH. *See* BUTLAND RJA, COULSON IH
COUTTS II, MACKENZIE S, WHITE RJ: Clinical and radiographic features of psittacosis infection, 530
COWELL TK. *See* TREACHER DF, COWELL TK, *et al*
COWIE H, LLOYD MH, SOUTAR CA: Study of lung function data by principal components analysis, 438
CRACKNELL N. *See* ASHFORD N, CRACKNELL N, *et al*
CRAKE T. *See* BROUGHTON DL, GIBSON CJ, *et al*
CRAMER D. *See* AL-HILLAWI AH, CRAMER D, *et al*
CREYSSEL R. *See* CORDIER JF, CELLIER CC, *et al*
CROMPTON GK. *See* DOUGLAS JG, RAFFERTY P, *et al*
——. *See* WILLEY RF, FERGUSSON RJ, *et al*
CROMWELL O. *See* MACKAY JA, CROMWELL O, *et al*
——. *See* SHAW RJ, DRAKE-LEE A, *et al*
——. *See* SHAW RJ, WALSH GM, *et al*
——. *See* WARDLAW AJ, CROMWELL O, *et al*
CROSS CE. *See* LINK DP, PARSONS GH, *et al*
CROUGHAN MJ. *See* GOULD GA, RHIND GB, *et al*
——. *See* MCLEOD DT, AHMAD F, *et al*
CUNDELL DR, DAVIES RJ: Human lymphocyte derived neutrophil chemotactic activity—partial characterisation and inhibition of release (P), 719
CURRIE DC, COLE PJ: Nebuliser therapy: patient compliance and problems (P), 705
——. *See also* COOKE J, CURRIE D, *et al*
CURZON FGD. *See* JOHNSON CE, CURZON FGD
CUSHLEY MJ, HOLGATE ST: Bronchodilator actions of xanthine derivatives administered by inhalation in asthma, 176
——. *See also* REED S, DIGGLE S, *et al*
CUSS F, LININGTON A, HULME B: The diagnostic problem of tuberculosis in uraemia: high incidence in ethnic minorities (P), 223
CUSS FMC, PALMER JBD, BARNES PJ: Rapid analysis of plasma theophylline concentrations in the clinical setting (P), 230
——. *See also* GRANDORDY B, CUSS FMC, *et al*
——. *See also* PALMER JBD, CUSS FMC, *et al*
Cyanoacrylates and methyl methacrylate, occupational asthma due to, 836
Cyanosis, multiple microscopic pulmonary arteriovenous connections presenting as, case of, 316
Cystic fibrosis, adenocarcinoma in, case of, 199

fibrosis, adverse reactions to piperacillin in adults with, 184
fibrosis, airflow obstruction in adults with, prednisolone in treatment of (P), 211
fibrosis, British Paediatric Association study (P), 693
fibrosis, 4 cases diagnosed in middle and later life, 23; *(Letter)*, 639
fibrosis in adults, factors affecting survival (P), 227
fibrosis, nasal electrical potential recordings as new diagnostic test for (P), 704
fibrosis, prednisolone pharmacokinetics in adults with (P), 708
fibrosis, *Ps aeruginosa* infected adults with, nebulised ceftazidime compared with gentamicin and carbenicillin in (P), 704
fibrosis, relationship of breathlessness to ventilation in, influence of regular exercise (P), 721
fibrosis, transepithelial potential difference in, 493
fibrosis with pulmonary pseudomonas infection and exacerbation of respiratory symptoms, ceftazidime compared with gentamicin and carbenicillin in, 358; *Errata*, 728
Cysts, hydatid, pulmonary, albendazole treatment in naturally infected sheep and implications for man, 453
of lung, longstanding, bronchioloalveolar carcinoma arising in *(Letter)*, 960

D

DACOSTA P. *See* VENN GE, DACOSTA P, *et al*
Dairy farmers in Quebec, serum precipitins to farmer's lung antigen in, factors influencing development of, 138
DALLIMORE NS: Squamous bronchial carcinoma arising in a case of multiple juvenile papillomatosis, 797
DALLY MB. *See* ASSOUFI BK, DALLY MB, *et al*
DALTON G. *See* ROBERTSON AS, BURGE PS, *et al*
Danazol, effect on biochemical abnormality of inherited antithrombin III deficiency, 646
DANEL C. *See* CORRIN B, DANEL C, *et al*
DANIEL EE. *See* JUNIPER EF, KLINE PA, *et al*
DARBYSHIRE JH, BYFIELD SP, CITRON KM, HUMPHRIES MJ, NUNN AJ, FOX W: Geographical distribution of notifications of tuberculosis in England and Wales in 1983 (P), 229
——. *See also* NUNN AJ, BYFIELD SP, *et al*
DAS R. *See* GARRARD CS, DAS R
DAVIDSON AC. *See* COOPER CB, DAVIDSON AC, *et al*
DAVIDSON K. *See* MILROY R, SMITH L, *et al*
DAVIDSON KG. *See* VIGNESWARAN WT, REECE IJ, *et al*
DAVIES BH. *See* FENNERTY AG, JONES KP, *et al*
DAVIES D. *See* LOZEWICZ S, DAVISON AG, *et al*
DAVIES EE. *See* JONES HA, DAVIES EE, *et al*
DAVIES H, GORDON I, HEAF D, HELMS P, MATTHEW D, NOVELLI V: Long term consequence of inhaling a foreign body (P), 700
DAVIES PDO, BROWN RC, WOODHEAD JS: Serum concentrations of vitamin D metabolities in untreated tuberculosis, 187; *(Letter)*, 640
DAVIES PS. *See* BURGE PS, FINNEGAN M, *et al*
DAVIES RJ. *See* BENNETT J, TOOLEY M, *et al*
——. *See* BLAINEY AD, OLLIER S, *et al*
——. *See* CORRADO OJ, GOMEZ E, *et al*
——. *See* CUNDELL DR, DAVIES RJ
——. *See* OSMAN J, CORRADO OJ, *et al*
——. *See* SHEINMAN BD, DEVALIA JL, *et al*
DAVIS PB, HUBBARD VS, GARVIN AJ: Bronchiectasis and oligospermia: two families, 376
DAVIS TME, SAWICKA EH: Adenocarcinoma in cystic fibrosis, 199
DAVISON A. *See* DURHAM SR, LEE TH, *et al*
——. *See* VENABLES K, DAVISON A, *et al*
DAVISON AG. *See* LOZEWICZ S, DAVISON AG, *et al*
DAWSON P. *See* FLINT KC, JOHNSON N MCI, *et al*
DE BACKER W. *See* VERMEIRE P, JANSSENS E, *et al*
DELAHUNT JW. *See* FORD HC, SAVAGE T, *et al*
DELANY D. *See* COOKE J, CURRIE DC, *et al*
DEMPSEY JP. *See* HOLGATE ST, BROOKS JR, *et al*
DENCH M. *See* MOGHISSI K, JESSOP A, *et al*
DENISON DM. *See* AL-HILLAWI AH, CRAMER D, *et al*
——. *See* ASSOUFI BK, DALLY MB, *et al*
——. *See* BUSH A, BUSST CM, *et al*
——. *See* GOLDMAN JM, MORGAN MDL, *et al*
——. *See* MORGAN MDL, BUSST CM, *et al*
——. *See* MORGAN MDL, GOURLAY AR, *et al*
DENNISON AR, WATKINS RM, GUNNING AJ: Simultaneous aortic and pulmonary artery aneurysms due to giant cell arteritis, 156
DEPLEDGE MH: Peak inspiratory flow: measurement using a modified mini Wright peak flow meter, 205
DERNEVIK L: Exogenous particles in lymph nodes in patients with shrinking pleuritis with atelectasis, 948
——, GATZINSKY P: Long term results of operation for shrinking pleuritis with atelectasis, 448
DESAI J. *See* ROYSTON D, FLEMING JS, *et al*
DE SMET J-M. *See* ESTENNE M, YERNAULT J-C, *et al*
DE TROYER A. *See* ESTENNE M, YERNAULT J-C, *et al*
DEVALIA JL. *See* SHEINMAN BD, DEVALIA JL, *et al*
DEWAR A. *See* HAY JG, DEWAR A, *et al*
——. *See* PANTIN CFA, DEWAR A, *et al*
DHILLON DP. *See* BOOKER HA, PANTIN DFA, *et al*
Diabetes with and without autonomic neuropathy, bronchial histamine reactivity in (P), 217
Diaphragm and phrenic nerve function after coronary artery bypass grafting, 293
effect of aminophylline, 288
weakness, and orthopnoea (P), 701
weakness, bilateral, case of, 631
weakness, severe, in multiple sclerosis, case of, 633
Diaphragmatic paralysis, bilateral, with neuralgic amyotrophy, case of, 635
paralysis, unilateral, exercise tests in (P), 214
DIAZ M. *See* BORZONE G, DIAZ M, *et al*
Didymella exitialis as cause of late summer asthma (P), 223
Diethylene triamine pentacetate, ^{99m}Tc labelled, clearance of, and bronchoalveolar lavage in asbestos workers without evidence of asbestosis (P), 221
triamine pentacetate, ^{99m}Tc-labelled, clearance of, in sarcoidosis with and without pulmonary involvement (P), 722
DIGGLE S. *See* REED S, DIGGLE S, *et al*
Digital subtraction angiography, intravenous, in suspected pulmonary embolism, comparison with radionuclide ventilation-perfusion lung scanning, 576
DIJKMAN JH. *See* STOCKLEY RA, MORRISON HM, *et al*
DIMOND AH. *See* BOOKER HA, PANTIN CFA, *et al*
DIXON CMS. *See* FULLER RW, DIXON CMS, *et al*
DOBSON N. *See* GREENING AP, NUNN P, *et al*
DODDS M. *See* O'NEILL PA, DODDS M, *et al*
DODGE JA, GEDDES DM, GOODALL J, LITTLEWOOD JM, MEARNS MB, RUSSELL G: British Paediatric Association cystic fibrosis study (P), 693
DOLBEN J. *See* FENNERTY AG, DOLBEN J, *et al*
DOLLERY CT. *See* FULLER RW, KEMENY DM, *et al*
——. *See* IND PW, BARNES PJ, *et al*
——. *See* IND PW, PETERS AM, *et al*
DOMBERNOWSKY P. *See* ØSTERLIND K, HANSEN M, *et al*
DONNELLY RJ, SASTRY MR, WRIGHT CD: Oesophagogastrectomy using the end to end anastomotic stapler: results of the first 100 patients, 958
DORNAN JC, MEBAN C: The capillary plexus in the gas exchange zone of human neonatal lung: an ultrastructural study, 787
DOUGLAS AC. *See* MACNEE W, BUIST TAS, *et al*
DOUGLAS JG, RAFFERTY P, FERGUSSON RJ, PRESCOTT RJ, CROMPTON GK, GRANT IWB: Nebulised salbutamol without oxygen in severe acute asthma: how effective and how safe?, 180
DOUGLAS NJ. *See* RHIND GB, CATTERALL JC, *et al*
——. *See* TWEEDDALE PM, DOUGLAS NJ

Down's syndrome and congenital heart disease, lung changes in, significance as cause of postoperative respiratory failure, 380
DOYLE P. *See* ASHFORD N, CRACKNELL N, *et al*
DRAKE-LEE A. *See* SHAW RJ, DRAKE-LEE A, *et al*
DROSZCZ W, PIOTROWSKA B: Comparison of oral prednisolone and intramuscular depot triamcinolone in patients with severe chronic asthma *(Letter)*, 207
D'SOUZA MF. *See* BENNETT J, TOOLEY M, *et al*
DU BOIS RM: The alveolar macrophage (E), 321
——. *See also* CAMPBELL DA, DU BOIS RM, *et al*
——. *See also* CAMPBELL DA, POULTER LW, *et al*
Ductus arteriosus, patent, chylothorax after surgery for *(Letter)*, 960
arteriosus, patent, ligation of, in very low birthweight premature neonates, 533
DUNCAN F. *See* HODSON ME, WISE AE, *et al*
DURAND P. *See* CORMIER Y, BÉLANGER J, *et al*
DURHAM SR, GLEICH GJ, LOEGERING D, KAY AB: Eosinophils and eosinophil major basic protein in allergen induced late phase asthmatic reactions (P), 218
——, GRANEEK BJ, HAWKINS R, NEWMAN-TAYLOR AJ: The temporal relationship between airway reactivity and late asthmatic reactions induced by occupational agents (P), 703
——, LEE TH, LOZEWICZ S, DAVISON A, BURGE PS, NEWMAN-TAYLOR AJ, KAY AB: Neutrophil chemotactic activity in asthmatic reactions induced by occupational exposure (P), 218
——. *See also* MOQBEL R, DURHAM SR, *et al*
DUSSEK JE. *See* HOCKEN DB, DUSSEK JE
Dyspnoea, grading of, and exercise performance in pulmonary and cardiac disease, comparison of (P), 721
severe, sternomastoid muscle function and fatiguability in (P), 721

E

Ear oximeter, Biox IIA, for measurement of arterial oxygenation, evaluation of (P), 708; 825
EBDEN P, LEOPOLD D, BUSS D, SMITH AP, ROUTLEDGE PA: Relationship between saliva and free and total plasma theophylline concentrations in patients with chronic airflow obstruction, 526
——. *See also* BANKS J, BEVAN C, *et al*
——. *See also* FANCOURT GJ, EBDEN P, *et al*
——. *See also* WALTERS EH, EBDEN, P, *et al*
EBEJER MJ, SINGH H, HIGGINS DA, FORSLING ML, HENDERSON AH, CAMPBELL IA: Chronic cor pulmonale: hormones and haemodynamics at rest and on exercise before and after nifedipine (P), 225
——. *See also* SINGH H, EBEJER MJ, *et al*
EDINBURGH LUNG CANCER GROUP: Lung cancer in south east Scotland 1981–1984: the Edinburgh lung cancer group (P), 209
Editorials:
The alveolar macrophage, 321
Chemotherapy in non-small cell bronchial carcinoma, 641
Contaminated humidifiers and the lung, 244
Difficulties in the treatment of acute pulmonary embolism, 729
Early lung development, 401
Funding respiratory research, 81
Heterogeneity of mechanisms in exercise induced asthma, 481
High frequency ventilation, 161
The pleural interface, 1
Pneumocystis carinii pneumonia, 561
Prognosis in occupational asthma, 241
Provision of long term oxygen therapy, 801
EDMONDSTONE WM. *See* HETZEL MR, NIXON C, *et al*
EDWARDS CW. *See* LAMB RK, EDWARDS CW, *et al*
——. *See* PACKE GE, CAYTON RM, *et al*
——. *See* PACKE GE, EDWARDS CW, *et al*
EDWARDS J. *See* MCCONNOCHIE K, EDWARDS J, *et al*
EDWARDS RHT. *See* EFTHIMIOU J, FLEMING J, *et al*
EFTHIMIOU J, FLEMING J, EDWARDS RHT, SPIRO SG: The effect of aminophylline on fatique of the sternomastoid muscle in man (P), 720
——, ——, ——, ——: Sternomastoid muscle function and fatiguability in patients with severe dyspnoea (P), 721
——, SPIRO SG: Pulmonary disease in Behçet's syndrome (P), 231
Ehlers-Danlos syndrome, lung and thoracic cage abnormalities in, 300
EISER NM. *See* CHAN TB, ANDERSON J, *et al*
——. *See* CHAN TB, SHELTON DM, *et al*
——. *See* REES PJ, SHELTON DM, *et al*
——. *See* SHELTON DM, REES PJ, *et al*
——. *See* SHELTON DM, YOULTEN LJF, *et al*
Elastase, neutrophil, inhibition by sputum, variability and relationship to known inhibitors (P), 725
Elderly, lung function in, 54
Electrical potential difference, transepithelial, in cystic fibrosis, 493
Electrocardiogram monitoring, 24 hour, in patients using air driven nebulisers (P), 231
EL-GAMAL FM, CHINN DJ, WELLER JJ, COTES JE: Effect of welding fumes on the lungs of young shipyard welders (P), 702
ELL PJ. *See* FLINT KC, JOHNSON N MCI, *et al*
ELLARD GA. *See* PEACH H, ELLARD GA, *et al*
ELLIOTT S. *See* LAMONT G, ELLIOTT S, *et al*
ELLIS CJ. *See* LEWIS RA, ELLIS CJ, *et al*
EMANUEL MB: Comparative trial of two non-sedative H_1 antihistamines, terfenadine and astemizole, for hay fever *(Letter)*, 799
Embolisation of disc and strut after minor strut fracture in Björk-Shiley mitral valve prosthesis, case of, 158
Embolism, pulmonary, acute, treatment of, problems in (E), 729
pulmonary, suspected, comparison of intravenous digital subtraction angiography with radionuclide ventilation-perfusion lung scanning in, 576
Embolus, pulmonary, and deep vein thrombosis, 3 weeks' versus 6 weeks' anticoagulation in treatment of (P), 707
EMERSON PA. *See* BLAKE PR, CATTERALL M, *et al*
——. *See* WALLIS PJW, BRANFOOT AC, *et al*
EMERY D. *See* BURGE PS, FINNEGAN M, *et al*
EMPEY DW. *See* APPS MCP, KOPELMAN PG, *et al*
——. *See* APPS MCP, WALLIS PJW, *et al*
——. *See* WALLIS PJW, APPS MCP, *et al*
——. *See* WALLIS PJW, FEW JD, *et al*
Emphysema and chronic bronchitis, 'invalidity' due to, authenticity of, 828
and chronic bronchitis, oxygen conserving devices in, clinical assessment of 3 types, 820
and chronic bronchitis, right ventricular size at necropsy in, comparison with interstitial pulmonary fibrosis (P), 712
and chronic bronchitis, significance of single measurement of right ventricular ejection fraction in (P), 225
production in smokers and oxygen centred free radicals in cigarette smoke (P), 220
Empyema and lung abscess (P), 691
pleural, *Streptococcus milleri* as cause of, 626
Endocardectomy for treatment of endomyocardial fibrosis of left ventricle, with results in 2 cases, 621
Endocrine cells, bronchopulmonary, immunoreactive for calcitonin, in lungs of fetal and neonatal rats, 862
cells, bronchopulmonary, immunoreactive for calcitonin, in normal adult human lung, quantitative study, 866
cells, bronchopulmonary, immunoreactive for calcitonin, widespread distribution in lung of normal adult rat, 194
Endomyocardial fibrosis of left ventricle, endocardectomy for treatment of, with results in 2 cases, 621
Endothelial cell dependent relaxation of pulmonary artery in man, evidence of (P), 715
Endotoxin, *E coli*, lung damage induced by, and angiotensin converting enzyme in mouse, 774
ENGLISH J. *See* STEAD RJ, PANTIN CFA, *et al*

ENGLISH TAH. *See* HAKIN M, WHEELDON D, *et al*
——. *See* LARGE SR, HEYWOOD LJ, *et al*
Enteric Gram negative bacilli, antibodies to, increase after open heart surgery, postoperative pyrexia due to?, 538
Eosinophil and total white cell counts in blood and bronchial reactivity to histamine in smokers and ex-smokers (P), 718
Eosinophilia, pulmonary, associated with cutaneous larva migrans, case of, 76
Eosinophils and eosinophil major basic protein in allergen induced late phase asthmatic reactions (P), 218
human, IgG mediated release of leucotriene C_4 from, relevance to asthma and hypereosinophilia (P), 716
Epidermal growth factor and receptor in normal and malignant lung tissue (P), 698
Epithelial markers in mesotheliomas, immunoperoxidase study of epithelial membrane antigen, cytokeratin, and carcinoembryonic antigen as (P), 215
permeability and histamine in normal and asthmatic subjects (P), 217
Escherichia coli antiendotoxin in prevention of fever and Gram negative infection after open heart surgery, 846
coli endotoxin, lung damage induced by, and angiotensin converting enzyme in mouse, 774
ESSCHER T, STEINHOLTZ L, BERGH J, NÖU E, NILSSON K, PÅHLMAN S: Neurone specific enolase: a useful diagnostic serum marker for small cell carcinoma of the lung, 85
ESSEX E. *See* HORN CR, ESSEX E, *et al*
ESTENNE M, YERNAULT J-C, DE SMET J-M, DE TROYER A: Phrenic and diaphragm function after coronary artery bypass grafting, 293
Ethanol, effect on transfer factor (P), 233
Etoposide in advanced squamous carcinoma of lung, trials of etoposide *v* no treatment and etoposide *v* etoposide + cyclophosphamide (P), 703
EVANS AR, WOLSTENHOLME RJ, SHETTAR SP, YOGISH H: Primary pleural liposarcoma, 554
EVANS CC. *See* GRAHAM DR, LUKSZA AR, *et al*
——. *See* WALSHAW MJ, EVANS CC
EVEMY K. *See* RHODES KM, EVEMY K, *et al*
Exercise and allergen, asthma induced by, nedocromil inhibition of (P), 219
and 12 minute walk, effect on sternomastoid muscle (P), 721
asthma induced by, heterogeneity of mechanisms in (E), 481
asthma induced by, neutrophil and monocyte cytotoxicity enhanced after (P), 218
asthma induced by, plasma sodium cromoglycate levels with nebuliser and metered dose aerosol in (P), 212
asthma induced by, sodium cromoglycate aerosol in, dose-duration effect of (P), 706
asthma induced by, sodium cromoglycate pressurised aerosol in, dose-response effect of, 41
bronchoconstriction induced by, protective role for circulating adrenaline against? (P), 715
carbon monoxide transfer factor during, in normal subjects and in fibrosing alveolitis (P), 236
in asthma with warm, humid inspirate, absence of refractoriness after, 418
late asthmatic response induced by, factors predisposing to (P), 219
maximal, and rest in chronic cor pulmonale, acute haemodynamic effects of nifedipine during, 910
performance and carbon monoxide transfer factor in bronchial carcinoma before and after lobectomy (P), 723
performance and grading of dyspnoea in pulmonary and cardiac disease, comparison of (P), 721
performance and static lung function, effects of mitral valve surgery, 107
regular, influence on relationship of breathlessness to ventilation in cystic fibrosis (P), 721
steady state, in chronic lung disease, effect of oral high frequency oscillation (P), 213
tests in unilateral diaphragmatic paralysis (P), 214
tests, 3 types of, in chronic obstructive lung disease, performance, ventilation, and oxygen consumption in, 581
tolerance, inprovement of, and relief of breathlessness, portable oral high frequency oscillator for (P), 710
Expiratory volume, forced, in one second. *See* FEV_1
EYKYN SJ. *See* NEILD JE, EYKYN SJ, *et al*

F

FAARUP P. *See* FAURSCHOU P, FRANCIS D, *et al*
FABA J. *See* BORZONE G, DIAZ M, *et al*
FAICHNEY A. *See* MILROY R, SMITH L, *et al*
——. *See* VIGNESWARAN WT, HARDIE R, *et al*
FAIRFAX AJ, IBBOTSON RM: Effect of danazol on the biochemical abnormality of inherited antithrombin II deficiency, 646
FANCOURT GJ, EBDEN P, STOYLE TF, GARNER P: Bone tuberculosis in Leicestershire (P), 696
——. *See also* FARROW PR, PILLAI DK, *et al*
Farmer's lung antigen, serum precipitins to, factors influencing development in Quebec dairy farmers, 138
FARR B (for BTS Research Committee): BTS pneumonia study: design and outcome (P), 693
FARROW PR, JONES DA, STANLEY PJ, BAILEY JS, WALES JM, COOKSON JB: Thoracic lymphadenopathy in Asians resident in the United Kingdom: role of mediastinoscopy in initial diagnosis, 121
——, PILLAI DK, FANCOURT GJ, COOKSON JB: Hypoxia and secondary polycythaemia: their relative effects on mental function in respiratory disease (P), 231
Fat necrosis, local, secondary to continuous subcutaneous terbutaline infusion in unstable asthmatics (P), 705
FAURSCHOU P, FRANCIS D, FAARUP P: Thoracoscopic, histological, and clinical findings in nine cases of rheumatoid pleural effusion, 371
FAUX JA. *See* SHALE DJ, FAUX JA, *et al*
FAYERS PM. *See* BLEEHEN NM, FAYERS PM, *et al*
FENNERTY AG, BANKS J, BEVAN C, SMITH AP: Role of airway receptors in the breathing pattern of patients with chronic obstructive lung disease, 268; *(Letter)*, 880
——, DOLBEN J, CAMPBELL IA, ROUTLEDGE PA: Three weeks' versus six weeks' anticoagulation in the treatment of deep vein thrombosis and pulmonary embolus (P), 707
——, JONES KP, DAVIES BH: How does immunotherapy work in hay fever? (P), 727
——, ——, ——: Nasal sensitivity and suppressor cell function in hay fever sufferers (P), 239
——. *See also* BANKS J, BEVAN C, *et al*
——. *See also* WALTERS EH, EBDEN P, *et al*
FERGUSON J. *See* CLEE MD, FERGUSON J, *et al*
FERGUSON JC. *See* VIGNESWARAN WT, HARDIE R, *et al*
FERGUSSON RJ, CARMICHAEL J, ANDERSON LE, SMYTH JF: Heterotransplantation of human bronchial tumours to immunosuppressed mice: a useful model for assessing anticancer drugs (P), 698
——. *See also* DOUGLAS JG, RAFFERTY P, *et al*
——. *See also* WILLEY RF, FERGUSSON RJ, *et al*
FERNANDEZ REGO G, ROMÁN ROJO A: Asthma and irreversible airflow obstruction *(Letter)*, 80
FEV_1, annual rate of decline in, and bronchial reactivity to inhaled histamine in male smokers and non-smokers, 9; *Erratum*, 208
decline over 10 years in middle aged men, effects of number and tar content of cigarettes smoked (P), 690
longitudinal decline in US coalminers, 132
normal and accelerated rate of decline in, smoking pattern in middle aged men with (P), 710
Fever and Gram negative infection after open heart surgery, prevention by *E coli* antiendotoxin, 846
FEW JD. *See* WALLIS PJW, FEW JD, *et al*

Fibreoptic bronchoscopy, flexible, in rapid diagnosis of sputum negative miliary tuberculosis (P), 696
bronchoscopy in investigation of community acquired pneumonia (P), 210
Fibroblast growth promoting activity, secretion by lavage inflammatory cells in bleomycin induced pulmonary fibrosis in rabbit (P), 222
Fibrosis, endomyocardial, of left ventricle, endocardectomy for treatment of, with results in 2 cases, 621
pulmonary, induced by bleomycin in rabbits, progress of (P), 222
pulmonary, induced by bleomycin in rabbits, secretion of fibroblast growth promoting activity by lavage inflammatory cells in (P), 222
pulmonary, interstitial, right ventricular size at necropsy in comparison with chronic bronchitis and emphysema (P), 712
pulmonary, ventilation and gas exchange during sleep in (P), 236
FIELD GB: Occupational asthma due to heated freon *(Letter)*, 320
——: Pulmonary function in aluminium smelters *(Letter)*, 319
FIFIELD R. *See* MCCONNOCHIE K, EDWARDS J, *et al*
FINCH RG. *See* MACFARLANE JT, FINCH RG
FINLAYSON NDC. *See* MACNEE W, BUIST TAS, *et al*
FINNEGAN M. *See* BURGE PS, FINNEGAN M, *et al*
——. *See* HONEYBOURNE D, FINNEGAN M, *et al*
——. *See* ROBERTSON AS, BURGE PS, *et al*
FINNEGAN OC. *See* WARLEY ARH, NICHOLSON EM, *et al*
FISHER A. *See* SHAW DJ, CHAPEL H, *et al*
Fistula, bronchopleural, aetiology of, role of automatic staplers in, 27; *(Letters)*, 879
FITZGERALD MD. *See* MANNION P, HONAN RP, *et al*
FITZGERALD MX. *See* COFFEY M, MCNICHOLAS WT, *et al*
——. *See* NOLAN MT, FITZGERALD MX
——. *See* NOLAN MT, GIBNEY N, *et al*
——. *See* O'CONNOR CM, O'BRIEN A, *et al*
FITZHARRIS P. *See* SHAW RJ, DRAKE-LEE, *et al*
——. *See* WARDLAW AJ, CROMWELL O, *et al*
FLEMMING J. *See* EFTHIMIOU J, FLEMING J, *et al*
FLEMMING JS. *See* ROYSTON D, FLEMING JS, *et al*
FLENLEY DC. *See* CALVERLEY PMA, FLENLEY DC
——. *See* FRANCE AJ, PRINCE KL, *et al*
——. *See* GOULD GA, HAYHURST MD, *et al*
——, *See* GOULD GA, SCOTT W, *et al*
——. *See* MACNEE W, WHYTE KF, *et al*
——. *See* SCOTT W, GOULD GA, *et al*
——. *See* WOOD NE, FLENLEY DC, *et al*
FLETCHER CM, PRIDE NB: A substitute for 'small airway disease'? *(Letter)*, 479
FLINT KC, HUDSPITH BN, BROSTOFF J, LEUNG KBP, PEARCE FL, JAMES DG, JOHNSON N MCI: Hyperresponsiveness of bronchoalveolar mast cells in sarcoidosis (P), 220
——, ——, LEUNG KBP, PEARCE FL, BROSTOFF J, JOHNSON N MCI: The hyperosmolar release of histamine from bronchoalveolar mast cells and its inhibition by sodium cromoglycate (P), 717
——, ——, ——, ——, SIEGER K, HAMMOND MDG, BROSTOFF J, JOHNSON N MCI: IgE dependent release of leucotriene C_4 and prostaglandin D_2 from human bronchoalveolar cells (P), 716
——, JOHNSON N MCI, MANNHIRE A, DAWSON P, GEORGE S, ELL PJ: Comparison of intravenous digital subtraction angiography with radionuclide ventilation-perfusion lung scanning in patients with suspected pulmonary embolism, 576
——, POZNIAK AL, HUDSPITH BN, BROSTOFF J, JAMES DG, JOHNSON N MCI: Increased production of gamma interferon in sarcoidosis (P), 726
——. *See also* SWINBURN CR, POZNIAK AL, *et al*
FLOWER CDR. *See* JONES DK, CAVANAGH P, *et al*
——. *See* JONES DK, HIGENBOTTAM TW, *et al*
——. *See* LARGE SR, HEYWOOD LJ, *et al*
——. *See* ROBINSON AA, FLOWER CDR, *et al*
Fluorescence as guide to bronchial biopsy, 38
FORD HC, SAVAGE T, DELAHUNT JW: Anterior mediastinal mass and Graves's disease, 469
Foreign body, inhalation of, long term consequence of (P), 700
FORESI A, SHAW D, PISTELLI R, HIGENBOTTAM TW: Simultaneous measurement of TLCO, pulmonary capillary blood flow, and lung tissue volume (P), 226
Formaldehyde, occupational asthma due to, 255
FORRESTER-WOOD CP. *See* WHITE SH, IBRAHIM NBN, *et al*
FORSLING ML. *See* EBEJER MJ, SINGH H, *et al*
FOSTER RW. *See* ALLEN SL, FOSTER RW, *et al*
FOX B. *See* MCCARTNEY A, BULL TB, *et al*
FOX RM. *See* STUART-HARRIS R, FOX RM, *et al*
FOX W. *See* DARBYSHIRE JH, BYFIELD SP, *et al*
——. *See* NUNN AJ, BYFIELD SP, *et al*
FRANCE AJ, CAPEWELL SJ, ANDERSON M, LEITCH AG: The detection and management of tuberculosis in common hostel dwellers (P), 697
——, ——, LEITCH AG: Positive tuberculin tests: the influence of age and previous BCG vaccination (P), 697
——, PRINCE KL, PRESCOTT RJ, MUIR AL, MACNEE W, FLENLEY DC: Significance of a single measurement of right ventricular ejection fraction in patients with chronic bronchitis and emphysema (P), 225
——. *See also* CAPEWELL SJ, FRANCE AJ, *et al*
FRANCIS D. *See* FAURSCHOU P, FRANCIS D, *et al*
FREEDMAN BJ: Comparative trial of two non-sedative H_1 antihistamines, terfenadine and astemizole, for hay fever *(Letter)*, 399
FREEDMAN D. *See* POZNIAK AL, BIHARI D, *et al*
FREEMAN R, GOULD FK: Prevention of fever and Gram negative infection after open heart surgery by antiendotoxin, 846
——, ——: Rises in antibody to enteric Gram negative bacilli after open heart surgery: a possible mechanism for postoperative pyrexia, 538
Freon, heated, occupational asthma due to *(Letters)*, 320
FREW AJ. *See* CHADWICK GA, STRADLING JR, *et al*
——. *See* STRADLING JR, CHADWICK GA, *et al*
FRITH RW, CANT BR: Severe obstructive sleep apnoea treated with long term nasal continuous positive airway pressure, 45
FULLER RW, DIXON CMS, MAXWELL D, BARNES PJ: Effect of inhaled and intravenous substance P on human airway function (P), 714
——, KEMENY DM, HOLGATE ST, MORRIS PK, DOLLERY CT, MACDERMOT J: Mediators released from human alveolar macrophages by IgE/anti-IgE complexes (P), 716

G

GAER J, GOLDSTRAW P: Intraoperative assessment of nodal staging in carcinoma of the bronchus (P), 700
Galanin immunoreactivity, distribution in respiratory tract of pig, guinea pig, rat, and dog, 889
Gallium scanning by conventional imaging and emission computed tomography in pretreatment evaluation of lung cancer, 96
Gamma interferon, increased production in sarcoidosis (P), 726
Gammopathies, monoclonal, in chest disease, 629
GANT A, BARBOSA I, GREY B, HAMBLIN A, BATEMAN NT, STOKES TC: Alveolar macrophage phagocytosis in sarcoidosis (P), 220
GARABEDIAN M. *See* CADRANEL J, MILLERON B, *et al*
GARNER P. *See* FANCOURT GJ, EBDEN P, *et al*
GARRARD CS, DAS R: Observer error in the estimation of anaerobic threshold (P), 236
GARVIN AJ . *See* DAVIS PB, HUBBARD VS, *et al*
Gas dilution method, rapid, for measuring lung volumes in airflow obstruction (P), 226
exchange and ventilation during sleep in pulmonary fibrosis (P), 236
exchange zone of human neonatal lung, capillary plexus in, ultrastructural study, 787
Gastro-oesophageal reflux. *See* Reflux, gastro-oesophageal
Gastropancreatic duplication and intralobar pulmonary seques-

tration of ectopic pancreatic tissue, case of, 637
GATZINSKY P. *See* DERNEVIK L, GATZINSKY P
GAUTHIER D. *See* KAY JM, KEANE PM, *et al*
GEDDES DM, HUNT B: Newly diagnosed cystic fibrosis in middle and later life *(Letter)*, 639 (*see also* HUNT B, GEDDES DM)
——. *See also* ALTON EW, HAY JG, *et al*
——. *See also* DODGE JA, GEDDES DM, *et al*
——. *See also* GEORGE RJD, HOWARD RS, *et al*
——. *See also* GEORGE RJD, JOHNSON MA, *et al*
——. *See also* GEORGE RJD, STEARN AJ, *et al*
——. *See also* GEORGE RJD, WINTER RJD, *et al*
——. *See also* HAY JG, GEDDES DM
——. *See also* MOORE-GILLON JC, GEORGE RJD, *et al*
——. *See also* WINTER RJD, GEORGE RJD, *et al*
GELLERT AR, LANGFORD JA, UTHAYAKUMAR S, RUDD RM: Bronchoalveolar lavage and clearance of ^{99m}Tc labelled DTPA in asbestos workers without evidence of asbestosis (P), 221
——, ——, WINTER RJD, UTHAYAKUMAR S, SINHA G, RUDD RM: Asbestosis: assessment by bronchoalveolar lavage and measurement of pulmonary epithelial permeability, 508
——, LEWIS CA, LANGFORD JA, TOLFREE SEJ, RUDD RM: Regional distribution of pulmonary epithelial permeability in normal subjects and patients with asbestosis, 734
——, RUDD RM: Breathlessness caused by hypoxia is not due only to stimulation of ventilation (P), 234
Gentamicin and carbenicillin in adults with cystic fibrosis infected with *Ps aeruginosa*, comparison with nebulised ceftazidime (P), 704
and carbenicillin in cystic fibrosis with pulmonary pseudomonas infection and exacerbation of respiratory symptoms, comparison with ceftazidime, 358; *Errata*, 728
solution, jet nebulisers for use with, evaluation of, 671
GEORGE RJD, HOWARD RS, STEARN AJ, GEDDES DM: The effects of oral high frequency oscillations on steady state exercise in chronic lung disease (P), 213
——, JOHNSON MA, PAVIA D, AGNEW JE, CLARKE SW, GEDDES DM: Increase in mucociliary clearance in normal man induced by oral high frequency oscillation, 433
——, STEARN AJ, GEDDES DM: A portable, oral high frequency oscillator for relieving breathlessness and improving exercise tolerance (P), 710
——, WINTER RJD, JOHNSON MA, SLEE IP, GEDDES DM: Effect of oral high frequency ventilation by jet or oscillator on minute ventilation in normal subjects, 749
——. *See also* MOORE-GILLON JC, GEORGE RJD, *et al*
——. *See also* WINTER RJD, GEORGE RJD, *et al*
GEORGE S. *See* FLINT KC, JOHNSON N MCI, *et al*
GHATEI MA. *See* PALMER JBD, CUSS FMC, *et al*
GHOSH PK, LUBLINER J, MOGILNAR M, YAKIREVICH V, VIDNE BA: Ligation of patent ductus arteriosus in very low birthweight premature neonates, 533
Giant cell arteritis, simultaneous aortic and pulmonary artery aneurysms due to, case of, 156
GIBBONS JR. *See* MAXWELL RJ, GIBBONS JR, *et al*
GIBBS AR, HARACH R, WAGNER JC, JASANI B: Comparison of tumour markers in malignant mesothelioma and pulmonary adenocarcinoma, 91
GIBNEY N. *See* NOLAN MT, GIBNEY N, *et al*
GIBSON CJ. *See* BROUGHTON DL, GIBSON CJ, *et al*
GIBSON GJ. *See* CORRIS PA, GIBSON GJ
——. *See* CORRIS PA, KENDRICK AH, *et al*
——. *See* GILMARTIN JJ, MOHAMEDANI AA, *et al*
——. *See* GILMARTIN JJ, VEALE D, *et al*
——. *See* GILMARTIN JJ, WRIGHT AJ, *et al*
——. *See* RHODES KM, EVEMY K, *et al*
——. *See* VEALE D, GILMARTIN JJ, *et al*
——. *See* VEALE D, MARSH C, *et al*
GIBSON LE: Newly diagnosed cystic fibrosis in middle and later life *(Letter)*, 639
GIEMBYCZ MA, RODGER IW: Does thromboxane A_2 mediate the indirect contractile effect of leucotriene D_4 in guinea pig lung parenchyma? (P), 713
——. *See also* ROBERTS JA, GIEMBYCZ MA, *et al*
GILL F. *See* ROBERTSON AS, BURGE PS, *et al*
GILLAM SJ. *See* HETZEL MR, CLARKE JH, *et al*
GILLETT MK, SNASHALL PD: Asthmatic subjects are hyperresponsive to inhaled but not intravenous atropine (P), 217
GILMARTIN JJ, MOHAMEDANI AA, ASHCROFT T, GIBSON GJ: Can tumour volume be estimated accurately from the plain chest radiograph? (P), 699
——, VEALE D, COOPER BG, KEAVEY PM, GIBSON GJ, MORRITT GN: Functional effects of laser therapy in malignant narrowing of the central airway (P), 723
——, WRIGHT AJ, GIBSON GJ: Effects of pneumothorax or pleural effusion on pulmonary function, 60
——. *See also* VEALE D, GILMARTIN JJ, *et al*
GIN W, KAY AB: Effect of corticosteroids on neutrophil function in bronchial asthma (P), 211
GIRLING DJ. *See* BLEEHEN NM, FAYERS PM, *et al*
GLAZEBROOK K. *See* CHADWICK GA, GLAZEBROOK K, *et al*
GLEICH GJ. *See* DURHAM SR, GLEICH GJ, *et al*
Glucocorticoid hypersensitivity in asthmatic patient, presentation and treatment, 477
Glutaraldehyde exposure, asthma and rhinitis after (P), 224
Gluten, asthma induced by, in adult coeliac disease (P), 229
GODARD A. *See* CHAILLEUX E, BIGNON JD, *et al*
GODDEN D. *See* WILLEY RF, FERGUSSON RJ, *et al*
GODFREY RC. *See* AGIUS RM, GODFREY RC, *et al*
GOLDMAN JM, MORGAN MDL, DENISON DM: Measurement of abdominal wall compliance (P), 701
——. *See also* KENNEDY HG, WYATT SE, *et al*
GOLDMAN MD. *See* WATSON A, JOYCE H, *et al*
GOLDSTRAW P. *See* GAER J, GOLDSTRAW P
——. *See* VENN GE, DACOSTA P, *et al*
——. *See* VENN GE, KAY PH, *et al*
GOMEZ E. *See* CORRADO OJ, GOMEZ E, *et al*
GOODALL J. *See* DODGE JA, GEDDES DM, *et al*
GORDON I. *See* DAVIES H, GORDON I, *et al*
GORDON IJ, COAKLEY J, SMITH P, LUKSZA AR, ATHERTON ST: Therapeutic bronchial lavage in asthma (P), 707
GORMLEY IP. *See* ROBERTSON MD, RAEBURN JA, *et al*
GOSNEY JR, SISSONS MCJ: Widespread distribution of bronchopulmonary endocrine cells immunoreactive for calcitonin in the lung of the normal adult rat, 194
——, ——, O'MALLEY JA: Quantitative study of endocrine cells immunoreactive for calcitonin in the normal adult human lung, 866
——. *See also* SISSONS MCJ, GOSNEY JR
GOULD FK. *See* FREEMAN R, GOULD FK
——. *See* FREEMAN R, GOULD FK, *et al*
GOULD GA, HAYHURST MD, SCOTT W, FLENLEY DC: Clinical assessment of oxygen conserving devices in chronic bronchitis and emphysema, 820
——, RHIND GB, AHMAD F, CROUGHAN MJ, CALDER MA: *Haemophilus* biotyping in respiratory disease (P), 237
——, SCOTT W, HAYHURST MD, FLENLEY DC: Technical and clinical assessment of oxygen concentrators, 811
——. *See also* RHIND GB, GOULD GA, *et al*
——. *See also* SCOTT W, GOULD GA, *et al*
GOURLAY AR. *See* MORGAN MDL, GOURLAY AR, *et al*
GOVAN JR. *See* BANNER NR, GOVAN JR
GOVE RI, BURGE PS: Acute effects of corticosteroids in chronic airflow obstruction (P), 232
——, ——: Enhancement of the peripheral adrenergic response by hydrocortisone (P), 212
Grafts, vein, native coronary arteries, and myocardium, state of, and principal cause of death in patients dying after aortocoronary bypass grafting, 940
GRAHAM AN, MARTIN PD, HAAS LF: Neuralgic amyotrophy with bilateral diaphragmatic palsy, 635
GRAHAM DR, LUKSZA AR, EVANS CC: Bronchoalveolar lavage in asthma

(P), 717
Gram negative bacilli, enteric, antibodies to, increase after open heart surgery, postoperative pyrexia due to?, 538
negative infection and fever after open heart surgery, prevention by *E coli* antiendotoxin, 846
GRANDORDY B, CUSS FMC, PALMER JBD, SAMPSON A, BARNES PJ: Muscarinic receptors and phosphatidylinositol turnover in airway smooth muscle (P), 713
GRANEEK BJ. *See* DURHAM SR, GRANEEK BJ, *et al*
GRANT IWB. *See* DOUGLAS JG, RAFFERTY P, *et al*
——. *See* WILLEY RF, FERGUSSON RJ, *et al*
GRANT WB: Nedocromil sodium: a new drug for the management of bronchial asthma *(Letter)*, 400
Granular cell myoblastoma and squamous cell carcinoma, contiguous, in oesophagus, case of, 551
Granulomatosis, bronchocentric, associated with seropostive polyarthritis, case of, 396
Grass pollen season, change in non-specific reactivity in rural population sample during (P), 694
Graves's disease and anterior mediastinal mass, 2 cases of, 469
GRAY B. *See* BORZONE G, DIAZ M, *et al*
GREEN JF. *See* LINK DP, PARSONS GH, *et al*
GREEN M: Funding respiratory research (E), 81
——. *See also* BROPHY CJ, MIER AK, *et al*
——. *See also* MIER AK, MILLER J, *et al*
——. *See also* MOOTOOSAMY IM, REZNEK RH, *et al*
——. *See also* MOXHAM J, MILLER J, *et al*
——. *See also* SPITERI MA, MIER AK, *et al*
GREENBERG B, RHODEN K, BARNES PJ: Characteristics of VIP and PHI relaxation of bovine and human pulmonary artery (P), 715
——, ——, ——: Evidence of endothelial cell dependent relaxation of pulmonary artery in man (P), 715
GREENING AP, NUNN P, DOBSON N, RODOLF M, REES ADM: Pulmonary sarcoidosis: alterations in bronchoalveolar lymphocytes and T cell subsets, 278
——. *See also* BOYD PA, HASTIE ND, *et al*
——. *See also* WOOD NE, FLENLEY DC, *et al*
GREENSTONE MA, RUTMAN A, PAVIA D, LAWRENCE D, COLE PJ: Normal axonemal structure and function in Kartagener's syndrome: an explicable paradox, 956
——, STANLEY PJ, MACKAY IS, COLE PJ: The effect of chronic denervation on mucociliary transport *in vivo* (P), 239
——. *See also* STANLEY PJ, GRIFFIN WM, *et al*
GREENWOOD B. *See* SHAW RJ, YOUNGCHAIYUD P, *et al*
GREWAL PK, MANN JS, HOLGATE ST: Effect of theophylline in plasma on cyclic AMP metabolism (P), 211
GREY B. *See* GANT A, BARBOSA I, *et al*
GRIFFIN WM. *See* STANLEY PJ, GRIFFIN WM, *et al*
GRIFFITHS M. *See* MOSS FM, BOBROW LG, *et al*
GROSS E. *See* TAYLOR RG, GROSS E, *et al*
——. *See* TAYLOR RG, JOYCE H, *et al*
GRZELEWSKA-RZYMOWSKA I. *See* KOWALSKI ML, GRZELEWSKA-RZYMOWSKA I, *et al*
GRZYBOWSKI S. *See* YEUNG M, GRZYBOWSKI S
GUNNING AJ. *See* DENNISON AR, WATKINS RM, *et al*
GUNTHER RA. *See* LINK DP, PARSONS GH, *et al*
GUY RJC. *See* HEATON RE, GUY RJC, *et al*
GUZ A. *See* BEAUMONT A, COCKCROFT A, *et al*
——. *See* WINNING AJ, HAMILTON RD, *et al*

H

HAAS LF. *See* GRAHAM AN, MARTIN PD, *et al*
Haemodialysis and haemofiltration during cardiopulmonary bypass, 101
pulmonary epithelial permeability changes in (P), 723
Haemodynamic effects, acute, of nifedipine at rest and during maximal exercise in chronic cor pulmonale, 910
Haemodynamics and hormones in chronic cor pulmonale at rest and on exercise before and after nifedipine (P), 225
β Haemolytic streptococcus, Lancefield group A, pericarditis caused by, cardiac tamponade due to, case of, 549
Haemophilus biotyping in respiratory disease (P), 237
influenzae and *H parainfluenzae*, differentiation in sputum, bacteriological medium for (P), 237
Haemoptysis, bronchography in assessment of patients with, reevaluation of, with analysis of 96 cases (1975–83), 668
HAHN AG, NOGRADY SG, BURTON GR, MORTON AR: Absence of refractoriness in asthmatic subjects after exercise with warm, humid inspirate, 418
HAKIM, MILSTEIN BB: Role of automatic staplers in the aetiology of bronchopleural fistula, 27; (*Letter* by Hakin), 879
——, TIMBS A, MILSTEIN BB: Clinical and laboratory evaluation of two automatic staplers in bronchial closure (P), 215
——, WHEELDON D, BETHUNE DW, MILSTEIN BB, ENGLISH TAH, WALLWORK J: Haemodialysis and haemofiltration on cardiopulmonary bypass, 101
HALL DR. *See* REEVE P, LAPP NL, *et al*
HALL R: Difficulties in the treatment of acute pulmonary embolism (E), 729
Harmartoma, oesophageal, giant, case of, 684
HAMBLIN A. *See* GANT A, BARBOSA I, *et al*
HAMILTON RD. *See* WINNING AJ, HAMILTON RD, *et al*
HAMMOND MDG. *See* FLINT KC, HUDSPITH BN, *et al*
HANSEN HH. *See* ØSTERLIND K, HANSEN M, *et al*
HANSSON M. *See* ØSTERLIND K, HANSEN M, *et al*
HANSEN S-B. *See* OLAFSSON M, SIMONSSON BG, *et al*
HARACH R. *See* GIBBS AR, HARACH R, *et al*
HARDIE R. *See* VIGNESWARAN WT, HARDIE R, *et al*
HARDY C. *See* BOTTRILL I, HARDY C, *et al*
HARGREAVE FE. *See* JUNIPER EF, KLINE PA, *et al*
——. *See* O'BYRNE PM, ADELROTH E, *et al*
——. *See* RAMSDALE EH, ROBERTS RS, *et al*
HARRIES MG, LACEY J, TEE RD, NEWMAN-TAYLOR AJ: *Didymella exitialis*: a cause of late summer asthma (P), 223
——. *See also* BURGE PS, HARRIES MG, *et al*
HARRIS AL. *See* VEALE D, MARSH C, *et al*
HARRISON BDW (for BTS Research Committee): BTS pneumonia study: clinical features and *x* ray and laboratory data available soon after admission which affect prognosis (P), 694
——. *See also* ALI NJ, HARRISON BDW, *et al*
HARROW EM, OLDENBURG FA, SMITH AM: Transbronchial needle aspiration in clinical practice, 756
HASHISH A. *See* LEWIS RA, ELLIS CJ, *et al*
HASLAM PL. *See* HAY JG, DEWAR A, *et al*
——. *See* HAY JG, HASLAM PL, *et al*
——. *See* LIN YH, HASLAM PL, *et al*
——. *See* PANTIN CFA, DEWAR A, *et al*
HASLETON PS. *See* MANNION P, HONAN RP, *et al*
HASTIE ND. *See* BOYD PA, HASTIE ND, *et al*
HAWKINS R. *See* DURHAM SR, GRANEEK BJ, *et al*
HAY JG, DEWAR A, ADDIS B, TURNER-WARWICK M, LAURENT GJ, HASLAM PL: The role of oxygen in inducing acute lung injury following intravenous bleomycin (P), 727
——, GEDDES DM: Transepithelial potential difference in cystic fibrosis, 493
——, HASLAM PL, TURNER-WARWICK M, LAURENT GJ: The importance of iron in bleomycin induced lung injury (P), 727
——. *See also* ALTON EW, HAY JG, *et al*
Hay fever, immunotherapy in, mechanism of (P), 727
fever, nasal sensitivity and suppressor cell function in (P), 239
fever, terfenadine and astemizole as non-sedative H_1 antihistamines for, comparative trial of *(Letters)*, 399, 799
HAYHURST MD. *See* GOULD GA, HAYHURST MD, *et al*
——. *See* GOULD GA, SCOTT W, *et al*
——. *See* SCOTT W, GOULD GA, *et al*

HEAF D. *See* DAVIES H, GORDON I, *et al*
Heart disease and lung disease, comparison of exercise performance and grading of dyspnoea in (P), 721
disease, congenital, and Down's syndrome, lung changes in, significance as cause of postoperative respiratory failure, 380
surgery, open, fever and Gram negative infection after, prevention by *E coli* antiendotoxin, 846
surgery, open, increase in antibodies to enteric Gram negative bacilli after, postoperative pyrexia due to?, 538
surgery, open, jaundice after, prospective study *(Letter)*, 80
valves. *See* Valves
HEATON RE, GUY RJC, WATKINS PJ, COSTELLO JF: Bronchial histamine reactivity in diabetic subjects with and without autonomic neuropathy (P), 217
HEATON RW. *See* JENKINS SC, HEATON RW, *et al*
HEDGE A. *See* ROBERTSON AS, BURGE PS, *et al*
HEDLEY D. *See* STUART-HARRIS R, FOX RM, *et al*
HELMS P. *See* DAVIES H, GORDON I, *et al*
Hemidiaphragm, raised, after cardiopulmonary bypass, incidence and aetiology, 44
HENDERSON AH. *See* EBEJER MJ, SINGH H, *et al*
——. *See* SINGH H, EBEJER MJ, *et al*
HENDRICK DJ: Contaminated humidifiers and the lung (E), 244
——. *See also* CONNOLLY MJ, HENDRICK DJ
HENNIG WS: Role of automatic staplers in the aetiology of bronchopleural fistula *(Letter)*, 879
HETZEL MR, CLARKE JH, GILLAM SJ, ISAAC P, PERKINS M: Is sodium cromoglycate effective in nocturnal asthma?, 793
——, NIXON C, EDMONDSTONE WM, MITCHELL DM, MILLARD FJC, NANSON EM, WOODCOCK AA, BRIDGES CE, HUMBERSTONE AM: Laser therapy in 100 tracheobronchial tumours, 341
——. *See also* MILLAR AB, O'REILLY AP, *et al*
HEYDERMAN E, LARKIN S, MAKIN CA, CORRIN B: Epithelial markers in mesotheliomas: an immunoperoxidase study of epithelial membrane antigen, cytokeratin, and carcinoembryonic antigen (P), 215
HEYWOOD LJ. *See* LARGE SR, HEYWOOD LJ, *et al*
HIGENBOTTAM TW. *See* ASHFORD N, CRACKNELL N, *et al*
——. *See* BORLAND C, HIGENBOTTAM TW, *et al*
——. *See* FORESI A, SHAW D, *et al*
——. *See* HOLGATE ST, BROOKS JR, *et al*
——. *See* JONES DK, HIGENBOTTAM TW, *et al*
——. *See* JONES K, HIGENBOTTAM TW, *et al*
——. *See* KINNEAR WJM, SHNEERSON JM, *et al*
HIGGINS DA. *See* EBEJER MJ, SINGH H, *et al*
——. *See* SINGH H, EBEJER MJ, *et al*
HIGGS CMB, JONES P, TANSER AR, LASZLO G: What are the symptoms of asthma and their importance? (P), 688
——. *See also* SELLERS WFS, HIGGS CMB
HIGGS E. *See* COLE PJ, ROBERTS D, *et al*
——. *See* ROBERTS D, HIGGS E, *et al*
HILL RA, BRITTON JR, TATTERSFIELD AE: Management of asthma in schools (P), 688
HILL SL. *See* MORRISON HM, HILL SL, *et al*
——. *See* STOCKLEY RA, HILL SL, *et al*
HILLS BA: The pleural interface (E), 1
HIRSCHLER-SCHULTE CJW, HYLKEMA BS, MEYER RW: Mechanical ventilation for acute postoperative respiratory failure after surgery for bronchial carcinoma, 387
Histamine, airway responsiveness *in vivo* and *in vitro* to, and effect of atropine, 261
and epithelial permeability in normal and asthmatic subjects (P), 217
and mast cell content of human bronchoalveolar lavage fluid, 760
and methacholine, increased responsiveness to, after challenge with ultrasonically nebulised water in asthma, 427
as mediator of nasal hypersecretion and blockage in atopic and non-atopic perennial rhinitis (P), 719
bronchial hyperreactivity to, in aspirin sensitive asthmatics, relationship to aspirin threshold and effect of aspirin desensitisation, 598
bronchial reactivity to, and blood eosinophil and total white cell counts in smokers and ex-smokers (P), 718
bronchial reactivity to, in diabetics with and without autonomic neuropathy (P), 217
bronchospasm in asthmatics provoked by, refractory period following (P), 216
changes in pulmonary epithelial permeability induced by, mediated via H_1-receptors (P), 720
effect on lung permeability in normal and asthmatic subjects, 603
hyperosmolar release from bronchoalveolar mast cells and inhibition by sodium cromoglycate (P), 717
in sputum in acute exacerbations of chronic bronchitis, genesis of, and role of bacteria (P), 238
inhaled, bronchial reactivity to, and annual rate of decline in FEV_1 in male smokers and ex-smokers, 9; *Erratum*, 208
inhaled, response of asthmatics to, affected by baseline airway calibre? (P), 216
plasma concentration during propranolol induced bronchoconstriction, 903
release and newly generated mediators from human bronchoalveolar lavage cells (P), 220
topical, nasal airway response to, assessment of, comparison of 3 methods (P), 216
HO SY. *See* RUSSO PA, WRIGHT JEC, *et al*
HOCKEN DB, DUSSEK JE: *Streptococcus milleri* as a cause of pleural empyema, 626
HODSON ME, WISE AE, DUNCAN F, BATTEN JC: Factors affecting survival of adult patients with cystic fibrosis (P), 227
——. *See also* STEAD RJ, HODSON ME, *et al*
——. *See also* STEAD RJ, KENNEDY HG, *et al*
——. *See also* STEAD RJ, PANTIN CFA, *et al*
HOFSTEE N. *See* BERENDSEN HH, HOFSTEE N, *et al*
HOLGATE ST: Comparative trial of two non-sedative H_1 antihistamines, terfenadine and astemizole, for hay fever *(Letter)*, 399
——, BROOKS JR, KEARNEY JP, HIGENBOTTAM TW, STARK JE, DEMPSEY JP, SMITH RM: An expert system to improve the diagnosis and treatment of asthma (P), 689
——. *See also* AGIUS RM, GODFREY RC, *et al*
——. *See also* AGIUS RM, JONES D, *et al*
——. *See also* AGIUS RM, ROBINSON C, *et al*
——. *See also* BOTTRILL I, HARDY C, *et al*
——. *See also* CUSHLEY MJ, HOLGATE ST
——. *See also* FULLER RW, KEMENY DM, *et al*
——. *See also* GREWAL PK, MANN JS, *et al*
HOLLAND F. *See* TAYLOR RG, GROSS E, *et al*
——. *See also* TAYLOR RG, JOYCE H, *et al*
——. *See also* WATSON A, JOYCE H, *et al*
HOLT DA, WEBER J, KEAL EE, PINCHING AJ: What is the value of TLCO estimation in patients with AIDS and persistent generalised lymphadenopathy? (P), 223
HOMASSON JP, BONNIOT JP, ANGEBAULT M, RENAULT P, CARNOT F, SANTELLI G: Fluorescence as a guide to bronchial biopsy, 38
HONAN RP. *See* MANNION P, HONAN RP, *et al*
HONEYBOURNE D, FINNEGAN M, PICKERING CAC: Prevalence and effects of atopy in byssinosis (P), 224
HOPKIRK A. *See* LOZEWICZ S, DAVISON AG, *et al*
HOPPER L. *See* KENNEDY HG, WYATT SE, *et al*
HORIUCHI T. *See* YAMAKI S, HORIUCHI T, *et al*
Hormones and haemodynamics in chronic cor pulmonale at rest and on exercise before and after nifedipine (P), 225
HORN CR, COCHRANE GM: Use of asthma treatment in general practice (P), 230
——, ESSEX E, COCHRANE GM: Measurement of urine salbutamol to monitor the compliance of asthmatics (P), 705
——. *See also* LEWIS LD, O'DRISCOLL R, *et al*
HORNE NW. *See* MCLEOD DT, CALVERLEY PMA, *et al*
HORSFIELD N. *See* BURGE PS, FINNEGAN M, *et al*
Hostels, common, dwellers in, detection and management of tuber-

culosis in (Edinburgh, 1976–82) (P), 697
House dust allergen avoidance in adult asthma, trial of (P), 224
HOWARD RS. *See* GEORGE RJD, HOWARD RS, *et al*
HOWELL JBL. *See* MORTAGY AK, HOWELL JBL, *et al*
HUBBARD VS. *See* DAVIS PB, HUBBARD VS, *et al*
HUDSON L. *See* PEPPER J, KIRBY J, *et al*
HUDSPITH BN. *See* FLINT KC, HUSPITH BN, *et al*
——. *See* FLINT KC, POZNIAK AL, *et al*
HUGGINS R. *See* CAMPBELL AH, BARTER CE, *et al*
HUGHES AO. *See* CARSWELL F, BREWIN M, *et al*
HUGHES JMB. *See* JONES HA, DAVIES EE, *et al*
——. *See* KENNEDY HG, IND PW, *et al*
——. *See* KENNEDY HG, WYATT SE, *et al*
——. *See* MAXWELL DL, ROYSTON D, *et al*.
——, *See* OPENSHAW PJM, HUGHES JMB, *et al*
——. *See* ORPHANIDOU D, AL-SUHALI AR, *et al*
HULME B. *See* CUSS F, LININGTON A, *et al*
HUMBERSTONE AM. *See* HETZEL MR, NIXON C, *et al*
Humidifier at 15°C, antigen from, extrinsic allergic alveolitis due to (P), 229
fever, immunoglobulin measurements in (P), 703
fever, radiographic changes in case of, 312
Humidifiers, contaminated, and lung disorders (E), 244
contaminated, asthma due to *(Letter)*, 560
contaminated, occupational asthma in factory with, 248
HUMPHRIES MJ. *See* DARBYSHIRE JH, BYFIELD SP, *et al*
——. *See* NUNN AJ, BYFIELD SP, *et al*
HUNT B, GEDDES DM: Newly diagnosed cystic fibrosis in middle and later life, 23 (*see also* GEDDES DM, HUNT B)
HUNTON IH. *See* NEILLY JB, CLARK CJ, *et al*
HURLEY P, CORBISHLEY C, PEPPER J: Bronchioloaveolar carcinoma arising in longstanding lung cysts *(Letter)*, 960
HURST DN . *See* BURR ML, PHILLIPS KM, *et al*
HUSSAIN A. *See* SHAW DJ, CHAPEL H, *et al*
Hydatid cysts, pulmonary, albendazole treatment in naturally infected sheep and implications for man, 453
Hydrocortisone enhancement of peripheral adrenergic response (P), 212
HYLKEMA BS. *See* HIRSCHLER-SCHULTE CJW, HYLKEMA BS, *et al*
Hypertension, pulmonary, primary, long term prostacyclin in, practical experience of (P), 232
Hyperventilation and methacholine in asthma and chronic bronchitis, differences in responsiveness to, 422
Hypoventilation and sleep apnoea in obesity (P), 235
nocturnal, in restrictive chest wall disease, protriptyline for (P), 702
Hypoxaemia, arterial, correction of, effects on respiratory resistance in chronic airflow obstruction (P), 709
Hypoxia and secondary polycythaemia, relative effects on mental function in respiratory disease (P), 231
breathlessness caused by, not due only to stimulation of ventilation (P), 234
chronic, lung angiotensin converting enzyme activity in rats with, 587
chronic, systemic administration of beta$_2$ adrenoceptor agonist during, polycythaemia and right ventricular hypertrophy enhanced by (P), 707
ventilatory response to, successive rebreathe procedure for measurement of, clinical evaluation of (P), 234
Hypoxic chronic bronchitis, pulmonary haemodynamics in, improved by long term therapy with oral beta$_2$ agonist? (P), 707
cor pulmonale, long term oxygen for, 8-year follow up and prognostic factors (P), 711

I

IBBOTTSON RM. *See* FAIRFAX AJ, IBBOTSON RM
IBRAHIM NBN. *See* JEYASINGHAM K, ANDRIANOPOULOS E, *et al*
——. *See* WHITE SH, IBRAHIM NBN, *et al*
IIKURA. *See* LEE TH, INUI H, *et al*
Immune deficiency syndrome, acquired. *See* AIDS
response, local, suggested by immunohistological analysis of lung tissue from patients with cryptogenic fibrosing alveolitis (P), 221; 405
Immunocytoma, primary, of lung, diagnostic value of bronchoalveolar lavage in case of, 542
Immunoglobulin E, leucotriene C_4 and prostaglandin D_2 release from human bronchoalveolar cells dependent on (P), 716
E/anti-IgE complexes, mediators released from human alveolar macrophages by (P), 716
G, leucotriene C_4 release from human eosinophils mediated by, relevance to asthma and hypereosinophilia (P), 716
measurements in humidifier fever (P), 703
Immunotherapy in hay fever, mechanisms of (P), 727
IND PW, BARNES PJ, BROWN MJ, DOLLERY CT: Plasma histamine concentration during propranolol induced bronchoconstriction, 903
——, PETERS AM, MALIK F, LAVENDER JP, DOLLERY CT: Pulmonary platelet kinetics in asthma, 412
——. *See also* KENNEDY HG, IND PW, *et al*
^{111}Indium autologous leucocyte scanning in lobar pneumonia and lung abscesses, 925
Influenza virus, killed, intramuscular, effect on airway responsiveness and clinical state in asthmatics (P), 217
INGLIS CC. *See* BERKIN KE, INGLIS CC, *et al*
INGRAM D. *See* JOHNSTON I, PATEL S, *et al*
INGRAM DA. *See* APPS MCP, WALLIS PJW, *et al*
INNES JA. *See* CHIODINI PL, WILLIAMS AJ, *et al*
Inspiration phased oxygen delivery (P), 213
Inspiratory flow, peak, measurement with modified mini Wright peak flow meter, 205
Interferon, gamma, increased production in sarcoidosis (P), 726
Interleukin 2 production, T lymphocyte subsets, and phytohaemagglutinin responsiveness of blood lymphocytes in sarcoidosis, 768
Intra-aortic balloon pumping, 7 years' experience, 858
Intraepithelial nerves in human airway tract, ultrastructural organisation of, 488
Intrapulmonary thymoma, 2 cases of, 471
INUI H. *See* LEE TH, INUI H, *et al*
'Invalidity' due to chronic bronchitis and emphysema, authenticity of, 828
Ipratropium bromide, high dose, long term, effect on lung mucociliary clearance (P), 212
Iridium 192 and Neodym-YAG laser in treatment of inoperable malignant tumours of trachea and main bronchi (P), 700
Iron, importance in bleomycin induced lung injury (P), 727
ISAAC P. *See* HETZEL MR, CLARKE JH, *et al*
Isphaghula, allergy to, in workers manufacturing bulk laxative (P), 702

J

JACKSON JD. *See* MCCULLOCH, AJ MCEVOY A, *et al*
JAMES DG. *See* FLINT KC, HUDSPITH BN, *et al*
——. *See* FLINT KC, POZNIAK AL, *et al*
——. *See* STUDDY PR, BIRD R, *et al*
JANNI A. *See* MUSSI A, JANNI A, *et al*
JANOSSY G. *See* CAMPBELL DA, DU BOIS RM, *et al*
——. *See* CAMPBELL DA, POULTER LW, *et al*
JANSSENS E. *See* VERMEIRE P, JANSSENS E, *et al*
JARVIS EH. *See* MCCULLOCH AJ, MCEVOY A, *et al*
JASANI B. *See* GIBBS AR, HARACH R, *et al*
Jaundice after open heart surgery, prospective study *(Letter)*, 80
JENKINS PA. *See* BANKS J, JENKINS PA
JENKINS PF. *See* ALI NJ, HARRISON BDW, *et al*

JENKINS SC, HEATON RW, MOXHAM J: Comparison of domiciliary salbutamol nebuliser and metered dose inhaler in stable chronic airflow limitation (P), 232
JENNER PJ. *See* PEACH H, ELLARD GA, *et al*
JESSOP A. *See* MOGHISSI K, JESSOP A, *et al*
JEYASINGHAM K, ANDRIANOPOULOS E, IBRAHIM NBN: The influence of tumour size and positive lymph nodal invasion on five year survival after surgery for oat cell carcinoma (P), 701
——. *See also* WHITE SH, IBRAHIM NBN, *et al*
JOHN S. *See* COOKSON WOCM, JOHN S, *et al*
JOHNS DP, ROCHFORD PD, STREETSON JA: Evaluation of six oxygen concentrators, 806
JOHNSON CE, CURZON PGD: Comparison of intrapleural bleomycin and tetracycline in the treatment of malignant pleural effusion (P), 210
JOHNSON MA. *See* GEORGE RJD, JOHNSON MA, *et al*
——. *See* GEORGE RJD, WINTER RJD, *et al*
JOHNSON N MCI. *See* FLINT KC, HUDSPITH BN, *et al*
——. *See* FLINT KC, JOHNSON N MCI, *et al*
——. *See* FLINT KC, POZNIAK AL, *et al*
——. *See* POZNIAK AL, BIHARI D, *et al*
——. *See* SWINBURN CR, POZNIAK AL, *et al*
JOHNSTON I, ANDERSON HR, PATEL S, BLAND JM: Ethnic variation in respiratory symptoms and lung function in London primary school children (P), 712
——, PATEL S, ANDERSON HR, LAMBERT HP, INGRAM D, WARNER JO: Respiratory symptoms, lung function and bronchial reactivity after pertussis in infancy (P), 690
JONES D. *See* AGIUS RM, JONES D, *et al*
JONES DA. *See* FARROW PR, JONES DA, *et al*
JONES DK, CAVANAGH P, SHNEERSON JM, FLOWER CDR: Does bronchography have a role in the assessment of patients with haemoptysis?, 668
——, HIGENBOTTAM TW, BAYLISS J, BARBER R, WRAIGHT P, FLOWER CDR: Clearance of ^{99m}Tc DTPA in sarcoidosis with and without pulmonary involvement (P), 722
JONES HA, DAVIES EE, HUGHES JMB: A rapid gas dilution method for measuring lung volumes in airflow obstruction (P), 226
——. *See also* KENNEDY HG, IND PW, *et al*
JONES K, HIGENBOTTAM TW, WALLWORK J: Practical experience of long term prostacyclin in patients with primary pulmonary hypertension (P), 232
JONES KP. *See* FENNERTY AG, JONES KP, *et al*
JONES P. *See* HIGGS CMB, JONES P, *et al*
JONES PW. *See* SWINBURN CR, WAKEFIELD JM, *et al*
JONES RS. *See* MORRIS DL, CLARKSON MJ, *et al*
JOSEPH AEA. *See* BUTLAND RJA, JOSEPH AEA, *et al*
JOYCE H. *See* TAYLOR RG, GROSS E, *et al*
——. *See* TAYLOR RG, JOYCE H, *et al*
——. *See* WATSON A, JOYCE H, *et al*
JUNG RT. *See* CLEE MD, FERGUSON J, *et al*
JUNIPER EF, KLINE PA, DANIEL EE, HARGREAVE FE: Airways responsiveness to methacholine during the natural menstrual cycle: effect of oral contraceptive (P), 718

K

KAPSENBERG PD. *See* BERENDSEN HH, HOFSTEE N, *et al*
Kartagener's syndrome, normal axonemal structure and function in case of, 956
KAY AB. *See* DURHAM SR, GLEICH GJ, *et al*
——. *See* DURHAM SR, LEE TH, *et al*
——. *See* GIN W, KAY AB
——. *See* MACKAY JA, CROMWELL O, *et al*
——. *See* MOQBEL R, DURHAM SR, *et al*
——. *See* SHAW RJ, DRAKE-LEE A, *et al*
——. *See* SHAW RJ, WALSH GM, *et al*
——. *See* SHAW RJ, YOUNGCHAIYUD P, *et al*
——. *See* WARDLAW AJ, CROMWELL O, *et al*
KAY JM, KEANE PM, SUYAMA KL, GAUTHIER D: Lung angiotensin converting enzyme activity in chronically hypoxic rats, 587
KAY PH. *See* VENN GE, KAY PH, *et al*
KEAL EE. *See* HOLT DA, WEBER J, *et al*
——. *See* MORICE AH, SCHOFIELD PM, *et al*
——. *See* WARREN JB, WEBER J, *et al*
KEANE PM. *See* KAY JM, KEANE PM, *et al*
KEARNEY JP. *See* HOLGATE ST, BROOKS JR, *et al*
KEAVEY PM. *See* GILMARTIN JJ, VEALE D, *et al*
KELLY CA, CHETTY MN: Primary sternal osteomyelitis, 872
KEMENY DM. *See* FULLER RW, KEMENY DM, *et al*
KENDRICK AH. *See* CORRIS PA, KENDRICK AH, *et al*
KENNEDY C. *See* MORICE AH, KENNEDY C, *et al*
KENNEDY HG, IND PW, JONES HA, HUGHES JMB: Effect of β_1 receptor blockade in pulmonary capillary blood volume and transit time (P), 712
——, WYATT SE, APPERLEY J, HOPPER L, GOLDMAN JM, HUGHES JMB: Bone marrow transplantation: prospective study of lung function (P), 233
——. *See also* STEAD RJ, KENNEDY HG, *et al*
KERR I. *See* COOKE J, CURRIE DC, *et al*
Ketoconazole in non-invasive pulmonary aspergillosis, trial of (P), 231
KHALIL Y, SETHIA B, QUIN RO, BAIN WH: Disc and strut ebolisation after minor strut fracture in a Björk-Shiley mitral valve prosthesis, 158
KHIN MA. *See* KUNG ITM, LOKE SL, *et al*
KINNEAR WJM, SHNEERSON JM: Acute pleural effusions in inactive ankylosing spondylitis, 150
——, ——: The Newmarket pump: a new suction pump for external negative pressure ventilation, 677
——, ——, SHAW GD, HIGENBOTTAM TW: Cuirass assisted ventilation in chest wall and neuromuscular disease (P), 701
KIRBY J. *See* PEPPER J, KIRBY J, *et al*
KIRSTEN K, SCHAEDEL C: Sudden death due to myocardial tuberculosis *(Letter)*, 799
KLEPETKO W, MIHOLIC J: Jaundice after open heart surgery: a prospective study *(Letter)*, 80
KLINE PA. *See* JUNIPER EF, KLINE PA, *et al*
KNIGHT BA, ROSE AG: Pulmonary veno-occlusive disease after chemotherapy, 874
KNIGHT RK. *See* AGIUS RM, KNIGHT RK, *et al*
——. *See* AGIUS RM, PETRICEVIC I, *et al*
KOCH K. *See* MACHA HN, KOCK K, *et al*
KOPELMAN PG. *See* APPS MCP, KOPELMAN PG, *et al*
KOWALSKI ML, GRZELEWSKA-RZYMOWSKA I, SZMIDT M, ROZNIECKI J: Bronchial hyerreactivity to histamine in aspirin sensitive asthmatics: relationship to aspirin threshold and effect of aspirn desensitisation, 598
KRAMPS JA. *See* STOCKLEY RA, MORRISON HM, *et al*
KRUMHAAR D. *See* MACHA HN, KOCH K, *et al*
Krypton 81m, tomographic measurements of regional ventilation-perfusion and $\dot{V}_A/\dot{Q}$ using (P), 233
KUNG ITM, LOKE SL, SO SY, LAM WK, MOK CK, KHIN MA: Intrapulmonary thymoma: report of two cases, 471
KURTZ A. *See* POZNIAK AL, BIHARI D, *et al*
Kveim test for sarcoidosis, *in vivo* effects of different spleen suspensions on macrophage distribution and phenotype in (P), 725
test for sarcoidosis, local cell mediated response induced in normal but not Kveim positive subjects by (P), 725

L

Laboratories for lung function, external quality assessment of (P), 710

LACEY J. *See* HARRIES MG, LACEY J, *et al*
LAITINEN A: Ultrastructural organisation of intraepithelial nerves in the human airways tract, 488
LAL S: Nedocromil sodium: a new drug for the management of bronchial asthma *(Letter)*, 400
LAM WK. *See* BURGE PS, HARRIES MG, *et al*
——. *See* KUNG ITM, LOKE SL, *et al*
LAMB D. *See* BARLOW Y, LAMB D
——. *See* MACNEE W, BUIST TAS, *et al*
——. *See* MALONEY DJL MORRITT A, *et al*
LAMB RK, EDWARDS CW, PATTISON CW, MATTHEWS HR: Squamous carcinoma *in situ* of the oesphagus in a patient with achalsia, 795
LAMBERT HP. *See* JOHNSTON I, PATEL S, *et al*
LAMONT G, ELLIOTT S, MORRIS DL: Spontaneous intramural oesophageal dissection, 558
LANE DJ. *See* CHADWICK GA, GLAZEBROOK K, *et al*
——. *See* COOKSON WOCM, JOHN S, *et al*
——. *See* SHALE DJ, FAUX JA, *et al*
LANGFORD JA. *See* GELLERT AR, LANGFORD JA, *et al*
——. *See* GELLERT AR, LEWIS CA, *et al*
LANIGAN C. *See* BROPHY CJ, MIER AK, *et al*
LANTZ BMT. *See* LINK DP, PARSONS GH, *et al*
LAPP NL. *See* REEVE P, LAPP NL, *et al*
LARGE SR, HEYWOOD LJ, FLOWER CDR, CORY-PEARCE R, WALLWORK J, ENGLISH TAH: Incidence and aetiology of a raised hemidiaphragm after cardipulmonary bypass, 444
LARKIN S. *See* HEYDERMAN E, LARKIN S, *et al*
Larva migrans, cutaneous, pulmonary eosinophilia associated with, case of, 76
Laser photoresection, carbon dioxide, in treatment of 2 cases of tracheobronchial amyloidosis, 870
therapy, amyloidosis of respiratory tract treated by, case of, 544
therapy, bronchoscopic, new rigid bronchoscope for (P), 700
therapy, functional effects in malignant narrowing of central airway (P), 723
therapy in 100 patients with tracheobronchial tumours, 341
LASZLO G: Standardised lung function tesing *(Letter)*, 479
——. *See also* HIGGS CMB, JONES P, *et al*
——. *See also* WARLEY ARH, NICHOLSON EM, *et al*
LAURENT GJ. *See* HAY JG, DEWAR A, *et al*
——. *See* HAY JG, HASLAM PL, *et al*
——. *See* OLIVER MH, COLE PJ, *et al*
LAVENDER JP. *See* IND PW, PETERS AM, *et al*
——. *See* OPENSHAW PJM, HUGHES JMB, *et al*
——. *See* ORPHANIDOU D, AL-SUHALI AR, *et al*
——. *See* SAVERYMUTTU SH, PHILLIPS G, *et al*
LAVIOLETTE M: Lymphocyte fluctuation in bronchoalveolar lavage fluid in normal volunteers, 651
LAW J. *See* MCLEOD DT, CAPEWELL SJ, *et al*
LAWRENCE D. *See* GREENSTONE MA, RUTMAN A, *et al*
LAWRENCE R. *See* SWEATMAN M, LAWRENCE R, *et al*
LAWSON C. *See* CHOWIENCZYK P, LAWSON C, *et al*
Laxative, bulk, allergy to isphaghula in workers manufacturing (P), 702
LEE G DE J. *See* SHAW DJ, CHAPEL H, *et al*
LEE TB. *See* SHAW RJ, YOUNGCHAIYUD P, *et al*
LEE TH, ANDERSON SD: Heterogeneity of mechanisms in exercise induced asthma (E), 481
——, INUI H, NAGAKURA T, IIKURA Y: Factors predisposing to exercise induced late asthmatic response (P), 219
——, PENNINGTON JE, ROSSING TH, BOERTH LW: The identification and partial characterisation of a human alveolar macrophage derived neutrophil activating factor (P), 221
——. *See also* DURHAM SR, LEE TH, *et al*
Legionnaires' disease, community acquired, review of 79 cases in Nottingham (P), 691
disease, diagnosis by bronchial lavage and transbronchial lung biopsy, 3 cases of, 154
Leiomyoma of lower respiratory tract, 3 cases of, 306
LEITCH AG. *See* CAPEWELL SJ, FRANCE AJ, *et al*
——. *See* FRANCE AJ, CAPEWELL SJ, *et al*
LENNARD-JONES T. *See* TAYLOR RG, PAVIA D, *et al*
LENNEY W. *See* CORRIN B, DANEL C, *et al*
LEONARD RCF. *See* BROUGHTON DL, GIBSON CJ, *et al*
LEOPOLD D. *See* EBDEN P, LEOPOLD D, *et al*
Leucocyte count, differential, in relation to smoking and allergy, 17; *Erratum*, 208
count, rise in smokers, due to plasma nicotine? (P), 696
count, total, and eosinophil count in blood and bronchial reactivity to histamine in smokers and ex-smokers (P), 718
Leucocytes, autologous, ^{111}In-labelled, scanning with, in lobar pneumonia and lung abscesses, 925
Leucotriene C_4 and prostaglandin D_2 release, IgE dependent, from human bronchoalveolar cells (P), 716
C_4, IgG mediated release from human eosinophils, relevance to asthma and hypereosinophilia (P), 716
D_4 and other agonists, effects on ^{45}Ca efflux from airway smooth muscle (P), 713
D_4, bronchoconstriction in asthmatics induced by, effect of verapamil (P), 714
D_4, bronchoconstriction in normal subjects induced by, verapamil inhibition of (P), 217
D_4, indirect contractile effect in guinea pig lung parenchyma mediated by thromboxane A_2? (P), 713
Leucotrienes C_4, and D_4, inhaled, relative potency in asthmatics and normals compared with methacholine (P), 717
in nasal hypersensitivity and polyposis (P), 215
LEUNG KBP. *See* FLINT KC, HUDSPITH BN, *et al*
LEVI JA. *See* STUART-HARRIS R, FOX RM, *et al*
LEWIS CA. *See* GELLERT AR, LEWIS CA, *et al*
LEWIS LD, O'DRISCOLL R, HORN CR, COCHRANE GM: Local fat necrosis secondary to a continuous subcutaneous infusion of terbutaline in unstable asthmatics (P), 705
LEWIS RA, ELLIS CJ, BAILEY A, HASHISH A, BALACHANDRAN W: Cough induced by ultrasonically nebulised water is related to aerosol particle charge (P), 718
LIN YH, HASLAM PL, TURNER-WARWICK M: Chronic pulmonary sarcoidosis: relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests, 501
LINNGTON A. *See* CUSS F, LINNGTON A, *et al*
LINK DP, PARSONS GH, LANTZ BMT, GUNTHER RA, GREEN JF, CROSS CE: Measurement of bronchial blood flow in the sheep by video dilution technique, 143
Lipoprotein aggregates in bronchoalveolar lavage samples from patients with chronic widespread pulmonary shadows, relevance of (P), 221
Liposarcoma, pleural, primary, case of, 554
LITTLE WC: Coughs cause systemic blood flow *(Letter)*, 160
LITTLEWOOD JM. *See* DODGE JA, GEDDES DM, *et al*
LLOYD MH. *See* COWIE H, LLOYD MH, *et al*
Lobar pneumonia and lung abscesses, indium 111 autologous leucocyte scanning in, 925
Lobectomy, exercise performance and carbon monoxide transfer factor in bronchial carcinoma before and after (P), 723
functional results of, prediction from bronchoscopic single breath tests (P), 236
LOZEWICZ S. *See* DURHAM SR, LEE TH, *et al*
LOEGERING D. *See* DURHAM SR, GLEICH GJ, *et al*
LOFTUS BG, PRICE JF: Slow release theophylline in preschool asthma (P), 230
LOH L. *See* SAWICKA EH, LOH L, *et al*
LOIRE R. *See* CORDIER JF, CELLIER CC, *et al*
——. *See* WEYNANTS P, CORDIER JF, *et al*
LOKE SL. *See* KUNG ITM, LOKE SL, *et al*
LOPEZ-VIDRIERO MT. *See* MILLAR AB, AGNEW JE, *et al*
——. *See* TAYLOR RG, PAVIA D, *et al*
LOZEWICZ S, DAVISON AG, HOPKIRK A, BURGE PS, BOLDY DAR, RIORDAN JF, MCGIVERN DV, PLATTS BW, DAVIES D, NEWMAN TAYLOR AJ: Occupational asthma due to methyl methacrylate and cyanoacrylates, 836

LUBLINER J. *See* GHOSH PK, LUBLINER J, *et al*
LUCE PJ, TAOR WS, MCNICOL MW: Bone tuberculosis in Brent (P), 697
LUKSZA AR. *See* GORDON IJ, COAKLEY J, *et al*
——. *See* GRAHAM DR, LUKSZA AR, *et al*
Lung abscess and empyema (P), 691
abscess and lobar pneumonia, indium 111 autologous leucocyte scanning in, 925
and thoracic cage abnormalities in Ehlers-Danlos syndrome, 300
angiotensin converting enzyme activity in chronically hypoxic rats, 587
biopsy, needle, percutaneous, cytological diagnosis of pulmonary neoplasms from, accuracy of (P), 699
biopsy, open, in patients with diffuse pulmonary shadowing, 931
cancer, gallium scanning by conventional imaging and emission computed tomography in pretreatment evaluation of, 96
cancer in south east Scotland, 1981–84, Edinburgh Lung Cancer Group survey (P), 209
cancer, mediastinal imaging in (P), 209
cancer, non-small cell, inoperable, cisplantin, vinblastine, and bleomycin in, 346
cancer, oat cell, 5 year survival after surgery for, influence of tumour size and positive lymph nodal invasion (P), 701
cancer, primary, and solitary brain metastasis, combined surgical treatment of, 191
cancer, small cell, combination chemotherapy or selective palliative treatment for, adverse reactions and quality of life during (P), 699
cancer, small cell, maintenance *v* no maintenance chemotherapy for, trial of (P), 699
cancer, small cell, neurone specific enolase as diagnostic serum marker for, 85
cancer, small cell, treatment policy of surgery in, analysis of 874 consecutive patients (1973–81), 272
cancer, squamous cell, advanced, trials of etoposide *v* no treatment and etoposide *v* etoposide + cyclophosphamide (P), 703
carcinoid tumours of, atypical, histological features and prognosis after surgery (P), 215
changes in congenital heart disease and Down's syndrome, significance as cause of postoperative respiratory failure, 380
cysts, longstanding, bronchioloalveolar carcinoma arising in *(Letter)*, 960
damage induced by *E coli* endotoxin, and angiotensin converting enzyme, in mouse, 774
development, early, and origin of congenital abnormalities (E), 401
disease and heart disease, comparison of exercise performance and grading of dysnoea in (P), 721
disease, bullous, assessment of (P), 214
disease, bullous, structure and function in (P), 710
disease, chronic, steady state exercise in, effect of oral high frequency oscillation (P), 213
disease, detection and assessment of, ventilation-perfusion scans for, computer analysis of, 519
disease in AIDS, management of (P), 703
disease in Behçet's syndrome (P), 231
disease, interstitial, macrophage like cells in bronchoalveolar lavage fluid in, expression of abnormal phenotype by (P), 727
disease, obstructive, chronic, breathing pattern in, role of airway receptors in, 268; *(Letters)*, 879, 880
disease, obstructive, chronic, performance, ventilation, and oxygen consumption in 3 types of exercise test in, 581
disease, obstructive. *See also* Airflow obstruction
disorders and contaminated humidifiers (E), 244
disorders, role of alveolar macrophages in (E), 321
effect of welding fumes in young shipyard welders (P), 702
epithelial permeability changes in haemodialysis (P), 723
epithelial permeability changes induced by histamine, mediated via H_1-receptors (P), 720
epithelial permeability in bronchiectasis (P), 238
epithelial permeability, measurment of, and bronchoalveolar lavage in assessment of asbestosis, 508
epithelial permeability, regional distribution in normal subjects and asbestosis patients, 734
function and respiratory symptoms in London primary school children, ethnic variation in (P), 712
function change in response to intravenous radiological contrast material, and complement activation (P), 240
function data, study by principal components analysis, 438
function, effects of pneumothorax or pleural effusion, 60
function in aluminium smelters *(Letters)*, 319
function in bone marrow transplantation, prospective study of (P), 233
function in elderly, 54
function laboratories, external quality assessment of (P), 710
function, respiratory symptoms and bronchial reactivity after pertussis in infancy (P), 690
function, static, and exercise performance, effects of mitral valve surgery, 107
function testing, standardisation of *(Letters)*, 479
function tests, spirometric, in normal non-smoking Ethiopian men and women, 465
function. *See also* Ventilatory function
immunocytoma of, primary, diagnostic value of bronchoalveolar lavage in case of, 542
infarction, cavitating, after bland pulmonary thromboembolism in 5 patients with adult respiratory distress syndrome, 915
injury, acute, after intravenous bleomycin, role of oxygen in induction of (P), 727
injury inducced by bleomycin, importance of iron in (P), 727
mucociliary clearance, effect of long term high dose ipratropium bromide (P), 212
neonatal, human, capillary plexus in gas exchange zone of, ultrastructural study, 787
parenchyma, guinea pig, indirect contractile effect of leucotriene D_4 in, mediated by thromboxane A_2? (P), 713
permeability, effect of histamine in normal and asthmatic subjects, 603
permeability in adult obliterative bronchiolitis (P), 7232
tissue from patients with cryptogenic fibrosing alveolitis, immunohistological analysis suggesting local immune response (P), 221; 405
tissue, malignant, epidermal growth factor and receptor in (P), 698
tissue volume, TLCO, and pulmonary capillary blood flow, simultaneous measurement of (P), 226
transplantation, immunological monitoring after, role of bronchoalveolar lavage in (P), 726
tumour volume, estimation from plain chest radiograph, accuracy of (P), 699
volumes and compliance and airway calibre, measurements of, preferential sites of action of bronchoconstrictor agents differentiated by? (P), 718
volumes, measurement in airflow obstruction, rapid gas dilution method for (P), 226
See also Bronchopulmonary; Pulmonary
LUSK RH. *See* STANLEY SL, jun, LUSK RH
Lymph node aspiration, extrathoracic, in bronchial carcinoma, 398
node tuberculosis, trial of 9 versus 18 months' chemotherapy in (P), 223
nodes in shrinking pleuritis with atelectasis, asbestos and other exogenous particles in, 948
Lymphadenopathy, generalised, persistent, and AIDS, value of TLCO estimation in (P), 223
thoracic, in Asians resident in UK, role of mediastinoscopy in initial diagnosis, 121
Lymphangioleomyomatosis presenting in postmenopausal woman, 475
Lymphangitis, malignant, bilateral, case of diffuse malignant mesothelioma presenting as, 682
Lymphocytes, bronchoalveolar, and T cell subsets, changes in pulmonary sarcoidosis, 278
fluctuation in bronchoalveolar lavage fluid in normal volunteers,

651
human, neutrophil chemotactic activity derived from, partial characterisation and inhibition of release (P), 719
See also T cell
Lymphoid hyperplasia, angiofollicular (giant lymph node hyperplasia), in pulmonary fissure, case of, 686
Lymphoma, non-Hodgkin's, of bronchial mucosa, case presenting with reversible airflow obstruction, 954
LYONS D, MOSZORO H, MILLEDGE JS: Effect of ethanol on transfer factor (P), 233

M

MCCARTHY G. *See* COOKSON WOCM, JOHN S, *et al*
MCCARTHY S. *See* COOKSON WOCM, JOHN S, *et al*
MCCARTHY A, BULL TB, FOX B: Is the mast cell associated with chronic bronchitis and cancer? An electron microscopic study (P), 214
MCCARTY J. *See* ASHFORD N, CRACKNELL N, *et al*
MCCONNOCHIE K, EDWARDS J, FIFIELD R, COLLINS G, TROTMAN D: Allergy to isphaghula in workers manufacturing a bulk laxative (P), 702
MCCULLOCH AJ, MCEVOY A, JACKSON JD, JARVIS EH: Severe steroid responsive pneumonitis associated with pyoderma gangrenosum and ulcerative colitis, 314
MACDERMOT J. *See* FULLER RW, KEMENY DM, *et al*
MACDONALD AJ. *See* MOQBEL R, DURHAM SR, *et al*
MCEVOY A. *See* MCCULLOCH AJ, MCEVOY A, *et al*
MACFARLANE JT (for BTS Research Committee): BTS pneumonia study: mortality (P), 694
—— (for BTS Research Committee): Multicentre study of the effects of oral *N*-acetylcysteine in patients with chronic bronchitis and severe airways obstruction (P), 227
——, FINCH RG: *Pneumocystis carinii* pneumonia (E), 561
——. *See also* WOODHEAD MA, MACFARLANE JT
MCGAVIN CR (for British Thoracic Society Research Committee): Lymph node tuberculosis: a controlled trial of nine versus 18 months' chemotherapy (P), 223
MCGIVERN DV. *See* LOZEWICZ S, DAVISON AG, *et al*
MCGUINNESS JB. *See* NORTHCOTE RJ, SETHIA B, *et al*
MACHA HN, KOCH K, STADLER M, SCHUMACHER W, KRUMHAAR D: A new approach in the treatment of inoperable malignant tumours in the trachea and main bronchi, using iridium 192 and Neodym-YAG laser (P), 700
MCHARDY GJR. *See* RHIND GB, GOULD GA, *et al*
MCINTYRE D. *See* NEILLY JB, CLARK CJ, *et al*
MACKAY IS. *See* GREENSTONE MA, STANLEY PJ, *et al*
——. *See* STANLEY PJ, GRIFFIN WM, *et al*
MACKAY J. *See* MOQBEL R, DURHAM SR, *et al*
MACKAY JA, CROMWELL O, KAY AB: Allergen induced release of high molecular weight neutrophil chemotactic activity in nasal secretions from patients with allergic rhinitis (P), 719
MACKENZIE S. *See* COUTTS II, MACKENZIE S, *et al*
MCKILLOP J. *See* MILROY R, SMITH L, *et al*
MACLAREN W. *See* MCLEOD DT, CAPEWELL SJ, *et al*
MCLEOD DT, AHMAD F, CAPEWELL SJ, CROUGHAN MJ, CALDER MA, SEATON A: Increasing incidence of *Branhamella catarrhalis* bronchopulmonary infection: is ampicillin or trimethoprim responsible? (P), 691
——, CALVERLEY PMA, MILLAR JW, HORNE NW: Further experience of *Corynebacterium parvum* in malignant pleural effusion, 515
——, CAPEWELL SJ, LAW J, MACLAREN W, SEATON A: Intramuscular triamcinolone acetonide in chronic severe asthma, 840
——, ——, SEATON A: Intramuscular triamcinolone in chronic severe asthma (P), 228
MACNEE W, BUIST TAS, FINLAYSON NDC, LAMB D, MILLER HC, MUIR AL, DOUGLAS AC: Multiple microscopic pulmonary arteriovenous connections in the lungs presenting as cyanosis, 316
——, WHYTE KF, WATHEN CG, MUIR AL, FLENLEY DC: Right ventricular function in acute and chronic cor pulmonale—the acute effects of oxygen (P), 711
——. *See also* FRANCE AJ, PRINCE KL, *et al*
MCNICHOLAS WT. *See* COFFEY M, MCNICHOLAS WT, *et al*
MCNICOL MW. *See* LUCE PJ, TAOR WS, *et al*
Macrophage like cells in bronchoalveolar lavage in interstitial lung disease, expression of abnormal phenotype by (P), 727
Macrophages, alveolar, function and role in lung disorders (E), 321
alveolar, human, expression of α_1 proteinase inhibitor gene by (P), 219
alveolar, human, mediators released by IgE/anti-IgE complexes from (P), 716
alveolar, human, neutrophil activating factor derived from, identification and partial characterisation of (P), 221
alveolar, phagocytosis in sarcoidosis (P), 220
alveolar, release of reactive oxygen species by, modification by serum factors and proteinase inhibitors (P), 219
alveolar, with inclusions in cigarette smokers, persistence after stopping smoking (P), 725
MCSHARRY CP. *See* ANDERSON K, MCSHARRY CP, *et al*
MADDEN CA. *See* MASCIE-TAYLOR BH, WARDMAN AG, *et al*
MAISEY MN. *See* REES PJ, SHELTON DM, *et al*
MAKIN CA. *See* HEYDERMAN E, LARKIN S, *et al*
MALIK F. *See* IND PW, PETERS AM, *et al*
MALO J-L: Occupational asthma due to heated freon *(Letter)*, 320
MALONEY DJL, MORRITT A, WALBAUM PR, LAMB D: Atypical carcinoid tumours of the lung: histological features and prognosis after surgery (P), 215
MANEKSA JR. *See* RUSSO PA, WRIGHT JEC, *et al*
MANN JS. *See* GREWAL PK, MANN JS, *et al*
MANNHIRE A. *See* FLINT KC, JOHNSON N MCI, *et al*
MANNION P, HONAN RP, FITZGERALD MD, HASLETON PS: Contiguous granular cell myoblastoma and squamous cell carcinoma in the oesphagus, 551
MARCHAND P. *See* SOLOMONS K, POLAKOW R, *et al*
MARCHEVSKY A. *See* ROSEN MJ, TOW TWY, *et al*
MARSH C. *See* VEALE D, MARSH C, *et al*
MARTIN AJ. *See* STAUGAS R, MARTIN AJ
MARTIN B. *See* NEILLY JB, CARTER R, *et al*
MARTIN PD. *See* GRAHAM AN, MARTIN PD, *et al*
MARTIN W. *See* SETHIA B, REECE IJ, *et al*
MASCIE-TAYLOR BH, WARDMAN AG, MADDEN CA, PAGE RL: A case of alveolar microlithiasis: observation over 22 years and recovery of material by lavage, 952
Mast cell and histamine content of human bronchoalveolar lavage fluid, 760
cells, bronchoalveolar, hyperosmolar release of histamine from, and inhibition by sodium cromoglycate (P), 717
cells, bronchoalveolar, hyperresponsiveness in sarcoidosis (P), 220
cells, electron microscopic study for associations with chronic bronchitis and cancer (P), 214
cells in bronchoalveolar lavage fluid in asthma and other respiratory diseases (P), 717
cells, involvment in type I allergic reactions in man, direct evidence for (P), 218
cells, pulmonary, human, staining characteristics of (P), 214
cells, stabilisers of. *See* Nedocromil
MATTHEW D. *See* DAVIES H, GORDON I, *et al*
MATTHEWS HR. *See* LAMB RK, EDWARDS CW, *et al*
MAXWELL D. *See* FULLER RW, DIXON CMS, *et al*
MAXWELL DL, ROYSTON D, HUGHES JMB: Patterns of breathing during weaning from mechanical ventilation after thoracic surgery (P), 213
MAXWELL RJ, GIBBONS JR, O'HARA MD: Solitary squamous papilloma of the bronchus, 68
MAYBERRY JF, ATKINSON M: A study of swallowing difficulties in first degree relatives of patients with achalasia, 391
MEARNS MB. *See* DODGE JA, GEDDES DM, *et al*

MEBAN C. *See* DORNAN JC, MEBAN C
Mediastinal imaging in lung cancer (P), 209
Mediastinoscopy, role in initial diagnosis of thoracic lymphadenopathy in Asians resident in UK, 121
Mediastinum, anterior, mass in, and Graves's disease, 2 cases of, 469
MEDICAL RESEARCH COUNCIL TUBERCULOSIS AND CHEST DISEASES UNIT: Treatment of pulmonary tuberculosis in patients notified in England and Wales in 1978–9: chemotherapy and hospital admission, 113
MEINDOK HO. *See* COHEN RD, BUNTING PS, *et al*
MEKONNEN Y. *See* MENGESHA YA, MEKONNEN Y
MENDOZA J. *See* BORZONE G, DIAZ M, *et al*
MENGESHA YA, MEKONNEN Y: Spirometric lung function tests in normal non-smoking Ethiopian men and women, 465
Menstrual cycle, natural, airway responsiveness to methacholine during, and effect of oral contraceptives (P), 718
Mental function in respiratory disease, relative effects of hypoxia and secondary polycythaemia (P), 231
MERRET TG. *See* BURR ML, MULLINS J, *et al*
Mesothelioma, malignant, and pulmonary adenocarcinoma, comparison of tumour markers in, 91
malignant, diffuse, case presenting as bilateral malignant lymphangitis, 682
pleural, treated by fast neutron therapy, case of, 72
epithelial markers in, immunoperoxidase study of epithelial membrane antigen, cytokeratin, and carcinoembryonic antigen as (P), 215
Metabolic and cardiac effects of nebulised salbutamol in normal volunteers (P), 706
Methacholine, airway responsiveness during natural menstrual cycle to, and effect of oral contraceptives (P), 718
and histamine, increased responsiveness to, after challenge with ultrasonically nebulised water in asthma, 427
and hyperventilation in asthma and chronic bronchitis, differences in responsiveness to, 422
relative potency in asthmatics and normals compared with inhaled leucotrienes C_4 and D_4 (P), 717
Methionine sulfoxide-peptide reductase and catalase, effects *in vitro* and *in vivo* on oxidation of α_1-proteinase inhibitor (P), 724
Methyl methacrylate and cyanoacrylates, occupational asthma due to, 836
MEYER RW. *See* HIRSCHLER-SCHULTE CJW, HYLKEMA BS, *et al*
MICKISCH G. *See* TOOMES H, MICKISCH G, *et al*
Micro-catheter transtracheal oxygen administration in chronic obstructive airways disease (P), 709
Microlithiasis, alveolar, observation of case over 22 years and recovery of material by lavage, 952
MIDWOOD CJ. *See* VENN GE, KAY PH, *et al*
MIER AK, MILLER J, BROPHY CJ, MOXHAM J, GREEN M: Diaphragmatic weakness and orthopnoea (P), 701
——. *See also* BROPHY CJ, MIER AK, *et al*
——. *See also* SPITERI MA, MIER AK, *et al*
MIHOLIC J. *See* KLEPETKO W, MIHOLIC J
Miliary tuberculosis, sputum negative, rapid diagnosis with flexible fibreoptic bronchoscope (P), 696
MILLAR AB, AGNEW JE, NEWMAN SP, LOPEZ-VIDRIERO MT, PAVIA D, CLARKE SW: A comparison of nasal and tracheobronchial clearance using similar techniques in normal subjects (P), 724
——, O'REILLY AP, CLARKE SW, HETZEL MR: Amyloidosis of the respiratory tract treated by laser therapy, 544
MILLAR JW. *See* MCLEOD DT, CALVERLEY PMA, *et al*
MILLARD FJC. *See* HETZEL MR, NIXON C, *et al*
MILLEDGE JS. *See* LYONS D, MOSZORO H, *et al*
MILLER HC. *See* MACNEE W, BUIST TAS, *et al*
MILLER J. *See* MIER AK, MILLER J, *et al*
——. *See* MOXHAM J, MILLER J, *et al*
MILLER MR: Nifedipine enhances the bronchodilator effect of salbutamol *(Letter)*, 399
MILLERON B. *See* CADRANEL J, MILLERON B, *et al*
MILLS RJ. *See* AHMEDZAI S, CARTER R, *et al*
MILROY R, SMITH L, FAICHNEY A, ANDERSON D, STEWART I, MCKILLOP J, BANHAM S, DAVIDSON K: Mediastinal imaging in lung cancer (P), 209
MILSTEIN BB. *See* HAKIM M, MILSTEIN BB
——. *See* HAKIM M, TIMBS A, *et al*
——. *See* HAKIM M, WHEELDON D, *et al*
MITCHELL DM. *See* HETZEL MR, NIXON C, *et al*
MITCHELL DN. *See* MUNRO CS, MITCHELL DN, *et al*
Mitral valve prosthesis, Björk-Shiley, disc and strut embolisation after minor strut fracture in, case of, 158
valve surgery, effects on static lung function and exercise performance, 107
MITTAL PK. *See* TENDOLKAR AG, MITTAL PK, *et al*
MOGHISSI K, JESSOP A, DENCH M: A new rigid bronchoscope for bronchoscopic laser therapy (P), 700
MOGILNAR M. *See* GHOSH PK, LUBLINER J, *et al*
MOHAMEDANI AA, BENNETT MK: Angiofollicular lymphoid hyperplasia in pulmonary fissure, 686
——. *See also* GILMARTIN JJ, MOHAMEDANI A, *et al*
MOK CK. *See* KUNG ITM, LOKE SL, *et al*
Monoclonal antibodies, panel of, in immunostaining of bronchial carcinomas (P), 698
gammopathies in chest disease, 629
Monocytes and neutrophils, cytotoxicity enhanced after exercise induced asthma (P), 218
MOORE-GILLON JC, GEORGE RJD, GEDDES DM: An oxygen conserving nasal cannula (P), 233; 817
——. *See also* WINTER RJD, GEORGE RJD, *et al*
MOOTOOSAMY IM, REZNEK RH, OSMAN J, REES RSO, GREEN M: Assessment of bronchiectasis by computed tomography, 920
MOQBEL R, DURHAM SR, CARROLL M, MACDONALD AJ, WALSH GM, MACKAY J, SHAW RJ, KAY AB: Enhanced neutrophil and monocyte cytotoxicity after exercise induced asthma (P), 218
——. *See also* SHAW RJ, WALSH GM, *et al*
MORAN F. *See* AHMEDZAI S, CARTER R, *et al*
MORGAN A. *See* COOKE J, CURRIE DC, *et al*
MORGAN GP. *See* ALLEN SL, FOSTER RW, *et al*
MORGAN MDL, BUSST CM, DENISON DM, STICKLAND BS: Assessment of bullous lung disease (P), 214
——, GOURLAY AR, SILVER JR, WILLIAMS SJ, DENISON DM: Contribution of the rib cage to breathing in tetraplegia, 613
——. *See also* GOLDMAN JM, MORGAN MDL, *et al*
MORGAN WE. *See* SABANATHAN S, SALAMA FD, *et al*
MORICE AH, KENNEDY C, SEVER PS: Does circulating adrenaline protect against exercise induced bronchoconstriction? (P), 715
——, SCHOFIELD PM, SEVER PS, KEAL EE: A comparison of the effect of aminophylline and salbutamol on minute ventilation and the ventilatory response to carbon dioxide (P), 234
——, SEVER PS: The effect of intravenous VIP following cholinergic blockade (P), 714
MORRIS AJR. *See* MOXHAM J, MILLER J, *et al*
MORRIS DL, CLARKSON MJ, STALLBAUMER MF, PRITCHARD J, JONES RS, CHINNERY JB: Albendazole treatment of pulmonary hydatid cysts in naturally infected sheep: a study with relevance to the treatment of hydatid cysts in man, 453
——. *See also* LAMONT G, ELLIOTT S, *et al*
MORRIS M. *See* O'BYRNE PM, ADELROTH E, *et al*
MORRIS MM. *See* RAMSDALE EH, ROBERTS RS, *et al*
MORRIS PK. *See* FULLER RW, KEMENY DM, *et al*
MORRIS RW. *See* PEACH H, ELLARD GA, *et al*
MORRISON HM, HILL SL, STOCKLEY RA: Treatment response of bronchiectatic secretions with three amoxycillin regimes (P), 238
——, STOCKLEY RA: Oxidation of α_1-proteinase inhibitor: the effect of catalase and methionine sulfoxide-peptide reductase *in vitro* and *in vivo* (P), 724
——, SYKES D, COLE PJ, STOCKLEY RA: Cell profile and neutrophil chemotactic factor in lung fluid from patients with chronic bronchitis or α_1-proteinase inhibitor deficiency (P), 724
——. *See also* STOCKLEY RA, HILL SL, *et al*
——. *See also* STOCKLEY RA, MORRISON HM, *et al*

MORRITT A. *See* MALONEY DJL, MORRITT A, *et al*
MORRITT GN. *See* GILMARTIN JJ, VEALE D, *et al*
MORTAGY AK, HOWELL JBL, WATERS WE: Respiratory symptoms, bronchial reactivity and asthma (P), 695
MORTON AR. *See* HAHN AG, NORGRADY SG, *et al*
MORTON JJ. *See* NEILLY JB, CLARK CJ, *et al*
MOSS FM, BOBROW LG, SHEPPARD M, GRIFFITHS M, ROWE D, BEVERLEY PCL, ADDIS B, SOUHAMI RL: Immunostaining of bronchial carcinomas using a panel of monoclonal antibodies (P), 698
MOSZORO H. *See* LYONS D, MOSZORO H, *et al*
Moulds, indoor, exposure to, and asthma (P), 688
MOXHAM J, MILLER J, WILES CM, MORRIS AJR, GREEN M: Effect of aminophylline on the human diaphragm, 288
——. *See also* BROPHY CJ, MIER AK, *et al*
——. *See also* JENKINS SC, HEATON RW, *et al*
——. *See also* MIER AK, MILLER J, *et al*
Mucociliary clearance and ciliary beat frequency, nasal, human, effects of betamethasone alone and with neomycin nasal drops, 607
clearance in lung, effect of long term high dose ipratropium bromide (P), 212
clearance, increase induced by oral high frequency oscillation in normal man, 433
clearance, tracheobronchial, in asthma, impairment during remission, 171
transport *in vivo*, effect of chronic denervation (P), 239
Mucosa, bronchial, non-Hodgkin's lymphoma of, case presenting with reversible airflow obstruction, 954
MUERS MF. *See* SIMPSON FG, ARNOLD AG, *et al*
MUIR AL. *See* FRANCE AJ, PRINCE KL, *et al*
——. *See* MACNEE W, BUIST TAS, *et al*
——. *See* MACNEE W, WHYTE KF, *et al*
MULDERRY PK. *See* PALMER JBD, CUSS FMC, *et al*
MULLEY BA. *See* PEAKE MD, CHRYSTYN H, *et al*
MULLINS J. *See* BURR ML, MULLINS J, *et al*
MUNRO C. *See* ALTON EW, HAY JG, *et al*
MUNRO CS, MITCHELL DN, POULTER LW, COLE PJ: *In vivo* effects of different spleen suspensions on macrophage distribution and phenotype in the Kveim test (P), 725
——, ——, ——, ——: The Kveim test induces a local cell mediated response in normal but not Kveim positive subjects (P), 725
MURRAY A. *See* VEALE D, GILMARTIN JJ, *et al*
MURRAY CRH. *See* PARKES SA, BAKER SB DE C, *et al*
Muscarinic receptors and phosphatidylinositol turnover in airway smooth muscle (P), 713
MUSK AW. *See* COOKSON WOCM, MUSK AW, *et al*
MUSSI A, JANNI A, PISTOLESI M, RAVELLI V, BUONAGUIDI R, ANGELETTI CA: Surgical treatment of primary lung cancer and solitary brain metastasis, 191
Mustine hydrochloride pleurodesis in malignant pleural effusion, survival after, comparison with *Corynebacterium parvum pleurodesis*, 515
Mycobacterium malmoense and *M xenopi*, *in vitro* sensitivity patterns, comparison of effects of combined and single anti-tuberculosis drugs (P), 697
Mycoplasma pneumoniae, proved, secondary bacterial infections in children with, 5 cases of, 546
MYERS MJ. *See* ORPHANIDOU D, AL-SUHALI AR, *et al*
Myoblastoma, granular cell, and squamous cell carcinoma, contiguous, in oesophagus, case of, 551
Myocardial tuberculosis, sudden death due to *(Letters)*, 799

N

Nabilone, respiration not depressed by (P), 723
NAGAKURA T. *See* LEE TH, INUI H, *et al*
NANSON EM. *See* HETZEL MR, NIXON C, *et al*
NARIMAN S. *See* RHODES KM, EVEMY K, *et al*
NARUSE Y. *See* CHINN DJ, NARUSE Y, *et al*
Nasal airway response to topical histamine, assessment of, comparison of 3 methods (P), 216
and tracheobronchial mucociliary clearance, comparison of, using similar techniques in normal subjects (P), 724
cannula conserving oxygen, 817 (P), 233; 817
continuous positive airway pressure, long term, in treatment of severe obstructive sleep apnoea, 45
electrical potential recordings as new diagnostic test for cystic fibrosis (P), 704
hypersecretion and blockage in atopic and non-atopic perennial rhinitis, histamine as mediator of (P), 719
hypersensitivity and polyposis, leukotrienes in (P), 215
mucociliary clearance and ciliary beat frequency, human, effects of betamethasone alone and with neomycin nasal drops, 607
secretions in allergic rhinitis, allergen-induced release of high molecular weight neutrophil chemotactic activity in (P), 719
sensitivity and suppressor cell function in hay fever (P), 239
NEALE MG. *See* PATEL KR, TULLETT WM, *et al*
——. *See* TULLETT WM, TAN KM, *et al*
Nebulised antibiotics in treatment of purulent bronchiectasis (P), 704
Nebuliser aerosols for bronchodilation, droplet size matters? (P), 222
therapy and cardiac dysrhythmias in COAD (P), 704
therapy, patient compliance and problems (P), 705
Nebulisers, air driven, 24 hour ECG monitoring in patients using (P), 231
jet, and intermittent positive pressure breathing, effect on breathing pattern (P), 233
jet, for use with gentamicin solution, evaluation of, 671
Nedocromil inhibition of allergen and exercise induced asthma (P), 219
sodium for management of bronchial asthma, trial of *(Letters)*, 400
Needle aspiration, transbronchial, in clinical practice, 756
NEILD JE, EYKYN SJ, PHILLIPS I: Lung abscess and empyema (P), 691
NEILLY JB, CARTER R, TWEDDEL AC, MARTIN B, BANHAM SW, STEVENSON RD: Does long term therapy with oral beta$_2$ agonist improve pulmonary haemodynamics in hypoxic chronic bronchitis? (P), 707
——, CLARK CJ, TWEDDEL AC, RAE AP, MCINTYRE D, HUNTON IH, MORTON JJ, STEVENSON RD: Transpulmonary formation of angiotensin II in chronic stable cor pulmonale (P), 225
——, WINTER JH, STEVENSON RD: Progressive tracheobronchial polychondritis: need for early diagnosis, 78
Neodym-YAG laser and iridium 192 in treatment of inoperable malignant tumours of trachea and main bronchi (P), 700
Neomycin nasal drops, betamethasone with and without, effects on human nasal mucociliary clearance and ciliary beat frequency, 607
Neonatal lung, human, capillary plexus in gas exchange zone of, ultrastructural study, 787
Neonates, premature, of very low birthweight, ligation of patent ductus arteriosus in, 533
Neoplasms, pulmonary, cytological diagnosis from percutaneous lung needle biopsy, accuracy of (P), 699
Neuralgic amyotrophy with bilateral diaphragmatic palsy, case of, 635
Neuromuscular and chest wall disease, cuirass assisted ventilation in (P), 701
Neurone specific enolase as diagnostic serum marker for small cell carcinoma of lung, 85
Neuropathy, autonomic, diabetics with and without, bronchial histamine reactivity in (P), 217
Neutron therapy, fast, in treatment of case of pleural mesothelioma, 72
Neutrophil activating factor derived from human alveolar macrophages, identification and partial characterisation of (P), 221
chemotactic activity derived from human lymphocytes, partial characterisation and inhibition of release (P), 719
chemotactic activity, high molecular weight, allergen induced release in nasal secretions in allergic rhinitis (P), 719
chemotactic activity in asthmatic reactions induced by oc-

cupational exposure (P), 218
chemotactic factor and cell profile in lung lavage fluid in chronic bronchitis or α_1-proteinase inhibitor deficiency (P), 724
elastase inhibition by sputum, variability and relationship to known inhibitors (P), 725
function in bronchial asthma, effect of corticosteroids (P), 211
Neutrophils and monocytes, cytotoxicity enhanced after exercise induced asthma (P), 218
kinetics of, and oxidative injury associated with cardiopulmonary bypass (P), 240
NEWLAND AC. *See* WALLIS PJW, APPS MCP, *et al*
——. *See* WALLIS PJW, FEW JD, *et al*
NEWMAN SP, PELLOW PGD, CLAY MM, CLARKE SW: Evaluation of jet nebulisers for use with gentamicin solution, 671
——. *See also* MILLAR AB, AGNEW JE, *et al*
——. *See also* TAYLOR RG, PAVIA D, *et al*
NEWMAN-TAYLOR AJ. *See* ASSOUFI BK, DALLY MB, *et al*
——. *See* DURHAM SR, GRANEEK BJ, *et al*
——. *See* DURHAM SR, LEE TH, *et al*
——. *See* HARRIES MG, LACEY J, *et al*
——. *See* LOZEWICZ S, DAVISON AG, *et al*
——. *See* VENABLES K, DAVISON A, *et al*
Newmarket suction pump for external negative pressure ventilation, comparison with standard Cape pump, 677
NICHOLSON EM. *See* WARLEY ARH, NICHOLSON EM, *et al*
Nicotine, plasma level, raised white blood cell count in smokers due to? (P), 696
Nifedipine, acute haemodynamic effects at rest and during maximal exercise in chronic cor pulmonale, 910
enhancement of bronchodilator effect of salbutamol *(Letters)*, 399
hormones and haemodynamics in chronic cor pulmonale at rest and on exercise before and after (P), 225
NILSSON K. *See* ESSCHER T, STEINHOLTZ L, *et al*
Nitrogen, liquid, freezing with, heart valves preserved by, morphology of, 778
NIXON C. *See* HETZEL MR, NIXON C, *et al*
NOAH ND. *See* AYRES JG, NOAH ND
NOGRADY SG. *See* HAHN AG, NOGRADY SG, *et al*
NOLAN MT, FITZGERALD MX: Reversible airways obstruction in sarcoidosis (P), 722
——, GIBNEY N, BRENNAN N, FITZGERALD MX: Paradoxical vocal cord motion in asthma (P), 689
NORTHCOTE RJ, SETHIA B, MCGUINNESS JB: Aberrant origin of the left coronary artery with associated aortic stenosis, 152
Notices, 80, 160, 240, 320, 400, 480, 560, 640, 728, 800, 960
NÕU E. *See* ESSCHER T, STEINHOLTZ L, *et al*
NOVELLI V. *See* DAVIES H, GORDON I, *et al*
NUNN AJ, BYFIELD SP, CITRON KM, DARBYSHIRE JH, FOX W, HUMPHRIES MJ, SPRINGETT VH: Are the tuberculosis notification rates for the Indian subcontinent population in England declining as fast as the 1983 survey suggests? (P), 690
——. *See also* DARBYSHIRE JH, BYFIELD SP, *et al*
NUNN P. *See* GREENING AP, NUNN P, *et al*

O

Oat cell carcinoma of lung, 5 year survival after surgery for, influence of tumour size and positive lymph nodal invasion (P), 701
Obesity, sleep apnoea and hypoventilation in (P), 235
O'BRIEN A. *See* O'CONNOR CM, O'BRIEN A, *et al*
O'BRIEN IM. *See* BURGE PS, HARRIES MG, *et al*
O'BYRNE PM, ADELROTH E, MORRIS M, HARGREAVE FE: Relative potency of inhaled leucotrienes C_4 and D_4 compared with methacholine in asthmatics and normals (P), 717
O'CONNELL JM. *See* CAMPBELL AH, BARTER CE, *et al*
O'CONNOR CM, O'BRIEN A, SWEENEY E, FITZGERALD MX: Progress of bleomycin induced lung fibrosis in rabbits (P), 222
O'DRISCOLL R. *See* LEWIS LD, O'DRISCOLL R, *et al*
Oesphageal intramural pseudodiverticulosis, 12 cases and review of previous cases, 849
Oesophagogastrectomy using end to end anastomotic stapler, results of first 100 patients, 958
Oesophagoplasty, subcutaneous transposition of proximal oesophagus in, 936
Oesophagus, carcinoma of, squamous, *in situ*, in patient with achalasia, 795
contiguous granular cell myoblastoma and squamous cell carcinoma in, case of, 551
hamartoma of, giant, case of, 684
intramural dissection of, spontaneous, case of, 558
Office buildings, 2, with different ventilation systems, comparison of work related health problems and environmental measurements in (P), 211
O'HARA MD. *See* MAXWELL RJ, GIBBONS JR, *et al*
OLAFSSON M, SIMONSSON BG, HANSSON S-B: Bronchial reactivity in patients with recent pulmonary sarcoidosis, 51
OLDENBURG FA. *See* HARROW EM, OLDENBURG FA, *et al*
Oligospermia and bronchiectasis in 2 families, 376
OLIVER MH, COLE PJ, LAURENT GJ: Secretion of fibroblast growth promoting activity by lavage inflammatory cells in bleomycin induced pulmonary fibrosis in the rabbit (P), 222
OLLIER S. *See* BLAINEY AD, OLLIER S, *et al*
O'MALLEY JA. *See* GOSNEY JR, SISSONS MCJ, *et al*
O'NEILL PA, DODDS M, POOLE J, PHILIPS B, WEBB AK: Regular exercise and the relationship of breathlessness to ventilation in cystic fibrosis (P), 721
Open heart surgery. *See* Heart surgery, open
OPENSHAW PJM, HUGHES JMB, CARR D, VALIND S, LAVENDER JP, PRIDE NB: Structure and function in bullous lung disease (P), 710
O'REILLY AP. *See* MILLAR AB, O'REILLY AP, *et al*
ORPHANIDOU D, AL-SUHALI AR, LAVENDER JP, MYERS MJ, HUGHES JMB: Tomographic measurements of regional ventilation-perfusion and $\dot{V}_A/\dot{Q}$ using krypton 81m (P), 233
ORR TSC. *See* SHAW RJ, YOUNGCHAIYUD P, *et al*
Orthopnoea and diaphragmatic weakness (P), 701
Oscillation, high frequency, oral, effect on steady state exercise in chronic lung disease (P), 213
high frequency, oral, increased mucociliary clearance in normal man induced by, 433
Oscillator, high frequency, oral, portable, for relief of breathlessness and improvement of exercise tolerance (P), 710
OSMAN J, CORRADO OJ, DAVIES RJ: Asthma and rhinitis after glutaraldehyde exposure (P), 224
——. *See also* MOOTOOSAMY IM, REZNEK RH, *et al*
Osteomyelitis, sternal, primary, case of, 872
ØSTERLIND K, HANSEN M, HANSEN HH, DOMBERNOWSKY P, RØRTH M: Treatment policy of surgery in small cell carcinoma of the lung; retrospective analysis of a series of 874 consecutive patients, 272
Oxidative injury associated with cardiopulmonary bypass, and neutrophil kinetics (P), 240
Oxitropium bromide, inhaled, in treatment of nocturnal asthma (P), 705
Oxygen, acute effects of right ventricular function in acute and chronic cor pulmonale (P), 711
as pulmonary vasodilator, comparison with prostacyclin (P), 716
concentrators, evaluation of 6 molecular sieve models, 806
concentrators, technical and clinical assessment of 1 membrane oxygen enricher and 4 molecular sieve models (P), 708; 811
delivery, inspiration phased (P), 213
delivery to tissue and pulmonary capillary blood flow, correlation in ventilated patients (P), 711
devices conserving, in chronic bronchitis and emphysema, clinical assessment of 3 types, 820
long term, for hypoxic cor pulmonale, 8-year follow up and prognostic factors (P), 711
nasal cannula conserving (P), 233; 817
nebulised salbutamol without, in severe acute asthma, trial of efficiency and safety, 180
reactive species of, alveolar macrophage release of, modification

by serum factors and proteinase inhibitors (P), 219
role in induction of acute lung injury after intravenous bleomycin (P), 727
therapy, long term, provision of (E), 801
tracheal concentrations with Hudson and MC masks (P), 709
transtracheal administration via microcatheter in chronic obstructive airways disease (P), 709
Oxygen centred free radicals in cigarette smoke and emphysema production in smokers (P), 220
Oxygenation, arterial measurement of, Biox IIA ear oximeter for, evaluation of (P), 708; 825

P

PACKE GE, CAYTON RM, EDWARDS CW: Comparison of right ventricular size at necropsy in interstitial pulmonary fibrosis and in chronic bronchitis and emphysema (P), 712
——, EDWARDS CW, CAYTON RM: Non-Hodgkin's lymphoma of the bronchial mucosa presenting with reversible airflow obstruction, 954
PAGE RL. *See* MASCIE-TAYLOR BH, WARDMAN AG, *et al*
PAGES J. *See* WEYNANTS P, CORDIER JF, *et al*
PÅHLMAN S. *See* ESSCHER T, STEINHOLTZ L, *et al*
PALMER JBD, CUSS FMC, MULDERRY PK, GHATEI MA, BLOOM SR, BARNES PJ: Calcitonin gene related peptide is a potent constrictor of human airway smooth muscle (P), 713
——, ——, WARREN JB, BARNES PJ: Effect of infused vasoactive intestinal peptide in normal subjects (P), 714
——. *See also* CUSS FMC, PALMER JBD, *et al*
——. *See also* GRANDORDY B, CUSS FMC, *et al*
Pancreactic tissue, ectopic, intralobar pulmonary sequestration of, with gastropancreatic duplication, case of, 637
PANTIN CFA, DEWAR A, HASLAM PL: Relevance of lipoprotein aggregates in bronchoalveolar lavage samples from patients with chronic widespread pulmonary shadows (P), 221
——. *See also* BOOKER HA, PANTIN CFA, *et al*
——. *See also* SPITERI MA, MIER AK, *et al*
——. *See also* STEAD RJ, PANTIN CFA, *et al*
——. *See also* SWEATMAN M, LAWRENCE R, *et al*
PAPACOSTA AO. *See* BRITTON JR, BURNEY PGJ, *et al*
Papilloma, squamous, solitary, of bronchus, 68
Papillomatosis, juvenile, multiple, squamous bronchial carcinoma arising in case of, 797
Parainfluenza viruses 1 and 2, respiratory syncytial virus, winter acute bronchitis and autumnal asthma in general practice in UK (1976–84) (P), 690
PARKER RA. *See* SAWICKA EH, PARKER RA, *et al*
——. *See* SIMONDS AK, PARKER RA, *et al*
PARKES SA, BAKER SB DE C, BOURDILLON RE, MURRAY CRH, RAKSHIT M, SARKIES JWR, TRAVERS JP, WILLIAMS EW: Incidence of sarcoidosis in the Isle of Man, 284
PARRY D. *See* CHOWIENCZYK P, LAWSON C, *et al*
PARSONS GH. *See* LINK DP, PARSONS GH, *et al*
PARULKAR GB. *See* TENDOLKAR AG, MITTAL PK, *et al*
PATCHETT PA. *See* BURGE PS, HARRIES MG, *et al*
PATEL KR, TULLETT WM, NEALE MG, WALL RT: Dose-duration effect of sodium cromoglycate aerosol in exercise asthma (P), 706
——. *See also* TULLET WM, TAN KM, *et al*
PATEL S. *See* JOHNSTON I, ANDERSON HR, *et al*
——. *See* JOHNSTON I, PATEL S, *et al*
PATTISON CW. *See* LAMB RK, EDWARDS CW, *et al*
PAVIA D, BATEMAN JRM, SHEAHAN NF, AGNEW JE, CLARKE SW: Tracheobronchial mucociliary clearance in asthma: impairment during remission, 171
——. *See also* CLAY MM, PAVIA D, *et al*
——. *See also* GEORGE RJD, JOHNSON MA, *et al*
——. *See also* GREENSTONE MA, RUTMAN A, *et al*
——. *See also* MILLAR AB, AGNEW JE, *et al*
——. *See also* TAYLOR RG, PAVIA D, *et al*
PEACH H, ELLARD GA, JENNER PJ, MORRIS RW: A simple, inexpensive urine test of smoking, 351
PEAKE MD, CHRYSTYN H, MULLEY BA: Computer aided prescribing of theophylline (P), 230
PEARCE FL. *See* FLINT KC, HUDSPITH BN, *et al*
PEARCE SJ, POSNER V, ROBINSON AJ, BARTON JR, COTES JE: "Invalidity" due to chronic bronchitis and emphysema: how real is it?, 828
——. *See also* BROUGHTON DL, GIBSON CJ, *et al*
PEARSON D. *See* BRITTON JR, BURNEY PGJ, *et al*
PEEL ET. *See* ANDERSON G, PEEL ET
PELLOW PGD. *See* NEWMAN SP, PELLOW PGD, *et al*
PENNINGTON JE. *See* LEE TH, PENNINGTON JE, *et al*
PEPPER J, KIRBY J, READER J, HUDSON L: The role of bronchoalveolar lavage in immunological monitoring after lung transplantation (P), 726
——. *See also* HURLEY P, CORBISHLEY C, *et al*
Peptide histidine isoleucine. *See* PHI
Pericarditis, Lancefield group A β haemolytic streptococcal, cardiac tamponade due to, case of, 549
PERKINS M. *See* HETZEL MR, CLARKE JH, *et al*
PERSSON CGA: On the medical history of xanthines and other remedies for asthma: tribute to HH Salter, 881
Pertussis in infancy, respiratory symptoms, lung function and bronchial reactivity after (P), 690
PETERS AM. *See* IND PW, PETERS AM, *et al*
——. *See* SAVERYMUTTU SH, PHILLIPS G, *et al*
PETRICEVIE I. *See* AGIUS RM, PETRICEVIE I, *et al*
PEYRAT MA. *See* CHAILLEUX E, BIGNON JD, *et al*
Phagocytic cells, *Aspergillus fumigatus* spores ingested by? (P), 237
PHI and VIP relaxation of bovine and human pulmonary artery, characteristics of (P), 715
PHILIPS B. *See* O'NEILL PA, DODDS M, *et al*
PHILLIPS G. *See* SAVERYMUTTU SH, PHILLIPS G, *et al*
PHILLIPS I. *See* NEILD JE, EYKYN SJ, *et al*
PHILLIPS KM. *See* BURR ML, PHILLIPS KM, *et al*
PHILLIPS MS, BARKER V: Extrathoracic lymph node aspiration in bronchial carcinoma, 398
Pholcodine and salbutamol, oral, for cough (P), 210
Phosphatidylinositol turnover and muscarinic receptors in airway smooth muscle (P), 713
Phrenic nerve and diaphragm function after coronary artery bypass grafting, 293
Phytohaemagglutinin responsiveness of blood lymphocytes, T lymphocyte subsets, and interleukin 2 production in sarcoidosis, 768
PICKERING CAC. *See* BURGE PS, FINNEGAN M, *et al*
——. *See* HONEYBOURNE D, FINNEGAN M, *et al*
——. *See* ROBERTSON AS, BURGE PS, *et al*
Pigeon breeder's disease, long term protection using face masks in (P), 228
PILLAI DK. *See* FARROW PR, PILLAI DK, *et al*
PINCHING AJ. *See* HOLT DA, WEBER J, *et al*
——. *See* WARREN JB, WEBER J, *et al*
PIOTROWSKA B. *See* DROSZCZ W, PIOTROWSKA B
Piperacillin adverse reactions to, in adults with cystic fibrosis, 184
PISTELLI R. *See* FORESI A, SHAW D, *et al*
PISTOLESI M. *See* MUSSI A, JANNI A, *et al*
PITT T. *See* WILSON R, PITT T, *et al*
Plasma, free and total, and saliva theophylline concentrations in chronic airflow obstruction, relationship between, 526
histamine concentration during propranolol induced bronchoconstriction, 903
nicotine, raised white blood cell count in smokers due to? (P), 696
sodium cromoglycate levels with nebuliser and metered dose aerosol in exercise induced asthma (P), 212
theophylline concentrations, rapid analysis in clinical setting (P), 230
theophylline, effect on cyclic AMP metabolism (P), 211

Platelet kinetics, pulmonary, in asthma, 412
PLATTS BW. *See* LOZEWICZ S, DAVISON AG, *et al*
Pleural effusion, malignant, comparison of intrapleural bleomycin and tetracycline in treatment of (P), 210
effusion, malignant, survival after *Corynebacterium parvum* pleurodesis in, comparison with mustine pleurodesis, 515
effusion or pneumothorax, effects on lung function, 60
effusion, rheumatoid, thoracoscopic, histological, and clinical findings in 9 cases of, 371
effusions, acute, in inactive ankylosing spondylitis, case of, 150
empyema, *Streptococcus milleri* as cause of, 626
interface, physical and physiological principles (E), 1
liposarcoma, primary, case of, 554
mesothelioma, treated by fast neutron therapy, case of, 72
Pleuritis, shrinking, with atelectasis, asbestos and other exogenous particles in lymph nodes in, 948
shrinking, with atelectasis, long term results of operation for, 448
Pleurodesis with *Corynebacterium parvum* in malignant pleural effusion, survival after, comparison with mustine pleurodesis, 515
Plombage, history of, and survey of present day survivors and complications, 328
thoracoplasty, late complication of, case of, 394
Pneumocystis carinii pneumonia (E), 561
Pneumonia associated with AIDS in Britain, bronchoalveolar lavage and transbronchial biopsy in diagnosis of, early experience and difficulties, 166
BTS study—design and outcome (P), 693—microbiological results (P), 693—mortality (P), 694—clinical features and *x* ray and laboratory data affecting prognosis (P), 694
community acquired, fibreoptic bronchoscopy in investigation of (P), 210
due to *Pneumocystis carinii* (E), 561
in AIDS (P), 227
lobar, and lung abscesses, indium 111 autologous leucocyte scanning in, 925
Pneumonitis, severe, steroid responsive, associated with pyoderma gangrenosum and ulcerative colitis, case of, 314
Pneumothorax or pleural effusion, effects on lung function, 60
spontaneous, place for aspiration in treatment of, 66
POLAK JM. *See* CHEUNG A, POLAK JM, *et al*
POLAKOW R. *See* SOLOMONS K, POLAKOW R, *et al*
Polyarthritis, seropositive, bronchocentric granulomatosis associated with, case of, 396
Polychondritis, tracheobronchial, progressive, case showing need for early diagnosis, 78
Polycythaemia and right ventricular hypertrophy in chronic hypoxia enhanced by systemic administration of beta$_2$ adrenoceptor agonists (P), 707
reversal of, effects on renin-angiotensin system in hypoxic cor pulmonale (P), 226
secondary, and cor pulmonale, calf blood flow in, effects of packed cell volume reduction (P), 237
secondary, and hypoxia, relative effects on mental function in respiratory disease (P), 231
Polyposis and hypersensitivity, nasal, leukotrienes in (P), 215
POOLE J. *See* O'NEILL PA, DODDS M, *et al*
POPE FM. *See* AYRES JG, POPE FM, *et al*
POSNER V. *See* PEARCE SJ, POSNER V, *et al*
POTGIETER PD. *See* WILLCOX PA, BENATAR SR, *et al*
POULTER LW. *See* CAMPBELL DA, DU BOIS RM, *et al*
——. *See* CAMPBELL DA, POULTER LW, *et al*
——. *See* MUNRO CS, MITCHELL DN, *et al*
POUNSFORD JC, BIRCH MJ, SAUNDERS KB: Effect of bronchodilators on the cough response to inhaled citric acid in normal and asthmatic subjects, 662
——, SAUNDERS KB: Diurnal variation and adaptation of the cough response to citric acid in normal subjects, 657
——, ——: The effect of inhaled codeine on the cough response to citric acid in normal humans (P), 708
POZNIAK AL, BIHARI D, KURTZ A, FREEDMAN D, JOHNSON N MCI: Metabolic and cardiac effects of nebulised salbutamol in normal volunteers (P), 706
——. *See also* FLINT KC, POZNIAK AL, *et al*
——. *See also* SWINBURN CR, POZNIAK AL, *et al*
Prednisolone in treatment of airflow obstruction in adults with cystic fibrosis (P), 211
oral, daily, in chronic severe asthma, comparison with monthly intramuscular triamcinolone acetonide, 840
oral, in severe chronic asthma, comparison with intramuscular depot triamcinolone *(Letters)*, 207
pharmacokinetics in adults with cystic fibrosis (P), 708
PRESCOTT RJ. *See* DOUGLAS JG, RAFFERTY P, *et al*
——. *See* FRANCE AJ, PRINCE KL, *et al*
PRICE JF. *See* LOFTUS BG, PRICE JF
PRIDE NB. *See* COE CI, PRIDE NB
——. *See* FLETCHER CM, PRIDE NB
——. *See* OPENSHAW PJM, HUGHES JMB, *et al*
——. *See* TAYLOR RG, GROSS E, *et al*
——. *See* TAYLOR RG, JOYCE H, *et al*
——. *See* WATSON A, JOYCE H, *et al*
PRINCE KL. *See* FRANCE AJ, PRINCE KL, *et al*
PRIOR C. *See* COLE PJ, ROBERTS D, *et al*
——. *See* ROBERTS D, HIGGS E, *et al*
PRITCHARD J. *See* MORRIS DL, CLARKSON MJ, *et al*
Propranolol, bronchoconstriction induced by, plasma histamine concentration during, 903
Prostacyclin as pulmonary vasodilator, comparison with oxygen (P), 716
long term, in primary pulmonary hypertension, pratical experience of (P), 232
Prostaglandin D_2 and leucotriene C_4 release, IgE dependent, from human bronchoalveolar cells (P), 716
Proteinase inhibitors and serum factors, modification of alveolar macrophage release of reactive oxygen species (P), 219
α_1-Proteinase inhibitor deficiency or chronic bronchitis, lung lavage fluid cell profiles and neutrophil chemotactic factor in (P), 724
inhibitor gene, expression by human alveolar macrophage (P), 219
inhibitor, oxidation of, effects of catalase and methionine sulfoxide-peptide reductase *in vitro* and *in vivo* (P), 724
Protriptyline for nocturnal hypoventilation in restrictive chest wall disease (P), 702
Pseudodiverticulosis, intramural, oesophageal, 12 cases and review of previous cases, 849
Pseudomonas infection, pulmonary, and exacerbation of respiratory symptoms in cystic fibrosis, ceftazidime compared with gentamicin and carbenicillin in, 358; *Errata*, 728
Pseudomonas aeruginosa, cilioinhibitory factor produced by, characterisation of (P), 238
aeruginosa colonisation of human respiratory tract, pigment production as mechanism for (P), 692
aeruginosa, cystic fibrosis adult patients infected with, nebulised ceftazidime compared with gentamicin and carbenicillin in (P), 704
Psittacosis infection, clinical and radiographic features of, 530
PUGH S (for BTS Research Committee): BTS pneumonia study: microbiological results (P), 693
Pulmonary adenocarcinoma and malignant mesothelioma, comparison of tumour markers in, 91
and aortic artery aneurysms, simultaneous, due to giant cell arteritis, case of, 156
arteriovenous connections, microscopic, multiple, presenting as cyanosis, case of, 316
artery, bovine and human, VIP and PHI relaxtion of, characteristics of (P), 715
artery, endothelial cell dependent relaxation in man, evidence of (P), 715
aspergillosis, non-invasive, ketoconazole in, trial of (P), 231
capillary blood flow and oxygen delivery to tissues, correlation in ventilated patients (P), 711

capillary blood flow, TLCO, and lung tissue volume, simultaneous measurement of (P), 226
capillary blood volume and transit time, effect of β_1 receptor blockade (P), 712
complications of AIDS, diagnosis of, 571
embolism, acute, treatment of, problems in (E), 729
embolism, suspected, comparison of intravenous digital subtraction angiography with radionuclide ventilation-perfusion lung scanning in, 576
embolus and deep vein thrombosis, 3 weeks' versus 6 weeks' anticoagulation in treatment of (P), 707
eosinophilia associated with cutaneous larva migrans, case of, 76
fibrosis induced by bleomycin in rabbits, progress of (P), 222
fibrosis induced by bleomycin in rabbits, secretion of fibroblast growth promoting activity by lavage inflammatory cells in (P), 222
fibrosis, interstitial, right ventricular size at necropsy in, comparison with chronic bronchitis and emphysema (P), 712
fibrosis, ventilation and gas exchange during sleep in (P), 236
fissure, angiofollicular lymphoid hyperplasia in, case of, 686
haemodynamics in hypoxic chronic bronchitis improved by long term therapy with oral beta$_2$ agonist? (P), 707
hydatid cysts, albendazole treatment in naturally infected sheep and implications for man, 453
hypertension, primary, long term prostacyclin in, practical experience of (P), 232
infarction, aseptic, cavitation in (P), 209
involvement, sarcoidosis with and without, ^{99m}Tc DTPA clearance in (P), 722
mast cells, human, staining characteristics of (P), 214
metastases, regression with long term remission in patient with renal carcinoma, 201
nodules, asymptomatic, alveolar soft part sarcoma presenting as, case with ultrastructural diagnosis, 203
platelet kinetics in asthma, 412
pseudomonas infection and exacerbation of respiratory symptoms in cystic fibrosis, ceftazidime compared with gentamicin and carbenicillin in, 358; *Errata*, 728
sarcoidosis, bronchoalveolar lavage fluid immunocompetent cells as reflection of transbronchial biopsy cell populations in (P), 726
sarcoidosis, changes in bronchoalveolar lymphocytes and T cell subsets in, 278
sarcoidosis, chronic, relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests in, 501
sarcoidosis, diagnosis and evaluation of, serum angiotensin converting enzyme in (P), 228
sarcoidosis, recent, bronchial reactivity in patients with, 51
sequestration, intralobar, of ectopic pancreatic tissue with gastropancreatic duplication, case of, 637
shadowing, diffuse, open lung biopsy in patients with, 931
shadows, widespread, chronic, bronchoalveolar lavage samples from patients with, relevance of lipoprotein aggregates in (P), 221
tuberculosis, detection and management in common hostel dwellers (Edinburgh, 1976–82) (P), 697
tuberculosis, plombage in, history of, and survey of present day survivors and complications, 328
tuberculosis, plombage thoracoplasty in, late complication of, case of, 394
tuberculosis, 6-month and 4-month chemotherapy regimes in, clinical trial and long term follow up (P), 696
tuberculosis, survey of chemotherapy and hospital admission in patients notified in England and Wales in 1978–9, 113
vasodilators, comparison of oxygen and prostacyclin as (P), 716
veno-occlusive disease after chemotherapy with bleomycin and other drugs, case of, 874
See also Bronchopulmonary; Lung
Purulent infection, cilia from sites of, beat frequency reduced *in vitro* (P), 691
PURVIS A. *See* SIMPSON FG, ARNOLD AG, *et al*
Pyoderma gangrenosum and ulcerative colitis, severe steroid responsive pneumonitis associated with, case of, 314
Pyrexia after open heart surgery, due to increase in antibodies to enteric Gram negative bacilli?, 538

Q

Quadriceps and respiratory muscles, effect of aminophylline (P), 720
Quality assessment, external, of lung function laboratories (P), 710
QUIN RO. *See* KHALIL Y, SETHIA B, *et al*

R

Radiological contrast material, intravenous, lung function change with, and complement activation (P), 240
Radionuclide ventilation-perfusion lung scanning in suspected pulmonary embolism, comparison with intravenous digital subtraction angiography, 576
RAE AP. *See* NEILLY JB, CLARK CJ, *et al*
RAEBURN D. *See* BRYSON SE, RAEBURN D, *et al*
RAEBURN JA. *See* ROBERTSON MD, RAEBURN JA, *et al*
RAFFERTY P. *See* DOUGLAS JG, RAFFERTY P, *et al*
RAGHAVAN D. *See* STUART-HARRIS R, FOX RM, *et al*
RAHIMA MM, BARZILAY J: Regression of pulmonary metastases with long term remission in a patient with renal carcinoma, 201
RAKSHIT M. *See* PARKES SA, BAKER SB DE C, *et al*
RAMSDALE EH, ROBERTS RS, MORRIS MM, HARGREAVE FE: Differences in responsiveness to hyperventilation and methacholine in asthma and chronic bronchitis, 422
RAVELLI V. *See* MUSSI A, JANNI A, *et al*
READER J. *See* PEPPER J, KIRBY J, *et al*
REBUCK AS. *See* COHEN RD, BUNTING PS, *et al*
REDLINE S, TOMSHEFSKI JF jun, ALTOSE MD: Cavitating lung infarction after bland pulmonary thromboembolism in patients with the adult respiratory distress syndrome, 915
REECE IJ. *See* SETHIA B, REECE IJ, *et al*
——. *See* VIGNESWARAN WT, REECE IJ, *et al*
REED S, DIGGLE S, CUSHLEY MJ, SLEET RA, TATTERSFIELD AE: Assessment and management of asthma in an accident and emergency department, 897
REES ADM. *See* GREENING AP, NUNN P, *et al*
REES PJ, BELCHER NG: Oral salbutamol and pholcodine for cough (P), 210
——, SHELTON DM, CHAN TB, EISER NM, CLARK TJH, MAISEY MN: Effects of histamine on lung permeability in normal and asthmatic subjects, 603
——. *See also* BELCHER NG, REES PJ
——. *See also* CHAIEB J, BELCHER NG, *et al*
——. *See also* CHAN TB, ANDERSON J, *et al*
——. *See also* CHAN TB, SHELTON DM, *et al*
——. *See also* CHOWIENCZYK P, LAWSON C, *et al*
——. *See also* SHELTON DM, REES PJ, *et al*
REES RSO. *See* MOOTOOSAMY IM, REZNEK RH, *et al*
REEVE P, LAPP NL, SEATON D, HALL DR, COADY T: Small airways obstruction in sarcoidosis (P), 722
Reflux, gastro-oesophageal, in childhood asthma, acid test for, 592
REIDY JF. *See* AYRES JG, POPE FM, *et al*
Renal carcinoma, regression of pulmonary metastases with long term remission in patient with, 201
RENAULT P. *See* HOMASSON JP, BONNIOT JP, *et al*
Renin-angiotensin system in hypoxic cor pulmonale, effects of reversal of polycythaemia (P), 226

Respiration during sleep in normal men and women (P), 235
not depressed by nabilone (P), 723
Respiratory and quadriceps muscles, effect of aminophylline (P), 720
disability, evaluation of, maximum activity questionnaire for (P), 232
disease, bronchoalveolar lavage mast cells in (P), 717
disease, *Haemophilus* biotyping in (P), 237
disease, mental function in, relative effects of hypoxia and secondary polycythaemia (P), 231
distress syndrome, acute, septic, and angiotensin converting enzyme in mouse (P), 239
distress syndrome, adult, cavitating lung infarction after bland pulmonary thromboembolism in 5 patients with, 915
distress syndrome, adult, preservation of selective permeability at capillary-alveolar barrier in (P), 239
failure, acute, after surgery for bronchial carcinoma, mechanical ventilation for, 387
failure, postoperative, significance of lung changes in congenital heart disease and Down's syndrome as cause of, 380
function. *See* Lung function; Ventilatory function
research, funding for, and British Lung Foundation (E), 81
resistance in chronic airflow obstruction, effects of correcting arterial hypoxaemia (P), 709
symptoms and lung function in London primary school children, ethnic variation in (P), 712
symptoms, atopy and bronchial reactivity in young population sample (P), 695
symptoms, bronchial reactivity and asthma (P), 695
symptoms, exacerbation of, and pulmonary poseudomonas infection in cystic fibrosis, ceftazidime compared with gentamicin and carbenicillin in, 358; *Errata*, 728
symptoms, lung function and bronchial reactivity after pertussis in infancy (P), 690
syncytial virus, parainfluenza viruses 1 and 2, winter acute bronchitis and autumnal asthma in general practice in UK (1976–84) (P), 690
testing machine, computerised, low cost (P), 710
tract, amyloidosis of, treated by laser therapy, case of, 544
tract, galanin immunoreactivity in, distribution in pig, guinea pig, rat, and dog, 889
tract, human, colonisation by *Pseudomonas aeruginosa*, pigment production as mechanism for (P), 692
tract, lower, leiomyoma of, 3 cases of, 306
See also Ventilatory
REZNEK RH. *See* MOOTOOSAMY IM, REZNEK RH, *et al*
Rheumatoid pleural effusion, thoracoscopic, histological, and clinical findings in 9 cases of, 371
RHIND GB, CATTERALL JC, STEWART IC, SHAPIRO C, DOUGLAS NJ: Sleep deprivation reduces overnight bronchoconstriction in asthmatic patients (P), 225
——, GOULD GA, MCHARDY GJR: Exercise and 12 minute distance: their effect on the sternomastoid muscle (P), 721
——. *See also* GOULD GA, RHIND GB, *et al*
Rhinitis, allergic induced release of high molecular weight neutrophil chemotactic activity in nasal secretions in (P), 719
and asthma after glutaraldehyde exposure (P), 224
perennial, atopic and non-atopic, nasal hypersecretion and blockage in, histamine as mediator of (P), 719
RHODEN K. *See* GREENBERG B, RHODEN K, *et al*
RHODES KM, EVEMY K, NARIMAN S, GIBSON GJ: Effects of mitral valve surgery on static lung function and exercise performance, 107
Rib cage, contribution to breathing in tetraplegia, 613
RIORDAN JF. *See* LOZEWICZ S, DAVISON AG, *et al*
ROBERTS D, HIGGS E, PRIOR C, COLE PJ: A simple, selective bacteriological medium designed to distinguish *Haemophilus influenzae* from *H parainfluenzae* in sputum (P), 237
——. *See also* COLE PJ, ROBERTS D, *et al*
——. *See also* WILSON R, PITT T, *et al*
——. *See also* WILSON R, ROBERTS D, *et al*
ROBERTS JA, GIEMBYCZ MA, RODGER IW, THOMSON NC: Verapamil inhibits leukotriene D induced bronchoconstriction in normal subjects (P), 217
——, RODGER IW, THOMSON NC: Airway responsiveness to histamine in man: effect of atropine on *in vivo* and *in vitro* comparison, 261
——, ——, ——: Effect of verapamil on leucotriene D_4 induced bronchoconstriction in asthmatic patients (P), 714
ROBERTS RS. *See* RAMSDALE EH, ROBERTS RS, *et al*
ROBERTSON AS, BURGE PS, COCKRILL BL: The use of serum thiocynate estimations to validate smoking histories and to identify passive smokers (P), 695
——, ——, FINNEGAN M, PICKERING CAC, HEDGE A, SIMMS J, GILL F, DALTON G: Building sickness: a comparison of work related health problems and environmental measurements in two office buildings with different ventilation systems (P), 211
——, ——, WIELAND A: Extrinsic allergic alveolitis due to antigen from a humidifier at 15°C (P), 229
ROBERTSON MD, RAEBURN JA, GORMLEY IP, SEATON A: Do phagocytic cells ingest spores of *Aspergillus fumigatus*? (P), 237
ROBINSON AA, FLOWER CDR, BARKER V: The accuracy of cytological diagnosis from percutaneous lung needle biopsy in pulmonary neoplasms (P), 699
ROBINSON AJ. *See* PEARCE SJ, POSNER V, *et al*
ROBINSON C. *See* AGIUS RM, ROBINSON C, *et al*
ROCHFORD PD. *See* JOHNS DP, ROCHFORD PD, *et al*
RODGER IW. *See* BRYSON SE, RAEBURN D, *et al*
——. *See* GIEMBYCZ MA, RODGER IW
——. *See* ROBERTS JA, GIEMBYCZ MA, *et al*
——. *See* ROBERTS JA, RODGER IW, *et al*
ROMÁN ROJO A. *See* FERNANDEZ REGO G, ROMÁN ROJO A
RØRTH M. *See* ØSTERLIND K, HANSEN M, *et al*
ROSE AG: State of the vein grafts, native coronary arteries, and myocardium and principal cause of death in patients dying after aortocoronary bypass grafting, 940
——. *See also* KNIGHT BK, ROSE AG
ROSEN MJ, TOW TWY, TEIRSTEIN AS, CHUANG MT, MARCHEVSKY A, BOTTONE EJ: Diagnosis of pulmonary complications of the acquired immune deficiency syndrome, 571
ROSSING TH. *See* LEE TH, PENNINGTON JE, *et al*
ROUTLEDGE PA. *See* EBDEN P, LEOPOLD D, *et al*
——. *See* FENNERTY AG, DOLBEN J, *et al*
ROWE D. *See* MOSS FM, BOBROW LG, *et al*
ROYSTON D, FLEMING JS, WESTABY S, DESAI J, TAYLOR K: Neutrophil kinetics and oxidative injury associated with cardiopulmonary bypass (P), 240
——. *See also* MAXWELL DL, ROYSTON D, *et al*
ROZNIECKI J. *See* KOWALSKI ML, GRZELEWSKA-RZYMOWSKA I, *et al*
RUBINOW A. *See* BREUER R, SIMPSON GT, *et al*
RUDD RM. *See* GELLERT AR, LANGFORD JA, *et al*
——. *See* GELLERT AR, LEWIS CA, *et al*
——. *See* GELLERT AR, RUDD RM
——. *See* WINTER RJD, RUDDOCK PE, *et al*
RUDDOCK PE. *See* WINTER RJD, RUDDOCK PE, *et al*
RUDOLF M. *See* GREENING AP, NUNN P, *et al*
RUFFLES SP, AYRES JG: Diagnosis of acute bronchitis and asthma in general practice (P), 689
RUSSELL G. *See* DODGE JA, GEDDES DM, *et al*
RUSSO PA, WRIGHT JEC, HO SY, MANEKSA JR, CLITSAKIS D: Endocardectomy for the surgical treatment of endocardial fibrosis of the left ventricle, 621
RUTMAN A. *See* GREENSTONE MA, RUTMAN A, *et al*
RYAN G. *See* COOKSON WOCM, MUSK AW, *et al*

S

SABANATHAN S, SALAMA FD, MORGAN WE: Oesophageal intramural pseudodiverticulosis, 849

SAKULA A: Henry Hyde Salter (1823–71): a biographical sketch, 887
SALAMA FD. *See* SABANATHAN S, SALAMA FD, *et al*
Salbutamol and pholcodine, oral, for cough (P), 210
bronchodilator effect of, enhancement by nifedipine *(Letters)*, 399
effect on minute ventilation and ventilatory response to carbon dioxide, comparison with aminophylline (P), 234
measurement in urine for monitoring of compliance in asthmatics (P), 705
nebulised, metabolic and cardiac effects in normal volunteers (P), 706
nebulised, without oxygen, in severe acute asthma, trial of efficiency and safety, 180
nebuliser and metered dose inhaler, domiciliary, comparison in stable chronic airflow limitation (P), 232
Saliva and free and total plasma theophylline concentrations in chronic airflow obstruction, relationship between, 526
Salter, Henry Hyde (1823–71), biographical sketch, 887
Salter, Henry Hyde (1823–71), contribution to medical history of xanthines and other remedies for asthma, 881
SAMPSON A. *See* GRANDORDY B, CUSS FMC, *et al*
SANTELLI G. *See* HOMASSON JP, BONNIOT JP, *et al*
Sarcoidosis, alveolar macrophage phagocytosis in (P), 220
alveolitis in, intensity of, reflected by serum angiotensin converting enzyme?, 497
hyperresponsiveness of bronchoalveolar mast cells in (P), 220
incidence in Isle of Man, 284
increased production of gamma interferon in (P), 726
Kveim test for, in vivo effects of different spleen suspensions on macrophage distribution and phenotype in (P), 725
Kveim test for, local cell mediated response induced in normal but not Kveim positive subjects by (P), 725
pulmonary, bronchoalveolar lavage fluid immunocompetent cells as reflection of transbronchial biopsy cell populations in (P), 726
pulmonary, changes in bronchoalveolar lymphocytes and T cell subsets in, 278
pulmonary, chronic, relationship between lung lavage cell counts, chest radiograph, and results of standard lung function tests in, 501
pulmonary, diagnosis and evaluation of, serum angiotensin converting enzyme in (P), 228
pulmonary, recent, bronchial reactivity in patients with, 51
reversible airways obstruction in (P), 722
small airways obstruction in (P), 722
T lymphocyte subsets, phytohaemagglutinin responsiveness of blood lymphocytes, and interleukin 2 production in, 768
with and without pulmonary involvement, ^{99m}Tc DTPA clearance in (P), 722
Sarcoma, alveolar soft part, presenting as asymptomatic pulmonary nodules, case with ultrastructural diagnosis, 203
SARKIES JWR. *See* PARKES SA, BAKER SB DE C, *et al*
SASTRY MR. *See* DONNELLY RJ, SASTRY MR, *et al*
SAUNDERS KB. *See* BUTLAND RJA, JOSEPH AEA, *et al*
——. *See* POUNSFORD JC, BIRCH MJ, *et al*
——. *See* POUNSFORD JC, SAUNDERS KB
SAVAGE T. *See* FORD HC, SAVAGE T, *et al*
SAVERYMUTTU SH, PHILLIPS G, PETERS AM, LAVENDER JP: Indium 111 autologous leucocyte scanning in lobar pneumonia and lung abscesses, 925
SAWICKA EH, LOH L, BRANTHWAITE MA: Survival with long term respiratory support (P), 209
——, PARKER RA, BRANTHWAITE MA: Cardiorespiratory consequence of idiopathic scoliosis (P), 701
——. *See also* DAVIS TME, SAWICKA EH
——. *See also* SIMONDS AK, PARKER RA, *et al*
SCHAEDEL C. *See* KIRSTEN K, SCHAEDEL C
SCHOEFFEL RE. *See* BLACK JL, SCHOEFFEL RE, *et al*
SCHOFIELD PM. *See* MORICE AH, SCHOFIELD PM, *et al*
SCHUMACHER W. *See* MACHA HN, KOCH K, *et al*
Sclerosis, multiple, severe diaphragm weakness in, case of, 633
Scoliosis, idiopathic, cardiorespiratory consequences of (P), 701
SCOTT W, GOULD GA, HAYHURST MD, FLENLEY DC: Laboratory assessment of oxygen concentrators (P), 708
——. *See also* GOULD GA, HAYHURST MD, *et al*
——. *See also* GOULD GA, SCOTT W, *et al*
SEATON A. *See* MCLEOD DT, AHMAD F, *et al*
——. *See* MCLEOD DT, CAPEWELL SJ, *et al*
——. *See* ROBERTSON MD, RAEBURN JA, *et al*
SEATON D. *See* REEVE P, LAPP NL, *et al*
SEED WA. *See* BURTON GH, SEED WA, *et al*
SELLERS WFS, HIGGS CMB: Tracheal concentrations of oxygen with Hudson and MC masks (P), 709
Serum angiotensin converting enzyme in diagnosis and evaluation of pulmonary sarcoidosis (P), 228
angiotensin converting enzyme, reflects intensity of alveolitis in sarcoidosis? 497
concentrations of vitamin D metabolites in untreated tuberculosis, 187; *(Letters)*, 639, 640
factors and proteinase inhibitors, modification of alveolar macrophage release of reactive oxygen species by (P), 219
precipitins to farmer's lung antigen in Quebec dairy farmers, factors influencing development of, 138
thiocyanate estimations for validation of smoking histories and identification of passive smokers (P), 695
SETHIA B, REECE IJ, TWEDDEL AC, MARTIN W, TAYLOR KM: Evaluation of right ventricular function during right ventricular bypass, 876
——. *See also* KHALIL Y, SETHIA B, *et al*
——. *See also* NORTHCOTE RJ, SETHIA B, *et al*
SEVER PS. *See* MORICE AH, KENNEDY C, *et al*
——. *See* MORICE AH, SCHOFIELD PM, *et al*
——. *See* MORICE AH, SEVER PS
SHALE DJ, FAUX JA, LANE DJ: Double blind trial of ketoconazole in non-invasive pulmonary aspergillosis (P), 231
——. *See also* COOKSON WOCM, WISEMAN MS, *et al*
SHAPIRO C. *See* RHIND GB, CATTERALL JC, *et al*
SHAW D. *See* FORESI A, SHAW D, *et al*
SHAW DJ, CHAPEL H, HUSSAIN A, FISHER A, LEE G DE J: Preservation of selective permeability at the capillary-alveolar barrier in adult respiratory distress syndrome (P), 239
SHAW GD. *See* KINNEAR WJM, SHNEERSON JM, *et al*
SHAW RJ, DRAKE-LEE A, FITZHARRIS P, CROMWELL O, KAY AB: Leukotrienes in nasal hypersensitivity and polyposis (P), 215
——, WALSH GM, CROMWELL O, MOQBEL R, SPRY CJF, KAY AB: IgG mediated release of leucotriene C_4 from human eosinophils: relevance to asthma and other diseases associated with hypereosinophilia (P), 716
——, YOUNGCHAIYUD P, ORR TSC, WELLS E, GREENWOOD B, LEE TB, KAY AB: Nedocromil, a mucosal and connective tissue mast cell stabiliser, inhibits allergen and exercise induced asthma (P), 219
——. *See also* MOQBEL R, DURHAM SR, *et al*
SHEA SA. *See* WINNING AJ, HAMILTON RD, *et al*
SHEAHAN NF. *See* PAVIA D, BATEMAN JRM, *et al*
SHEINMAN BD, DEVALIA JL, DAVIES RJ: Genesis of histamine in sputum: a role for bacteria in the airflow obstruction of acute exacerbations of chronic obstructive airways disease? (P), 238
SHELTON DM, REES PJ, EISER NM, CHAN TB, CLARK TJH: Histamine and epithelial permeability in normal and asthmatic subjects (P), 217
——, YOULTEN LJF, CHAN TB, EISER NM: A comparison of three methods of assessing nasal airway response to topical histamine (P). 216
——. *See also* CHAN TB, SHELTON DM, *et al*
——. *See also* REES PJ, SHELTON DM, *et al*
SHEPHERD MP: Plombage in the 1980s, 328
SHEPPARD M. *See* MOSS FM, BOBROW LG, *et al*
SHETTAR SP. *See* EVANS AR, WOLSTENHOLME RJ, *et al*
SHINEBOURNE EA. *See* BUSH A, BUSST CM, *et al*
Shipyard welders, young, lungs of, effect of welding fumes (P), 702
SHNEERSON JM. *See* JONES DK, CAVANAGH P, *et al*
——. *See* KINNEAR WJM, SHNEERSON JM
——. *See* KINNEAR WJM, SHNEERSON JM, *et al*
Shock, necrosis of colon induced by, chest injury complicated by,

case of, 556

SIEGER K. *See* FLINT KC, HUDSPITH BN, *et al*

SIEWERTSZ VAN REESEMA DR. *See* BERENDSEN HH, HOFSTEE N, *et al*

Silicosis, bronchoalveolar lavage in (P), 726

SILVER JR. *See* MORGAN MDL, GOURLAY AR, *et al*

SILVERMAN M. *See* WILSON NM, CHARETTE L, *et al*

SIMMS J. *See* ROBERTSON AS, BURGE PS, *et al*

SIMONDS AK, BRANTHWAITE MA: Efficiency of negative pressure ventilatory equipment (P), 213

——, PARKER RA, SAWICKA EH, BRANTHWAITE MA: Protriptyline for nocturnal hypoventilation in restrictive chest wall disease (P), 702

SIMONSSON BG. *See* OLAFSSON M, SIMONSSON BG, *et al*

SIMPSON FG, ARNOLD AG, PURVIS A, MUERS MF, COOKE NJ: Postal survey of medical bronchoscopies in the United Kingdom: drugs and safety precautions (P), 210

SIMPSON GT. *See* BREUER R, SIMPSON GT, *et al*

SINCLAIR W, WRIGHT JL, CHURG A: Lymphangioleiomyomatosis presenting in a postmenopausal woman, 475

SINGH H, EBEJER MJ, HIGGINS DA, HENDERSON AH, CAMPBELL IA: Acute haemodynamic effects of nifedipine at rest and during maximal exercise in patients with chronic cor pulmonale, 910

——. *See also* EBEJER MJ, SINGH H, *et al*

SINHA G. *See* GELLERT AR, LANGFORD JA, *et al*

SISSONS MCJ, GOSNEY JR: Pulmonary endocrine cells immunoreactive for calcitonin in the lungs of fetal and neonatal rats, 862

——. *See also* GOSNEY JR, SISSONS MCJ

——. *See also* GOSNEY JR, SISSONS MCJ, *et al*

Skin atopy, airways obstruction, and asthma in adult coeliac disease (P), 224

SKINNER M. *See* BREUER R, SIMPSON GT, *et al*

SLEE IP. *See* GEORGE RJD, WINTER RJD, *et al*

Sleep apnoea and hypoventilation in obesity (P), 235

apnoea, obstructive, severe, treated with long term nasal continuous positive airway pressure, 45

changes in ventilation and components in normal subjects during (P), 235; 364

deprivation, reduction of overnight bronchoconstriction in asthma by (P), 225

respiration during, in normal men and women (P), 235

ventilation and gas exchange in pulmonary fibrosis (P), 236

SLEET RA. *See* REED S, DIGGLE S, *et al*

SLOVAK AJM: Pulmonary function in aluminium smelters *(Letter)*, 319

SMALL RC. *See* ALLEN SL, FOSTER RW, *et al*

Small cell carcinoma of lung, combination chemotherapy or selective palliative treatment for, adverse reactions and quality of life during (P), 699

carcinoma of lung, maintenance vs no maintenance chemotherapy for, trial of (P), 699

carcinoma of lung, neurone specific enolase as diagnostic serum marker for, 85

carcinoma of lung, treatment policy of surgery in, analysis of 874 consecutive patients (1973–81), 272

SMITH AM. *See* HARROW EM, OLDENBURG FA, *et al*

SMITH AP. *See* BANKS J, BEVAN C, *et al*

——. *See* EBDEN P, LEOPOLD D, *et al*

——. *See* FENNERTY AG, BANKS J, *et al*

SMITH L. *See* MILROY R, SMITH L, *et al*

SMITH P. *See* GORDON IJ, COAKLEY J, *et al*

SMITH RM. *See* HOLGATE ST, BROOKS JR, *et al*

Smokers and ex-smokers, blood eosinophil and total white cell counts and bronchial reactivity to histamine in (P), 718

and ex-smokers, male, bronchial reactivity to inhaled histamine and annual rate of decline in FEV_1 in, 9; *Erratum*, 208

cigarette, alveolar macrophages with inclusions in, persistence after stopping smoking (P), 725

emphysema production in, and oxygen centred free radicals in cigarette smoke (P), 220

raised white blood cell count in, due to plasma nicotine? (P), 696

Smoking, allergy, and differential white blood cell count, 17; *Erratum*, 208

cigarette, effect on cell number and proliferation in alveolar walls (P), 214

histories, validation of, and identification of passive smokers, serum thiocyanate estimations for (P), 695

pattern, effects of number and tar content of cigarettes smoked on decline in FEV_1 over 10 years in middle aged men (P), 690

pattern in middle aged men with normal and accelerated rate of decline in FEV_1 (P), 710

urine tests of, evaluation of 3 methods, 351

Smooth muscle, airway, ^{45}Ca efflux from, effects of leucotriene D_4 and other agonists (P), 713

muscle, airway, calcitonin gene related peptide as potent constrictor of (P), 713

muscle, airway, isolated, electrophysiological and mechanical behaviour of (P), 712

muscle, airway, muscarinic receptors and phosphatidylinositol turnover in (P), 713

SMYTH JF. *See* FERGUSSON RJ, CARMICHAEL J, *et al*

SNASHALL PD. *See* GILLETT MK, SNASHALL PD

SO SY. *See* KUNG ITM, LOKE SL, *et al*

Sodium cromoglycate aerosol in exercise induced asthma, dose-duration effect of (P), 706

cromoglycate, effective in nocturnal asthma?, 793

cromoglycate inhibition of hypersmolar release of histamine from bronchoalveolar mast cells (P), 717

cromoglycate, plasma levels with nebuliser and metred dose aerosol in exercise induced asthma (P), 212

cromoglycate pressurised aerosol in exercise induced asthma, dose-response effect of, 41

SOLOMONS K, POLAKOW R, MARCHAND P: Diffuse malignant mesothelioma presenting as bilateral malignant lymphangitis, 682

SOUHAMI RL: Chemotherapy in non-small cell bronchial carcinoma (E), 641

——. *See also* MOSS FM, BOBROW LG, *et al*

SOULILLOU JP. *See* CHAILLEUX E, BIGNON JD, *et al*

SOUTAR CA. *See* COWIE H, LLOYD MH, *et al*

SPENCER JONES J: A place for aspiration in the treatment of spontaneous pneumothorax, 66

SPIRO SG. *See* EFTHIMIOU J, FLEMING J, *et al*

——. *See also* EFTHIMIOU J, SPIRO SG

Spirometric lung function tests in normal non-smoking Ethiopian men and women, 465

SPITERI MA, MIER AK, BROPHY CJ, PANTIN CFA, GREEN M: Bilateral diaphragm weakness, 631

Spleen suspensions, different, *in vivo* effects on macrophage distribution and phenotype in Kveim test for sarcoidosis (P), 725

Spondylitis, ankylosing, inactive, acute pleural effusions in, case of, 150

SPRINGALL DR. *See* CHEUNG A, POLAK JM, *et al*

SPRINGETT VH. *See* NUNN AJ, BYFIELD SP, *et al*

——. *See* SUTHERLAND I, SPRINGETT VH

SPRY CJF. *See* SHAW RJ, WALSH GM, *et al*

Sputum, differentiation of *Haemophilus influenzae* and *H parainfluenzae* in, bacteriological medium for (P), 237

histamine in acute exacerbations of chronic bronchitis, genesis of, and role of bacteria (P), 238

inhibition of neutrophil elastase, variability and relationship to known inhibitors (P), 725

purulent, bronchographic abnormalities in patients chronically producing, recording and interpretation of (P), 692

Squamous bronchial carcinoma arising in case of multiple juvenile papillomatosis, 797

carcinoma and granular cell myoblastoma, contiguous, in oesophagus, case of, 551

carcinoma *in situ* of oesophagus in patient with achalasia, 795

cacinoma of lung, advanced, trials of etoposide *v* no treatment and etoposide *v* etoposide + cyclophosphamide (P), 703

papilloma, solitary, of bronchus, 68

STABLEFORTH DE. *See* WILLIAMS AJ, ASQUITH P, *et al*
STADLER M. *See* MACHA HN, KOCH K, *et al*
STALLBAUMER MF. *See* MORRIS DL, CLARKSON MJ, *et al*
STANLEY NN: Clinical evaluation of a successive rebreathe procedure to measure the ventilatory response to hypoxia (P), 234
STANLEY PJ, GRIFFIN WM, WILSON R, GREENSTONE MA, MACKAY IS, COLE PJ: Effect of betamethasone and betamethasone with neomycin nasal drops on human nasal mucociliary clearance and ciliary beat frequency, 607
——. *See also* FARROW PR, JONES DA, *et al*
——. *See also* GREENSTONE MA, STANLEY PJ, *et al*
——. *See also* SYKES D, WILSON R, *et al*
STANLEY SL, jun, LUSK RH: Thoracic actinomycosis presenting as a brachial plexus syndrome, 74
Stapler, end to end anastomotic, oesophagogastrectomy using, results for first 100 patients, 958
Staplers, automatic, in bronchial closure, clinical and laboratory evaluation of 2 types (P), 215
automatic, role in aetiology of bronchopleural fistula, 27; *(Letters)*, 879
STARK JE. *See* HOLGATE ST, BROOKS JR, *et al*
STAUGAS R, MARTIN AJ: Secondary bacterial infections in children with proved *Mycoplasma pneumoniae*, 546
STEAD RJ, HODSON ME, BATTEN JC: Nebulised ceftazidime compared with gentamicin and carbenicillin in adults with cystic fibrosis infected with *Ps aeruginosa* (P), 704
——, KENNEDY HG, HODSON ME, BATTEN JC: Adverse reactions to piperacillin in adults with cystic fibrosis, 184
——, PANTIN CFA, ENGLISH J, HODSON ME, BATTEN JC: Pharmacokinetics of prednisolone in adults with cystic fibrosis (P), 708
——, ——, HODSON ME, BATTEN JC: Prednisolone in the treatment of airflow obstruction in adult patients with cystic fibrosis (P), 211
STEARN AJ. *See* GEORGE RJD, HOWARD RS, *et al*
——. *See* GEORGE RJD, STEARN AJ, *et al*
STEINHOLTZ L. *See* ESSCHER T, STEINHOLTZ L, *et al*
STEPHENS RJ. *See* BLEEHEN NM, FAYERS PM, *et al*
STERLING GM. *See* BOTTRILL I, HARDY C, *et al*
Sternal osteomyelitis, primary, case of, 872
Sternomastoid muscle, effect of exercise and 12 minute walk (P), 721
muscle fatigue, effect of aminophylline (P), 720
muscle function and fatiguability in severe dyspnoea (P), 721
STEVENSON RD. *See* NEILLY JB, CARTER R, *et al*
——. *See* NEILLY JB, CLARK CJ, *et al*
——. *See* NEILLY JB, WINTER JH, *et al*
STEWART I. *See* MILROY R, SMITH L, *et al*
STEWART IC. *See* RHIND GB, CATTERALL JC, *et al*
STOCKLEY RA, HILL SL, MORRISON HM, BURNETT D: Treatment of purulent bronchiectasis with nebulised antibiotics (P), 704
——, MORRISON HM, KRAMPS JA, DIJKMAN JH, BURNETT D: Inhibition of neutrophil elastase by sputum: variability and relationship to known inhibitors (P), 725
——. *See also* MORRISON HM, HILL SL, *et al*
——. *See also* MORRISON HM, STOCKLEY RA
——. *See also* MORRISON HM, SYKES D, *et al*
STOKES TC. *See* GANT A, BARBOSA I, *et al*
STOTT NCH. *See* BURR ML, MULLINS J, *et al*
STOVIN PGI: Early lung development (E), 401
STOYLE TF. *See* FANCOURT GJ, EBDEN P, *et al*
STRADLING JR, CHADWICK GA, FREW AJ: Changes in ventilation and its components in normal subjects during sleep, 364
——. *See also* CHADWICK GA, GLAZEBROOK K, *et al*
——. *See also* CHADWICK GA, STRADLING JR, *et al*
STREETON JA. *See* JOHNS DP, ROCHFORD PD, *et al*
Streptococcus, β haemolytic, Lancefield group A, pericarditis caused by, cardiac tamponade due to, case of, 549
Streptococcus milleri as cause of pleural empyema, 626
STRETTON TB: Provision of long term oxygen therapy (E), 801
STRICKETT MG. *See* ARMIGER LC, THOMSON RW, *et al*
STRICKLAND B. *See* COOKE J, CURRIE DC, *et al*
STRICKLAND BS. *See* MORGAN MDL, BUSST CM, *et al*
STUART-HARRIS R, FOX RM, RACHAVAN D, COATES AS, HEDLEY D, LEVI JA, WOODS RK, TATTERSALL MHN: Cisplatin, vinblastine, and bleomycin in inoperable non-small cell lung cancer, 346
STUDDY PR, BIRD R, JAMES DG: Serum angiotensin converting enzyme in the diagnosis and evaluation of pulmonary sarcoidosis (P), 228
Substance P, inhaled and intravenous, effect on airway function (P), 714
SUNDRUM R. *See* BLACK JL, SCHOEFFEL RE, *et al*
Suppressor cell function and nasal sensitivity in hay fever (P), 239
SUTHERLAND I, SPRINGETT VH: Efficacy of BCG vaccination in England and Wales in 1983 (P), 693
SUTHERLAND S. *See* SWINBURN CR, POZNIAK AL, *et al*
SUYAMA KL. *See* KAY JM, KEANE PM, *et al*
Swallowing difficulties in first degree relatives of patients with achalasia, 391
SWANSTON AR. *See* CORRADO OJ, GOMEZ E, *et al*
SWEATMAN M, LAWRENCE R, PANTIN CFA, TURNER-WARWICK M: Lung permeability in adult obliterative bronchiolitis (P), 722
SWEENEY E. *See* O'CONNOR CM, O'BRIEN A, *et al*
SWINBURN CR, POZNIAK AL, FLINT KC, JOHNSON N MCI: Pneumonia in the acquired immune deficiency syndrome (P), 227
——, ——, SUTHERLAND S, BANKS RA, TEALL AJ, JOHNSON N MCI: Early experience and difficulties with bronchoalveolar lavage and transbronchial biopsy in the diagnosis of AIDS associated pneumonia in Britain, 166
——, WAKEFIELD JM, JONES PW: Performance, ventilation, and oxygen consumption in three different types of exercise test in patients with chronic obstructive lung disease, 581
SYKES D, WILSON R, STANLEY PJ, COLE PJ: The role of histamine as mediator of nasal hypersecretion and blockage in atopic and non-atopic perennial rhinitis (P), 719
——. *See also* MORRISON HM, SYKES D, *et al*
SYKES MK: High frequency ventilation (E), 161
SZMIDT M. *See* KOWALSKI ML, GRZELEWSKA-RZYMOWSKA I, *et al*

T

T cell subsets and bronchoalveolar lymphocytes, changes in pulmonary sarcoidosis, 278
cell subsets, phytohaemagglutinin responsiveness of blood lymphocytes, and interleukin 2 production in sarcoidosis, 768
TABONE E. *See* CORDIER JF, BAILLY C, *et al*
TAKAHASHI T. *See* YAMAKI S, HORIUCHI T, *et al*
TAN KM. *See* TULLETT WM, TAN KM, *et al*
TAN TH. *See* TEO SK, TAN TH
TANSER AR. *See* HIGGS CMB, JONES P, *et al*
TAOR WS. *See* LUCE PJ, TAOR WS, *et al*
TATTERSALL MHN. *See* STUART-HARRIS R, FOX RM, *et al*
TATTERSFIELD AE. *See* BRITTON JR, AGIUS RM, *et al*
——. *See* BRITTON JR, BURNEY PGJ, *et al*
——. *See* HILL RA, BRITTON JR, *et al*
——. *See* REED S, DIGGLE S, *et al*
TAYLOR K. *See* ROYSTON D, FLEMING JS, *et al*
TAYLOR KM. *See* SETHIA B, REECE IJ, *et al*
TAYLOR RG, GROSS E, JOYCE H, HOLLAND F, PRIDE NB: Blood eosinophil and total white cell counts and bronchial reactivity to histamine in smokers and ex-smokers (P), 718
——, ——, ——, ——, ——: Smoking, allergy, and the differential white blood cell count, 17; *Erratum*, 208
——, JOYCE H, GROSS E, HOLLAND F, PRIDE NB: Bronchial reactivity to inhaled histamine and annual rate of decline in FEV_1 in male smokers and ex-smokers, 9; *Erratum*, 208
——, PAVIA D, AGNEW JE, LOPEZ-VIDRIERO M-T, NEWMAN SP, LENNARD-JONES T, CLARKE SW: The effect of long term high dose

ipratropium bromide on lung mucociliary clearance (P), 212
——, WOODMAN G, CLARKE SW: Does plasma nicotine raise the white blood cell count in smokers? (P), 696
TEALL AJ. *See* SWINBURN CR, POZNIAK AL, *et al*
TECULESCU DB: A substitute for "small airway disease"? *(Letter)*, 479
TEE RD. *See* HARRIES MG, LACEY J, *et al*
TEIRSTEIN AS. *See* ROSEN MJ, TOW TWY, *et al*
TENDOLKAR AG, MITTAL PK, PARULKAR GB: Chylothorax after surgery for patent ductus arteriosus *(Letter)*, 960
TEO SK, TAN TH (for Singapore Tuberculosis Service and British MRC): Long term follow up of a clinical trial of six month and four month regimens of chemotherapy in the treatment of pulmonary tuberculosis (P), 696
Terbutaline infusion, subcutaneous, continuous, local fat necrosis in unstable asthmatics secondary to (P), 705
Terfenadine and astemizole as non-sedative H_1 antihistamines for hay fever, comparative trial of *(Letters)*, 399, 799
Tetracycline and bleomycin, intrapleural, comparison in treatment of malignant pleural effusion (P), 210
Tetraplegia, breathing in, contribution of rib cage to, 613
Theophylline, computer aided prescribing of (P), 230
in plasma, effect on cyclic AMP metabolism (P), 211
plasma concentrations, rapid analysis in clinical setting (P), 230
saliva and free and total plasma concentrations in chronic airflow obstruction, relationship between, 526
slow release, in preschool asthma (P), 230
Thiocyanate, serum estimations, for validation of smoking histories and identification of passive smokers (P), 695
THOM S. *See* WARREN JB, WEBER J, *et al*
THOMSON AH. *See* WILSON NM, CHARETTE L, *et al*
THOMSON NC. *See* BERKIN KE, INGLIS CC, *et al*
——. *See* ROBERTS JA, GIEMBYCZ MA, *et al*
——. *See* ROBERTS JA, RODGER IW, *et al*
THOMSON RW. *See* ARMIGER LC, THOMSON RW, *et al*
Thoracic actinomycosis presenting as brachial plexus syndrome, case of, 74
cage and lung abnormalities in Ehlers-Danlos syndrome, 300
lymphadenopathy in Asians resident in UK, role of mediastinoscopy in initial diagnosis, 121
surgery, breathing patterns during weaning from mechanical ventilation after (P), 213
Thoracoplasty with plombage, late complication of, case of, 394
Thromboembolism, pulmonary, bland cavitating lung infarction after, in 5 patients with adult respiratory distress syndrome, 915
Thrombosis, deep vein, and pulmonary embolus, 3 weeks' versus 6 weeks' anticoagulation in treatment of (P), 707
Thromboxane A_2, indirect contractile effect of leucotriene D_4 in guinea pig lung parenchyma mediated by? (P), 713
Thymoma, intrapulmonary, 2 cases of, 471
TIMBS A. *See* HAKIM M, TIMBS A, *et al*
TLCO. *See* Carbon monoxide transfer factor
TOLFREE SEJ. *See* GELLERT AR, LEWIS CA, *et al*
TOMASHEFSKI JF, jun. *See* REDLINE S, TOMASHEFSKI JF, jun, *et al*
Tomography, computed, emission, and conventional imaging for gallium scanning in pretreatment evalution of lung cancer, 96
computed, in assessment of bronchiectasis, 920
computed, in diagnosis of bronchiectasis, assessment of accuracy and sensitivity (P), 692
TOOLEY M. *See* BENNETT J, TOOLEY M, *et al*
TOOMES H, MICKISCH G, VOGT-MOYKOPF I: Experiences with prosthetic reconstruction of the trachea and bifurcation, 32
TOURAINE R. *See* COURDIER JF, BAILLY C, *et al*
TOW TWY. *See* ROSEN MJ, TOW TWY, *et al*
Trachea and bifurcation, prosthetic reconstruction of, 9 cases, 32
and main bronchi, inoperable malignant tumours of, treatment with iridium 192 and Neodym-YAG laser (P), 700
Tracheal concentrations of oxygen with Hudson and MC masks (P), 709
Tracheobronchial amyloidosis, treatment of 2 cases by carbon dioxide laser photoresection, 870
and nasal mucociliary clearance, comparison of, using similar techniques in normal subjects (P), 724
mucociliary clearance in asthma, impairment during remission, 171
polychondritis, progressive, case showing need for early diagnosis, 78
tumours, laser therapy in 100 patients with, 341
Transbronchial biopsy and bronchoalveolar lavage in diagnosis of AIDS associated pneumonia in Britain, early experience and difficulties, 166
biopsy cell populations in pulmonary sarcoidosis reflected by immunocompetent cells in bronchoalveolar lavage fluids (P), 726
lung biopsy and bronchial lavage in diagnosis of legionnaires' disease, 3 cases of, 154
needle aspiration in clinical pratice, 756
Transepithelial potential difference in cystic fibrosis, 493
Transplantation, bone marrow, lung function in, prospective study of (P), 233
of lung, immunological monitoring after, role of bronchoalveolar lavage in (P), 726
Transpulmonary formation of angiotensin II in chronic stable cor pulmonale (P), 225
TRAVERS JP. *See* PARKES SA, BAKER SB DE C, *et al*
TREACHER DF, COWELL TK, BATEMAN NT, BRADLEY RD: Correlation between pulmonary capillary blood flow and oxygen delivery to the tissues in ventilated patients (P), 711
TREASURE T. *See* ADAMS J, TREASURE T
TREND P ST J. *See* COOPER CB, TREND P ST J, *et al*
Triamcinolone, depot, intramuscular, in severe chronic asthma, comparison with oral prednisolone *(Letters)*, 207
intramuscular, in chronic severe asthma (P), 228
Triamcinolone acetonide, intramuscular, monthly, in chronic severe asthma, comparison with daily oral prednisolone, 840
Trimethoprim or ampicillin, increasing incidence of *Branhamella catarrhalis* bronchopulmonary infection due to? (P), 691
TROTMAN D. *See* MCCONNOCHIE K, EDWARDS J, *et al*
Tuberculin tests, positive, influence of age and previous BCG vaccination (P), 697
Tuberculosis in uraemia, diagnostic problem and high incidence in ethnic minorities (P), 223
miliary, sputum negative, rapid diagnosis with flexible fibreoptic bronchoscope (P), 696
myocardial, sudden death due to *(Letters)*, 799
notification rates for Indian subcontinent population in England, declining as fast as 1983 survey suggests? (P), 690
notifications, geographical distribution in England and Wales in 1983 (P), 229
of bone in Brent (P), 697
of bone in Leicestershire (1978–83) (P), 696
of lymph nodes, trial of 9 versus 18 months' chemotherapy in (P), 223
pulmonary, detection and management in common hostel dwellers (Edinburgh, 1976–82) (P), 697
pulmonary, plombage in, history of, and survey of present day survivors and complications, 328
pulmonary, plombage thoracoplasty in, late complications of, case of, 394
pulmonary, 6-month and 4-month chemotherapy regimes in, clinical trial and long term follow up (P), 696
pulmonary, survey of chemotherapy and hospital admission in patients notified in England and Wales in 1978–9, 113
untreated, serum concentrations of vitamin D metabolites in, 187; *(Letters)*, 639, 640
TULLETT WM, TAN KM, NEALE MG, WALL RT, PATEL KR: Plasma sodium cromoglycate levels with nebuliser and metered dose aerosol in patients with exercise induced asthma (P), 212
——, ——, WALL RT, PATEL KR: Dose-response effect of sodium cromoglycate pressurised aerosol in exercise induced asthma, 41
——. *See also* PATEL KR, TULLETT WM, *et al*
Tumour markers in malignant mesothelioma and pulmonary ade-

nocarcinoma, comparison of, 91
of lung, volume of, estimation from plain chest radiograph, accuracy of (P), 699
Tumours, bronchial, human, heterotransplantation to immunosuppressed mice as model for assessment of anticancer drugs (P), 698
carcinoid, atypical, of lung, histological features and prognosis after surgery (P), 215
malignant, inoperable, in trachea and main bronchi, treatment with iridium 192 and Neodym-YAG laser (P), 700
trachobronchial, laser therapy in 100 patients with, 341
TURNER-WARWICK M. *See* HAY JG, DEWAR A, *et al*
——. *See* HAY JG, HASLAM PL, *et al*
——. *See* LIN YH, HASLAM PL, *et al*
——. *See* SWEATMAN M, LAWRENCE R, *et al*
TWEDDEL AC. *See* NEILLY JB, CARTER R, *et al*
——. *See* NEILLY JB, CLARK CJ, *et al*
——. *See* SETHIA B, REECE IJ, *et al*
TWEEDDALE PM, DOUGLAS NJ: Accuracy of Biox IIA ear oximeter (P), 708
——, ——: Evaluation of Biox IIA ear oximeter, 825

U

Ultrasonically nebulised water, cough induced by, related to aerosol particle charge (P), 718
nebulised water, increased responsiveness to methacholine and histamine in asthma after challenge with, 427
UMACHANDRAN V. *See* ASHOUR M, CAMPBELL IA, *et al*
United States coalminers, longitudinal decline in FEV_1 in, 132
Uraemia, tuberculosis in, diagnostic problem and high incidence in ethnic minorities (P), 223
Urine, salbutamol measurement for monitoring of compliance in asthmatics (P), 705
tests of smoking, evaluation of 3 methods, 351
UTHAYAKUMAR S. *See* GELLERT AR, LANGFORD JA, *et al*
UZEL N. *See* CAPEWELL SJ, FRANCE AJ, *et al*

V

Vagal influence on breathing pattern of resting normal subjects (P), 234
VALIND S. *See* OPENSHAW PJM, HUGHES JMB, *et al*
Valves preserved by liquid nitrogen freezing, morphology of, 778
VAN ASSENDELFT AHW: Asthma due to contaminated humidifiers *(Letter)*, 560
Vasoactive intestinal peptide. *See* VIP
VEALE D, GILMARTIN JJ, MURRAY A, ADAMS PC, GIBSON GJ: Twenty four hour ECG monitoring in patients using air driven nebulisers (P), 231
——, MARSH C, ASHCROFT T, HARRIS AL, GIBSON GJ: Epidermal growth factor and its receptor in normal and malignant lung tissue (P), 698
——. *See also* GILMARTIN JJ, VEALE D, *et al*
Vein grafts, native coronary arteries, and mycardium, state of, and principal cause of death in patients dying after aortocoronary bypass grafting, 940
VENABLES K, DAVISON A, BROWN K, NEWMAN-TAYLOR AJ: Pseudo-occupational asthma (P), 229
VENN GE, DACOSTA P, GOLDSTRAW P: Giant oesophageal hamartoma, 684
——, KAY PH, MIDWOOD CJ, GOLDSTRAW P: Open lung biopsy in patients with diffuse pulmonary shadowing, 931
Venous thrombosis, deep, and pulmonary embolus, 3 weeks' versus 6 weeks' anticoagulation in treatment of (P), 707
Ventilation and components, changes during sleep in normal subjects (P), 235; 364
and gas exchange during sleep in pulmonary fibrosis (P), 236
correlation between pulmonary capillary blood flow and oxygen delivery to tissues in patients undergoing (P), 711
cuiras assisted, in chest wall and neuromuscular disease (P), 701
high frequency (E), 161
high frequency, oral, by jet or oscillator, reduction of minute ventilation in normal subjects by, 749
high frequency, oral. *See also* Oscillation, high frequency, oral
mechanical, for acute respiratory failure after surgery for bronchial carcinoma, 387
mechanical, weaning from, after thoracic surgery, breathing patterns during (P), 213
minute, and ventilatory response to carbon dioxide, comparison of effects of aminophylline and salbutamol (P), 234
negative pressure, external, Newmarket suction pump for, comparison with standard Cape pump, 677
relationship to breathlessness in cystic fibrosis, influence of regular exercise (P), 721
stimulation of, breathlessness caused by hypoxia not due only to (P), 234
systems, different, 2 office buildings with, comparison of work related health problems and environmental measurements in (P), 211
Ventilation-perfusion lung scanning, radionuclide, in suspected pulmonary embolism, comparison with intravenous digital subtraction angiography, 576
regional, and $\dot{V}_A/\dot{Q}$, tomographic measurements using krypton 81 m (P), 233
scans for detection and assessment of lung disease, computer analysis of, 519
Ventilatory equipment, negative pressure, efficiency of (P), 213
function, decline in chronic bronchitis, factors affecting, 741
response to hypoxia, successive rebreathe procedure for measurement of, clinical evaluation of (P), 234
support, long term, survival with (P), 209
Ventricle, left, endomyocardial fibrosis of, endocardectomy for treatment of, with results in 2 cases, 621
left, right coronary artery supply to, variable anatomy of, 618
Ventricular ejection fraction, right, single measurement of, significance in chronic bronchitis and emphysema (P), 225
function, right, evaluation during right ventricular bypass in patient with postoperative cardiogenic shock, 876
function, right, in acute and chronic cor pulmonale, acute effects of oxygen (P), 711
hypertrophy, right, and polycythaemia in chronic hypoxia enhanced by systemic administration of $beta_2$ adrenoceptor agonist (P), 707
size, right, at necropsy in interstitial pulmonary fibrosis compared with chronic bronchitis and emphysema (P), 712
Verapamil, effect on leucotriene D_4 induced bronchoconstriction in asthmatics (P), 714
inhibition of leucotriene D_4 induced bronchoconstriction in normal subjects (P), 217
VERMEIRE P, JANSSENS E, DE BACKER W, WITTESAELE W, CLARK TJH: How differently from their European colleagues do British chest specialists manage asthma? (P), 689
VERNON P. *See* BURTON GH, SEED WA, *et al*
Video dilution technique in measurement of bronchial blood flow in sheep, 143
VIDNE BA. *See* GHOSH PK, LUBLINER J, *et al*
VIGNESWARAN WT, HARDIE R, FERGUSON JC, FAICHNEY A: Cardiac tamponade due to Lancefield group A β haemolytic streptococcal pericarditis, 549
——, REECE IJ, DAVIDSON KG: Intra-aortic balloon pumping: seven years' experience, 858
Vinblastine, cisplatin, and bleomycin in inoperable non-small cell

lung cancer, 346
VINCENT M. *See* CORDIER JF, CELLIER CC, *et al*
VIP and PHI relaxation of bovine and human pulmonary artery, characteristics of (P), 715
infused, effect in normal subjects (P), 714
intravenous, effect after cholinergic blockade (P), 714
Vitamin D metabolites, serum concentrations in untreated tuberculosis, 187; *(Letters)*, 639, 640
Vocal cord motion, paradoxical, in asthma (P), 689
VOGT-MOYKOPF I. *See* TOOMES H, MICKISCH G, *et al*

W

WAGNER JC. *See* GIBBS AR, HARACH R, *et al*
WAKEFIELD JM. *See* SWINBURN CR, WAKEFIELD JM, *et al*
WALBAUM PR. *See* MALONEY DJL, MORRITT A, *et al*
WALES JM. *See* FARROW PR, JONES DA, *et al*
WALKER A. *See* BOYD G, WALKER A
Walking test, treadmill, self paced, for breathlessness, 459
WALL RT. *See* PATEL KR, TULLETT WM, *et al*
——. *See* TULLETT WM, TAN KM, *et al*
WALLIS PJW, APPS MCP, NEWLAND AC, EMPEY DW: Effects of packed cell volume reduction on calf blood flow in secondary polycythaemia and cor pulmonale (P), 237
——, BRANFOOT AC, EMERSON PA: Sudden death due to myocardial tuberculosis *(Letter)*, 799
——, FEW JD, NEWLAND AC, EMPEY DW: Effects of reversing polycythaemia on the renin-angiotensin system in patients with hypoxic cor pulmonale (P), 226
——. *See also* APPS MCP, KOPELMAN PG, *et al*
——. *See also* APPS MCP, WALLIS PJW, *et al*
WALLWORK J. *See* HAKIM M, WHEELDON D, *et al*
——. *See* JONES K, HIGENBOTTAM TW, *et al*
——. *See* LARGE SR, HEYWOOD LJ, *et al*
WALSH GM. *See* MOQBEL R, DURHAM SR, *et al*
——. *See* SHAW RJ, WALSH GM, *et al*
WALSHAW MJ, EVANS CC: House dust allergen avoidance in adult asthma: a controlled trial (P), 224
WALTERS EH, EBDEN P, BANKS J, FENNERTY AG, BEVAN C: Does baseline airway calibre affect the response to inhaled histamine in asthmatics? (P), 216
——. *See also* BANKS J, BEVAN C, *et al*
WARDLAW AJ, CROMWELL O, CELESTINO D, FITZHARRIS P, COLLINS JV, KAY AB: Bronchoalveolar lavage mast cells in asthma and other respiratory diseases (P), 717
WARDMAN AG. *See* MASCIE-TAYLOR BH, WARDMAN AG, *et al*
WARLEY ARH, NICHOLSON EM, FINNEGAN OC, LASZLO G: Comparison of exercise performance and grading of dyspnoea in pulmonary and cardiac disease (P), 721
WARNER JO. *See* CORRIN B, DANEL C, *et al*
——. *See* JOHNSTON I, PATEL S, *et al*
WARREN JB, WEBER J, THOM S, KEAL EE, PINCHING AJ: Management of pulmonary disease in the acquired immune deficiency syndrome (P), 703
——. *See also* PALMER JBD, CUSS FMC, *et al*
Water, ultrasonically nebulised, cough induced by, related to aerosol particle charge (P), 718
ultrasonically nebulised, increased responsiveness to methacholine and histamine in asthma after challenge with, 427
WATERS WE. *See* MORTAGY AK, HOWELL JBL, *et al*
WATHEN CG. *See* MACNEE W, WHYTE KF, *et al*
WATKINS PJ. *See* HEATON RE, GUY RJC, *et al*
WATKINS RM. *See* DENNISON AR, WATKINS RM, *et al*
WATSON A, JOYCE H, GOLDMAN MD, PRIDE NB: Smoking pattern in middle aged men with normal and accelerated rate of decline in FEV_1 (P), 710
——, ——, HOLLAND F, PRIDE NB: Effects of number and tar content of cigarettes smoked on decline in FEV_1 over ten years in middle aged men (P), 690
WEBB AK. *See* O'NEILL PA, DODDS M, *et al*
WEBB JR: Dose-response characteristics of oral corticosteroids in the treatment of exacerbations of asthma (P), 228
WEBER J. *See* HOLT DA, WEBER J, *et al*
——. *See* WARREN JB, WEBER J, *et al*
Welding fumes, effect on lungs of young shipyard welders (P), 702
WELLER JJ. *See* EL-GAMAL FM, CHINN DJ, *et al*
WELLS E. *See* SHAW RJ, YOUNGCHAIYUD P, *et al*
WESTABY S. *See* ROYSTONE D, FLEMING JS, *et al*
WEYNANTS P, CORDIER JF, CELLIER CC, PAGES J, LOIRE R, BRUNE J: Primary immunocytoma of the lung: the diagnostic value of bronchoalveolar lavage, 542
WHEELSON D. *See* HAKIM M, WHEELDON D, *et al*
WHITE RJ. *See* COUTTS II, MACKENZIE S, *et al*
WHITE SH, IBRAHIM NBN, FORRESTER-WOOD CP, JEYASINGHAM K: Leiomyomas of the lower respiratory tract, 306
White cell(s). *See* Leucocyte(s)
WHYTE KF. *See* MACNEE W, WHYTE KF, *et al*
WIELAND A. *See* ROBERTSON AS, BURGE PS, *et al*
WILES CM. *See* COOPER CB, TREND P ST J, *et al*
——. *See* MOXHAM J, MILLER J, *et al*
WILLCOX PA, BENATAR SR, POTGIETER PD, BATEMAN ED: Rapid diagnosis of sputum negative miliary tuberculosis using the flexible fibreoptic bronchoscope (P), 696
WILLEY RF, FERGUSSON RJ, GODDEN D, CROMPTON GK, GRANT IWB: Comparison of oral prednisolone and intramuscular depot triamcinolone in patients with severe chronic asthma *(Letter)*, 208
WILLIAMS AJ: Standardised lung function testing *(Letter)*, 479
——, ASQUITH P, STABLEFORTH DE: Airways obstruction, asthma, and skin atopy in adult coeliac disease (P), 224
——, ——, ——: Gluten induced asthma in adult coeliac disease (P), 229
——. *See also* CHIODINI PL, WILLIAMS AJ, *et al*
WILLIAMS EW. *See* PARKES SA, BAKER SB DE C, *et al*
WILLIAMS JG: Exercise tests in unilateral diaphragmatic paralysis (P), 214
WILLIAMS SJ. *See* MORGAN MDL, GOURLAY AR, *et al*
WILSON AG. *See* BUTLAND RJA, JOSEPH AEA, *et al*
WILSON NM, CHARETTE L, THOMSON AH, SILVERMAN M: Gastro-oesophageal reflux and childhood asthma: the acid test, 592
WILSON R, COLE PJ: Cilia from sites of purulent infection beat more slowly *in vitro* (P), 691
——, PITT T, ROBERTS D, COLE PJ: Pigment production is a probable mechanism by which *Pseudomonas aeruginosa* colonises the human respiratory tract (P), 692
——, ROBERTS D, COLE PJ: Characterisation of a cilioinhibitory factor produced by *Pseudomonas aeruginosa* (P), 238
——, ——, ——: Effect of bacterial products on human ciliary function *in vitro*, 125
——. *See also* STANELY PJ, GRIFFIN WM, *et al*
——. *See also* SYKES D, WILSON R, *et al*
WINNING AJ, HAMILTON RD, GUZ A: Role of airway receptors in the breathing pattern of patients with chronic obstructive lung disease *(Letter)*, 879
——, ——, SHEA SA, GUZ A: Vagal influence on the breathing pattern of resting normal subjects (P), 234
WINTER JH. *See* NEILLY JB, WINTER JH, *et al*
WINTER RJD, GEORGE RJD, MOORE-GILLON JC, GEDDES DM: Inspiration phased oxygen delivery (P), 213
——, RUDDOCK PE, RUDD RM: Systemic administration of a beta$_2$ adrenoceptor agonist during chronic hypoxia augments the polycythaemic response and increases right ventricular hypertrophy (P), 707
——. *See also* GELLERT AR, LANGFORD JA, *et al*
——. *See also* GEORGE RJD, WINTER RJD, *et al*
WISE AE. *See* HODSON ME, WISE AE, *et al*
WISEMAN MS. *See* COOKSON WOCM, WISEMAN MS, *et al*

WITTESAELE W. *See* VERMEIRE P, JANSSENS E, *et al*
WOLSTENHOLME RJ. *See* EVANS AR, WOLSTENHOLME RJ, *et al*
WOOD NE, FLENLEY DC, GREENING AP: Serum factors and proteinase inhibitors modify alveolar macrophage release of reactive oxygen species (P), 219
——. *See also* BOYD PA, HASTIE ND, *et al*
WOODCOCK AA. *See* HETZEL MR, NIXON C, *et al*
WOODHEAD JS. *See* DAVIES PDO, BROWN RC, *et al*
WOODHEAD MA, MACFARLANE JT: Community acquired legionnaires' disease—a review of 79 cases in Nottingham (P), 691
WOODMAN G. *See* TAYLOR RG, WOODMAN G, *et al*
WOODS RL. *See* STUART-HARRIS R, FOX RM, *et al*
WRAIGHT P. *See* JONES DK, HIGENBOTTAM TW, *et al*
WRIGHT AJ. *See* GILMARTIN JJ, WRIGHT AJ, *et al*
WRIGHT CD. *See* DONNELLY RJ, SASTY MR, *et al*
WRIGHT JEC. *See* RUSSO PA, WRIGHT JEC, *et al*
WRIGHT JL. *See* SINCLAIR W, WRIGHT JL, *et al*
WYATT SE. *See* KENNEDY HG, WYATT SE, *et al*

X

Xanthine derivatives adminstered by inhalation in asthma, bronchodilator actions of, 176
Xanthines and other remedies for asthma, medical history and contribution of HH Salter, 881

Y

YAKIREVICH V. *See* GHOSH PK, LUBLINER J, *et al*
YAMAKI S, HORIUCHI T, TAKAHASHI T: Pulmonary changes in congentital heart disease with Down's syndrome: their significance as a cause of postoperative respiratory failure, 380
YANNOPOULOS PA: Subcutaneous transposition of the proximal oesophagus in oesophagoplasty, 936
YERNAULT J-C. *See* ESTENNE M, YERNAULT J-C, *et al*
YEUNG M, GRZYBOWSKI S: Prognosis in occupational asthma (E), 241
YOGISH H. *See* EVANS AR, WOLSTENHOLME RJ, *et al*
YOULTEN LJF. *See* SHELTON DM, YOULTEN LJF, *et al*
YOUNGCHAIYUD P. *See* SHAW RJ, YOUNGCHAIYUD P, *et al*